Intracellular functions and interactions of age-related macular degeneration-associated variant B cystatin C. by Myerscough, Christopher
1 
 
 
 
 
 
 
 
Intracellular functions and interactions of Age-Related 
Macular Degeneration-associated variant B cystatin C. 
 
Thesis submitted in accordance with the requirements of the 
University of Liverpool for the degree of Doctor in Philosophy 
by Christopher John Myerscough 
 
June 2015  
2 
 
 
 
 
 
 
 
 
 
In memory of Nora Antonio whose belief in me kept me going 
and George Antonio who would be so proud of all I have accomplished  
3 
 
Acknowledgements 
With thanks to: 
Dr Luminita Paraoan and Professor Malcolm Jackson for extensive advice and assistance 
throughout this project 
Dr. T. Michael Redmond for the gift of D407 cells 
Dr Anna Kayani for her assistance with initial ATP assays 
Dr Tim Pearson for assistance with both confocal microscopy and the oxytherm oxygen 
probe 
Dr Dave Spiller for technical advice and guidance on cell imaging 
Dr Paul Kay for providing the HaloTag materials and oligonucleotides and for lots of 
excellent advice 
Mr Umar Sharif for his expert advice on western blotting 
Miss Samantha McDonnell for use of her HaloTag sequencing primers 
Professor Rob Beynon, Dr Phillip Brownridge and Dr Deborah Simpson at the University of 
Liverpool, Centre of Proteomic Research. Without whom the Mass Spectrometry would not 
have been possible. 
  
4 
 
Contents 
Title Page 1 
Dedication 2 
Acknowledgements 3 
Contents 4 
Figures 11 
Tables 13 
List of abbreviations 14 
Abstract 15 
1 Introduction 16 
1.1 The eye 17 
1.2 The posterior eye 19 
1.2.1 The photoreceptors 19 
1.2.2 The retinal pigment epithelium 21 
1.2.2A Overview 21 
1.2.2B Structure of the RPE 21 
1.2.2C Functions of and trafficking in the RPE 22 
1.2.3 Bruch's membrane 25 
1.2.4 The choroid 26 
1.3 Age Related Macular Degeneration 28 
1.3.1 Overview of AMD 28 
5 
 
1.3.2 Neovascular AMD 30 
1.3.3 Similarities to other diseases 30 
1.3.4 Factors associated with AMD 31 
1.3.5 Treatments for AMD 32 
1.4 Cystatin C 34 
1.4.1 Structure of cystatin C 35 
1.4.2 Mechanism of action and function of cystatin C 38 
1.4.3 Cystatin C in the eye 39 
1.4.4 Cystatin C in disease 40 
1.4.5 Cystatin C variant B 41 
1.5 Key intracellular processes investigated 43 
1.5.1 Overview 43 
1.5.2 Respiration 43 
1.5.2A The respiratory process 43 
1.5.2B Respiration in the RPE 44 
1.5.3 Apoptosis 46 
1.5.4 Autophagy 48 
1.5.5 Oxidative Stress 49 
1.5.5A Oxidative stress and ageing 49 
1.5.5B Oxidative stress in the eye and AMD 50 
1.6 Project aims and objectives 52 
6 
 
2 Materials and Methods 53 
2.1 Mammalian cell culture 54 
2.1.1 Mammalian cell lines cultured 54 
2.1.2 Maintenance of cultures 55 
2.1.3 Freezing and thawing cells 56 
2.1.4 Transfection 56 
2.2 Plasmids 59 
2.2.1 Plasmid constructs used 59 
2.2.1A EGFP-based 59 
2.2.1B HaloTag-based 59 
2.2.2 Bacterial transformation for routine amplification 62 
2.2.3 Plasmid preparation from transformed bacteria 62 
2.2.4 DNA restriction digestions and agarose gel electrophoresis 63 
2.2.5 DNA sequencing 64 
2.2.6 Site-directed mutagenesis 65 
2.2.7 Production of new plasmid constructs 66 
2.3 Polyacrylamide gel protein analysis 69 
2.3.1 Preparation of whole cell lysates 69 
2.3.2 Polyacrylamide gel electrophoresis 69 
2.3.3 Western blotting 70 
2.3.4 Coomassie staining 73 
7 
 
2.3.5 Silver staining 73 
2.4 Flow cytometry analysis for oxidative stress 74 
2.4.1 Cell preparation 74 
2.4.2 Flow cytometry 75 
2.5 Protein pull-down 76 
2.5.1 Cystatin C protein immunoprecipitation 76 
2.5.2 HaloTag® protein pull-down 77 
2.6 Mass Spectrometry 78 
2.7 Respiration assays 79 
2.7.1 Oxygen probe measurement of respiration rate 79 
2.7.2 Total ATP content assay 79 
2.7.3 Preliminary ATP measurements 80 
2.8 Statistics and calculations 82 
2.8.1 T-test 82 
2.8.2 ANOVA 82 
2.8.3 Combining standard deviations 82 
3 Mitochondrial associated cellular mechanisms 83 
3.1 Introduction 84 
3.2 Preparation of constructs 84 
3.3 Respiration 90 
3.3.1 Preliminary respiratory measurements 90 
8 
 
3.3.2 Respiratory rate by oxygen depletion 93 
3.3.3 Total ATP content of cells 97 
3.4 Apoptosis 100 
3.5 Autophagy 103 
3.6 Oxidative stress 106 
4 Protein-protein interactions: Mass Spectrometry analysis 110 
4.1 Introduction 111 
4.2 Preparation and optimisation 111 
4.2.1 Production of new plasmid constructs 111 
4.2.2 Optimisation of protein pull-down 117 
4.2.3 Preliminary mass spectrometry 119 
4.3 Protein interaction analysis 122 
4.3.1 Significant results by ANOVA analysis 122 
4.3.2 Other notable protein readings 126 
4.3.3 Summary 126 
5 Discussion 127 
5.1 Overview of results 128 
5.2 Respiration 129 
5.2.1 Overexpression of EGFP or cystatin C-EGFP fusion protein does not 
significantly affect the rate of respiration.................................................129 
9 
 
5.2.2 Rate of respiration is not significantly altered by variant B 
cystatin C 130 
5.2.3 Total cellular ATP content is not significantly altered by cystatin C wild 
type or cystatin C variant B overexpression...............................................131 
5.3 Apoptosis 132 
5.3.1 Caspase 3 is not activated by the presence of cystatin C variant B 132 
5.4 Autophagy 133 
5.4.1 Levels of autophagosomes are not changed by the presence of variant 
B cystatin C................................................................................................133 
5.5 Oxidative stress 134 
5.5.1 Overexpression of wild type cystatin C and variant B cystatin C results 
in an increase in oxidative stress within the cell........................................134 
5.6 Mass Spectrometry 136 
5.6.1 General observations on results 136 
5.6.2 Cathepsins are bound at an increased level by wild type cystatin C 
compared with variant B cystatin C...........................................................137 
5.6.3 Prohibitin 138 
5.6.3A Overview 138 
5.6.3B Variant B Cystatin C interacts with Prohibitin protein 
significantly more than wild type cystatin C does.........................139 
5.6.3C Variant B Cystatin C does not interact with Prohibitin-2 at a 
significant level.............................................................................139 
5.6.4 Voltage-dependent anion-selective channel protein 1 140 
10 
 
5.6.5 Other mass spectrometry implicated cystatin C binding partners 141 
5.6.5A 78 kDa glucose-regulated protein 141 
5.6.5B Leucyl-cystinyl aminopeptidase 141 
5.6.5C Mitochondrial stress-70 protein 141 
5.6.5D Heat shock protein beta-1 141 
5.6.5E Calmodulin-like protein 3 142 
5.7 Future work  143 
5.8 Concluding remarks 145 
References 146 
Appendix 1: Complete Mass Spectrometry Data 167 
Appendix 2: Methods Supplement - Recipes 218 
11 
 
Figures 
Figure 1.1 Cross sectional representation of the eye. 18 
Figure 1.2 Cross section of the layers of the retina. 20 
Figure 1.3 Degradation of the retina with age and AMD. 29 
Figure 1.4 DNA sequence and primary protein structure of cystatin C. 36 
Figure 1.5 Secondary and tertiary structure of cystatin C protein 37 
Figure 1.6 Schematic diagram of the mitochondrial electron transport chain 45 
Figure 1.7 The caspase dependent apoptotic pathway 47 
Figure 2.1 Bright field images of ARPE-19 cells and D407 cells. 55 
Figure 2.2 Plasmid map for pEGFP-N3 plasmid used for EGFP constructs. 60 
Figure 2.3 Plasmid map for pHTC Halotag plasmid used for Halotag constructs.  61 
Figure 2.4 Transfer cassette for western blotting and details of transfer process. 72 
Figure 3.1 DNA substitution repairs in wild type cystatin C fusion protein 86 
Figure 3.2 DNA substitution repairs in variant B cystatin C fusion protein 87 
Figure 3.3 Localisation of repaired EGFP cystatin C constructs. 89 
Figure 3.4 Preliminary data on the reduction in rate of ATP production in mitochondria from 
ARPE19 cells transfected with pEGFP-N3 vector or pEGFP-N3 vector based cystatin C 
constructs...............................................................................................................................92 
Figure 3.5 Optimisation of oxygen electrode. 94 
Figure 3.6 Oxygen consumption rate of D407 cells relative to untransfected control. 96 
Figure 3.7 Cell number test for ATP luminescence detection. 98 
12 
 
Figure 3.8  Relative luminescence for ATP content of transfected and untransfected D407 
cells........................................................................................................................................99 
Figure 3.9 Caspase 3 probed blot of D407 lysates transfected with EGFP, wild type cystatin C 
fusion protein and variant B cystatin C fusion protein ........................................................101 
Figure 3.10 Bright field images of untransfected and transfected D407 cells 102 
Figure 3.11  Sample western blot of autophagic marker LC3B in D407 cell lysates. 104 
Figure 3.12 LC3B ratios as an autophagy marker for D407 transfected and untransfected 
cells......................................................................................................................................105 
Figure 3.13 Mean oxidative stress in transfected and untransfected D407 cells treated with 
CellROX oxidative stress dye, 1 day post-transfection.........................................................108 
Figure 3.14 Mean oxidative stress in transfected and untransfected D407 cells treated with 
CellROX oxidative stress dye, 5 days post-transfection.......................................................109 
Figure 4.1 HaloTag® construct insert schematic. 114-5 
Figure 4.2 Restriction digest of Halotag constructs to confirm insert. 116 
Figure 4.3 Silver stain of Halotag protein pull-downs with different elution buffers. 118 
  
13 
 
Tables 
Table 2.1 Restriction enzymes used for restriction digest of plasmids. 63 
Table 2.2 Sequencing primers used to confirm the integrity of constructs used in 
experiments...........................................................................................................................65 
Table 2.3 Primers used for point mutagenesis of plasmid to repair original EGFP 
constructs. 66 
Table 2.4 Primers for amplification of cystatin C. 67 
Table 2.5 Antibodies used in western blotting 71 
Table 4.1 Preliminary mass spectrometry analysis by spectral counting, unique 
proteins. 120-1 
Table 4.2 ANOVA significant results of mass spectrometry Halotag pull down ion 
abundances for Halotag, Wild Type Cystatin C-Halotag fusion and Variant B Cystatin C-
Halotag fusion transfected D407.........................................................................................124 
Table 4.3 Individual T-test values for paired comparisons between differently transfected 
cells for ANOVA indicated significant proteins (Table 4.2)...................................................125 
Appendix 1 Table 1: Complete ion abundance data for mass spectrometry experiment. 168 
Appendix 1 Table 2: Complete spectral count data for mass spectrometry experiment. 193 
  
14 
 
List of abbreviations 
ADP = Adenosine diphosphate 
AGEs = Advanced glycation end products 
ALEs = Age-related lipooxidation products 
AMD = Age Related Macular Degeneration 
ANOVA = Analysis of variance 
APS = Ammonium persulphate 
ATP = Adenosine triphosphate 
CMV = Cytomegalovirus 
DMSO = Dimethyl sulfoxide 
DNA = Deoxyribonucleic acid 
dNTP = Deoxynucleotide triphosphates 
EDTA = Ethylenediaminetetraacetic acid 
EGFP = Enhanced green fluorescent protein 
ESI-FTICR = Electrospray Ionization Fourier Transform Ion Cyclotron Resonance 
FCS = Foetal calf serum 
GAPDH = Glyceraldehyde 3-phosphate dehydrogenase 
LC3 = Light Chain 3 protein 
PAGE = Polyacrylamide gel electrophoresis 
PBS = Phosphate buffered saline 
PCR = Polymerase chain reaction 
POS = Photoreceptor outer segments 
RPE = Retinal pigment epithelium 
ROS = Reactive oxygen species 
SDS = Sodium dodecyl sulfate 
VEGF = Vascular endothelial growth factor 
  
15 
 
PhD Thesis Abstract: Intracellular functions and interactions of Age-Related 
Macular Degeneration-associated variant B cystatin C. 
Christopher John Myerscough, June 2015 
 
Age related macular degeneration (AMD) is the leading cause of blindness among 
the elderly population. It occurs in two forms, a nonexudative "dry" form which can 
lead to geographic atrophy of the retinal pigment epithelial (RPE) cells in the region 
of the macula and an exudative "wet" form which involves neovascularisation from 
the choroid, through Bruch's membrane and the RPE layer and into the 
photoreceptor layer causing significant damage. 
Cystatin C is a cysteine protease inhibitor known to inhibit cathepsin activity. It is a 
highly abundant transcript in the RPE and is known to be processed through the 
secretory pathway . A variant form of this protein with an amino acid substitution in 
its signal sequence results in the protein being retained intracellularly and is found 
localised with the mitochondria. This variant form has been associated with 
increased risk of developing exudative AMD. 
In this study a number of key cellular processes were examined to elucidate the 
effect the variant B protein has on the RPE. These processes were respiration, 
apoptosis, autophagy and oxidative stress; all of which have been implicated in 
AMD pathology or ageing. In addition the protein-protein interactions of variant B 
cystatin C were assessed through mass spectrometry analysis of pulled-down 
cystatin C protein from transfected cell lysates. 
No effect on respiration, apoptosis or autophagy was identified. However a 
statistically significant difference in oxidative stress was identified as a result of 
overexpression of either wild type cystatin C or variant B cystatin C. Mass 
spectrometry analysis resulted in two highly promising  proteins that were found 
interacting with variant B cystatin C at a statistically significant level, prohibitin and 
voltage-dependent anion-selective channel protein 1 (VDAC1). 
Although oxidative stress was found for both proteins given the nature of the 
expression (driven by a CMV promoter) it seems likely that the oxidative stress 
response is due to a high level of intracellular cystatin C. This suggests that the 
retention of variant B protein within the cell would lead to increased oxidative 
stress levels. It can be speculated that this response could be a contributory factor 
to development of AMD. 
VDAC1 and prohibitin may offer an explanation of what happens to the variant B 
protein within RPE cells. VDAC1 is the major pore-forming protein in the 
mitochondrial membrane, disruption of its functioning by the binding of variant B 
protein might be expected to have detrimental effects. Prohibitin is an even more 
promising target as it has been associated with oxidative stress. In addition it is 
known to translocate between the nucleus and the mitochondria, offering the 
tantalising possibility of a complete explanation for the mitochondrial 
mislocalisation. 
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1.1 The eye 
The eye (figure 1.1) consists of a fluid filled chamber constructed from a number of tissues. 
Some of these tissues act to focus light, detect it or transmit it and some of which exist to 
protect and support its function of enabling vision. 
The sclera and the cornea comprise the majority of the outer layer of the eye and consist  
primarily of interwoven collagen fibres arranged differently in the two tissues (Komai & 
Ushiki, 1991). The sclera is the resilient, white layer which comprises the majority of the 
outer surface of the eye. The cornea is a similarly tough layer at the front of the eye but is 
clear , allowing light to pass through. The two are joined by the limbus, a tissue known to 
contain structures of importance to the balance of pressure in the eye; specifically this 
region includes Schlemm's canal and other linked vessels which are crucial for removing 
aqueous humour from the eye and passing it to the circulatory system (van der Merwe & 
Kidson, 2010). Taken as one these three present a durable and resilient protective outer 
layer. In addition they provide a surface to which the other layers are anchored in an 
organised way and help to maintain intraocular pressure. The only interruption to this layer 
is at the very back of the eye, where the optic nerve penetrates through the sclera. 
Behind the cornea is the iris, a flexible layer of tissue containing muscles which allow the 
pupil to contract and dilate. This allows for adjustment of the amount of light entering the 
eye, the speed of the response being proportional to the intensity of light (Ellis, 1981). Light 
passing through the pupil is focussed by the lens, a clear disc which redirects light onto the 
retina at the back of the eye. The lens is connected to the ciliary body, a muscular ring 
which is crucial for the adjustment of the refractory capability of the lens. 
At the back of the eye are a series of layers to detect and transmit light, as well as the 
supportive tissue for these layers. The outermost layer (aside from the sclera) is the 
choroid, a heavily vasculated tissue which supplies the eye with nutrients and removes 
waste product (1.2.4) The blood vessels within the choroid are thin capillaries, which are 
very leaky, consequently it is crucial to separate the capillaries from the retina itself. This is 
achieved by two layers between the capillaries and the retina known as the Bruch's 
membrane and the retinal pigment epithelium (RPE). 
Bruch's membrane (1.2.3) is a flexible layer which separates the RPE from the capillaries. It 
is a five-layered extracellular matrix made up primarily of elastins and collagens. The RPE is 
18 
 
the support layer for the retina, fulfilling a variety of crucial functions which are essential 
for the normal functioning of the eye (1.2.2). The innermost layer at the back of the eye is 
the photoreceptor layer itself (1.2.1), a series of light-sensitive cells interacting with a 
network of nerve cells which lead back to the optic nerve and, through that, to the brain. 
 
 
Figure 1.1 Cross sectional representation of the eye. A gross anatomical diagram with 
major structures labelled.  (Public domain image, Wikimedia commons). 
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1.2 The posterior eye 
1.2.1 The photoreceptors and neuronal cells 
The most functionally important layer of the eye is the retina. It is defined by its large, 
complex network of neuronal tissue (Figure 1.2) whose function is to detect the light that 
falls upon it and transmit signals produced by the reaction to light. This neuronal tissue is 
layered and detects light through photochemical reactions in specific photoreceptive cells, 
producing signals in response which are passed on through a series of neurons through the 
optic nerve to the brain where they can be deciphered. 
Photosensitive cells within the retina are organised with their outer segment (containing 
photosensitive pigment) as the closest structure to the retinal pigment epithelium layer; 
this outer segment is connected to the inner segment which contains large numbers of 
mitochondria. The uppermost part of the cell consists of the cell's nucleus with a protruding 
axon and a synaptic terminal which allows the release of neurotransmitters, initiating the 
neurological signal resulting from the presence of light. There are two types of 
photoreceptors known as rods and cones with cones providing superior resolution as well 
as utilising three different pigments in order to build up a colour image in bright light (Sung 
& Chuang, 2010). The central vision area of the eye is known as the macula and is 
responsible for high resolution imaging. In particular the fovea, a small depression in the 
macula region, is the focal point for central vision and contains an extremely high density of 
cones (Curcio et al., 1990). 
Connecting to the photoreceptor layer is a layer of bipolar cells. These act to transmit 
signals which originate in the photoreceptors through a network of neuronal tissue with 
signals diverging or converging as appropriate through these cells. Bipolar cells occur in a 
wide variety of different types (more than ten) and are crucial to vision, as all information 
for vision is relayed by these cells (Euler et al., 2014). The signals are then transmitted to 
ganglion neurons from where they are finally transmitted via the optic nerve to the brain. 
Cones in the central vision areas of the eye have divergent signalling by which they link to 
multiple bipolar cells and, consequently, multiple ganglion cells. This allows for a single 
stimulated cell to produce a signal in such a way that it can be detected and resolved. 
Further, this allows for highly sensitive vision as a result of nearby cones being able to 
detect differing amounts of incoming light and subsequently generating signals 
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proportional to the input. This central region of the retina is referred to as the macula and 
is the most crucial region of photoreceptors for high resolution vision. 
Peripheral areas of the eye tend to consist of convergently wired rods where a number of 
photoreceptors feed into one bipolar cell and hence one ganglion cell. Rods contain a single 
pigment known as rhodopsin (Brown & Wald, 1964) and respond to very low levels of light, 
as low as a single photon (Kawamura & Tachibanaki, 2008). This results in extremely light-
sensitive but poor resolution vision, allowing for vision in low-light conditions but reduced 
visual acuity. This is particularly important to note in the case of damage to the retina, 
central areas of the eye are of crucial importance to resolving high resolution images whilst 
peripheral regions of the eye do not have the same capacity for resolving shapes. 
Consequently damage to the central region will have a larger impact on visual capability. 
 
 
 
Figure 1.2 Cross section of the layers of the retina. A histological section of the retina 
showing the photoreceptors and RPE combined with a figure illustrating the various cells at 
each layer. The retinal pigment epithelium is the bottommost monolayer of cells and is a 
support tissue for the photoreceptors above. (adapted from Hartong et al., 2006). 
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1.2.2 The retinal pigment epithelium 
1.2.2A Overview 
The RPE is a supportive layer in the posterior eye which is crucial for the protection of the 
retinal cells from a variety of sources of potential damage as well as supporting the cells in 
their function. These include transport of nutrients and ions between the choroid and the 
photoreceptors, maintenance of the surrounding tissue by production of growth factors , 
homeostasis of ions in the subretinal space and recycling of retinal via the visual cycle. 
Neural retinal cells are highly active due to the constant processing of light signals and 
consequently have very high upkeep requirements; this is only possible due to these 
supportive tissues.  
 
1.2.2B Structure of the RPE 
The RPE layer is a tightly packed, highly polarised, monolayer cellular structure which acts 
as a physical barrier in the retina, contributing to protecting it from the choroid and 
supporting the photoreceptors (Boulton & Dayhaw-Barker, 2001). It is characterised by a 
dense "cobblestone" appearance and forms a barrier for control of transport. 
RPE cells are highly polarised with a structure which facilitates its supportive functions in 
relation to the retina and the surrounding tissue. The apical side of the RPE consists of a 
series of microvilli which surround and interact with the ends of the photoreceptor cells 
(Bok, 1993); these come as a mixture of long and short microvilli. The long microvilli provide 
a large surface area for transport and easy exchange of ions, and the short microvilli act to 
sheath the ends of the photoreceptors and to provide a surface for phagocytosis (Boulton & 
Dayhaw-Barker, 2001). In addition the basal surface of the RPE is infolded (Garron, 1963) 
which allows for the effective uptake of nutrients and removal of waste products via the 
choroid, again by providing a large surface area for transport. 
The layer as a whole is firmly anchored together by tight junctions. Rizzolo (2007) has 
reviewed tight junctions, both their development and their effects on the RPE. In brief, 
these are complex structures that join neighbouring cells and exist to regulate a variety of 
cellular functions as well as to regulate diffusion through epithelial membranes via the 
paracellular route. Tight junctions are made up of a variety of proteins that can be broadly 
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ascribed to four major classes. Transmembrane proteins anchor cells together and they are 
attached to adaptor proteins. These act as a scaffold to anchor the transmembrane 
proteins either to the cytoskeleton or to effector proteins. Effector proteins comprise both 
signalling proteins and transcriptional regulatory proteins; this allows the tight junctions to 
affect the cell’s internal environment. This seal caused by tight junctions allows for the 
formation of ion gradients by dramatically slowing any diffusion through the spaces 
between cells. Consequently allowing for ionic gradients to form and be used to drive 
transport in the RPE cells. 
The intracellular structure of RPE cells is organised in such a way as to facilitate the 
supportive functioning of the retina. Nutrients, ions and waste products must pass through 
these cells due to the tight junctions, consequently the RPE is crucial in the process of 
maintaining the environment of the neuronal cells (Bok, 1993). As a result, transport 
processes of the RPE are complex and utilise a large number of different exchange 
mechanisms. In addition, ionic balance is of crucial importance as it is ionic gradients that 
power many of the processes involved. 
 
1.2.2C Functions of and trafficking in the RPE 
One way by which the RPE acts to protect the retina is through protecting against excess 
light that enters the eye. As the name states the cells are pigmented and this pigment acts 
to absorb light focussed onto the retina by the lens. Excess light has significant potential for 
harm as a result of photo-oxidation leading to oxidative stress and damage to the cells in 
the retina. 
In addition to the photo-oxidative damage potential illustrated above, the retina itself is a 
high risk environment for oxidative stress. As photoreceptors are exposed to light over time 
this leads to a build up of photo-damaged proteins within in the photoreceptor cells and a 
build up of toxic substances. These damaged components are recycled through the process 
of shedding old photoreceptor outer segments to be broken down and the construction of 
new outer segments which occurs at the base of the region. The shed photoreceptor outer 
segments (POS) are taken up by the RPE by phagocytosis and are subsequently digested, 
with damaged proteins broken down and intact important molecules are returned to the 
photoreceptors for use in constructing new outer segments (Bok, 1993). These processes 
23 
 
are both tightly regulated in cooperation with each other as the shedding of POS and the 
construction of new segments must occur at the same rate in order to ensure that the 
length of the photoreceptors remains stable. The exact process by which this happens is 
not fully understood, however it is known that a circadian regulation is involved (La Vail, 
1976). This process of phagocytosis of shed photoreceptor outer segments is thus of crucial 
importance to the retina but is also a source of significant amounts of reactive oxygen 
species with great potential for causing harm (Miceli et al., 1994). 
Perhaps the most important role of the RPE is in the recycling of the photoreceptor 
photosensitive molecules in what is termed the retinoid cycle. In order for light to be 
translated into vision it must be transduced into electrical impulses and consequently be 
passed through the extensive neuronal networks contained within the eye. This is achieved 
by the light being used to modify the stores of 11-cis-retinal contained within the 
photoreceptors in the form of rhodopisn into all-trans-retinal (Hargrave, 2001). However, 
once this has occurred, the photoreceptors have no way of converting the retinal back into 
a form which can be triggered by new light. Consequently the RPE cells fulfil a key role in 
vision itself by acting as the site where retinal can be reisomerised. This occurs in a cycle 
where all-trans-retinal is converted to all-trans-retinol and transported to the RPE where 
the retinol is converted back to 11-cis-retinal and returned to the photoreceptors to be 
used (Tang et al., 2013). In addition a certain amount is also recovered from the shed POS 
when they are digested and returned to the photoreceptors via a similar pathway. 
A significant part of the RPE function is the transport of nutrients and ions; this is essential 
to both provide the RPE cells what they need to survive as well as to remove waste 
products. In addition due to the high metabolic activity in the retina a large amount of 
water is produced and consequently it must constantly be removed. This is achieved by a 
combination of Mϋller cells and the RPE cells themselves (Marmor, 1990) and acts to help 
establish adhesion between the RPE and the retina. In the RPE the removal of water is 
driven by epithelial transport of chlorine and potassium ions and given the tight junctions 
and consequent impermeability of the layer the water is primarily extracted by this 
transcellular pathway (Strauss, 2005). 
A large number of ions, nutrients and waste products are shifted across the RPE. With the 
polarity of the layer combined with the tight junctions making a barrier for careful control 
of the transport flow. The long microvilli on the apical side of the RPE sheath the 
photoreceptors and allow for efficient exchange, as do the folds on the basolateral side. 
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The polarisation of RPE is elegantly reviewed by Marmorstein (2001). However in brief, an 
apical Na+-K+-ATPase provides the driving force for transport, producing a sodium ion 
gradient that enables the functioning of a variety of cotransporters through which the ions 
are moved. As mentioned above this includes K+ and Cl- ions which are crucial in the uptake 
of water. However it also includes  the removal of lactic acid from the photoreceptors 
which is the major waste product, found at high subretinal concentrations, and which is 
taken up by the RPE cells and passed out through the basolateral membrane (Strauss, 
2005). In addition glucose is known to be transported from the choriocapillaries to the 
photoreceptors via the retina in a process which involves the glucose transporters GLUT1 
and GLUT3 in a variety of species (Ban & Rizzolo, 2000). 
The RPE is also crucial in the development of the retina. The two are co-dependent with 
specific stages of development of each depending upon corresponding developments in the 
other. The extension of microvilli of the RPE, for example, is coordinated with the 
lengthening of the photoreceptor outer segments forming the large surface of interaction 
necessary for high levels of transport. In addition the RPE is believed to be heavily involved 
in the development of the Bruch’s membrane as it is capable of synthesising the major 
components necessary in its composition (Booij et al., 2010). 
Aside from this developmental importance it is also crucial in the secretion of growth 
factors for maintenance of the retina. The RPE cells are known to produce and secrete a 
wide variety of growth factors which are crucial for maintaining a normal environment for 
the sensitive photoreceptors. Some of these growth factors are of particular importance. 
For example, the RPE is a source of low quantities of vascular endothelial growth factor 
(VEGF) which is essential to maintain the choriocapillaries (Adamis et al., 1993).  
Finally the RPE acts as part of the barrier between the leaky capillaries of the choroid and 
the sensitive neuronal tissue of the retina (along with Bruch's membrane). It functions both 
as a physical barrier and as a regulator, for example by its control of the secretion of VEGF 
mentioned above. As a physical barrier it prevents blood from entering the retina where it 
could cause significant harm, damaging and destroying cells and severely disrupting sight. 
This effect can be seen in neovascular age-related macular degeneration (section 1.3) 
where blood vessels entering the neuroretina itself leads to blood leakage and damage in 
the macular region. 
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1.2.3 Bruch's membrane 
Bruch's membrane is located between the RPE layer and the choroid and is commonly 
described by Hogan’s five-layer system (Hogan et al., 1971).  Nearest the RPE layer is the 
RPE basal lamina which is similar in structure to other basal laminas in the body (Curcio & 
Johnson, 2013) comprising a mesh of fibres and includes a variety of laminins which the RPE 
cells synthesise and adhere to. 
The second layer is the inner collagenous layer, a multilayered cross structure of collagens. 
Below that, the central layer of Bruch's membrane, is the elastic layer which is primarily a 
series of elastins forming a sheet, mixed with collagen, fibronectin and various other 
proteins; collagens from the collagenous layers can also cross into the elastic layer. The 
elastic layer is the most crucial layer of the Bruch’s membrane in resisting angiogenesis as 
well as being key in its biomechanical properties. 
The fourth layer is the outer collagenous layer which in many respects is very similar to the 
inner collagenous layer, although it also features intercapillary pillars which extend out 
between the choriocapillaries. Finally the choriocapillaris basal lamina is a very thin layer 
which is perforated by the intercapillary pillars. It is believed to inhibit cell migration into 
Bruch's membrane (Roberts & Forrester, 1990). 
It is well established that with age Bruch’s membrane undergoes a number of changes. 
There is a tendency for the membrane to thicken with age to varying extents between 
individuals. This is thought to be a result of misregulation of the extracellular matrix 
proteins leading to a build up as normal turnover is disrupted (Newsome et al., 1987). Note 
that this thickening is not uniform across the membrane; the collagenous layers tend to 
thicken at different rates (the outer layer more than the inner) and the elastic layer tends 
to thicken at a significantly lesser rate. In addition calcification of the membrane results in 
increased rigidity as a result of deposition of calcium phosphate onto elastin fibrils (Davis et 
al., 1981). 
In addition Bruch's membrane suffers from protein modification in long-lived proteins. 
Specifically the formation of advanced glycation end products (AGEs) and age-related 
lipooxidation end products (ALEs) (Curcio & Johnson, 2013). These together accumulate on 
Bruch's membrane and are a defining characteristic of ageing. In particular AGEs are the 
result of protein modification by Malliard reactions and tend to accumulate on long-lived 
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structural proteins and have been seen to effect the normal functioning of the RPE (Kay et 
al., 2014). AGEs have been heavily implicated in age-related degeneration of the retina. A 
study in ARPE-19 cells demonstrated that exposure to AGE treated basement membrane 
resulted in a mixture of up and down regulation of various mRNAs, particularly those 
related to extracellular matrix genes and signal peptides as well as lysosomal gene 
expression (Glenn et al., 2009). In addition an increase in lipofuscin accumulation was 
identified, a well-known indication of aging (Brunk & Terman, 2002). In addition an 
assortment of other proteins, such as complement components, are found to build up in 
aged Bruch's membrane. 
More significant is the accumulation of deposits on the surface of Bruch’s membrane with 
age. These are known as drusen and typically form small, hard yellow or white spots on the 
Bruch's membrane. These are a normal feature of ageing and are comprised of extracellular 
material and a mixture of proteins and lipids. However they are also linked with disease; 
large and diffuse drusen being a hallmark of AMD (AMD will be further discussed in section 
1.3). Further, the Bruch's membrane has been demonstrated to be digestable in the 
process of choroidal neovascularisation (Heriot et al., 1984), which means that it is not 
necessary for the Bruch's membrane itself to be directly damaged for invasion of the retina 
by the choroid. 
 
1.2.4 The choroid 
The choroid is a vascular structure which comprises a large network of blood vessels. Its 
purpose is to supply the retina with nutrients and oxygen, and to remove waste products. 
Closest to the Bruch's membrane is the choriocapillary layer, a high-surface-area network of 
small, fenestrated, leaky capillaries which provide a highly efficient exchange surface for 
nutrients and waste. These are supported by a network of medium sized blood vessels 
located immediately underneath this layer, which feed this capillary network, and then a 
layer of large blood vessels. Taken together these provide a significant supply of blood to 
the retina in an efficient and organised way. Finally a layer known as the suprachoroid acts 
as a transition layer between the choroid and the protective layer of the sclera. This layer 
contains aspects of both structures and effectively anchors the choroid to the sclera. In 
addition it contains large spaces which are believed to be part of the lymphatic system. 
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The primary purpose of the choroid is as a transport system of nutrients and oxygen to the 
retina and waste from the retina. Blood flow in the retina is typically extremely high and 
tightly regulated in order to ensure an optimal environment for the neuronal components 
of the eye (Pouranaras et al., 2008). However, blood flow has been shown to decrease with 
age (Emeterio Nateras et al., 2014) and in patients with  age-related macular degeneration 
(Burgansky-Eliash et al., 2014) which may lead to deficiencies of nutrients within the retina 
and insufficient removal of waste products. The RPE, Bruch's membrane and choroid all 
have been implicated in the development of AMD , with a "mutalistic symbiotic 
relationship" being disrupted in the disease state (Bhutto & Lutty, 2012). Indeed there is a 
clear link between degeneration of the choriocapillaries and the degeneration of the RPE 
layer resulting in a 50% decrease in vascular area compared with control eyes for dry AMD 
(McLeod et al., 2009). 
The choroid is also implicated in the development of and production of growth factors 
necessary for the RPE. As an example transdifferentiation of the RPE to neural retinal cells 
in embryonic mammals has long been known (Zhao et al., 1995). In addition it is known that 
the RPE of certain species of newt can regeneratively differentiate into neural retinal cells 
in a similar manner even in adults; the choroid has been demonstrated to be essential for 
this process (Mitsuda et al., 2005). In particular specific growth factors such as FGF-2 and 
IGF-1 appeared to be crucial in this development. 
In addition to the involvement of the choroid in supplying the retina and removing waste it 
is also believed to be involved in thermoregulation. There is some evidence to indicate that 
the constant high blood flow acts to maintain the retina near the body's core temperature 
by either dissipating excess heat or providing heat in the cold (Parver, 1991). However this 
view is not accepted by all, with some arguing that fluctuations in core body temperature 
would make maintaining a stable retina temperature unlikely (Nickla & Wallman, 2010).  
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1.3 Age Related Macular Degeneration 
1.3.1 Overview of AMD 
Age related macular degeneration (AMD) is a leading cause of irreversible blindness in the 
elderly population (Gehrs et al., 2006). The disease involves the progressive degeneration 
of the retinal cells in the macular region hence causing loss of central, high resolution, 
vision.  
The disease occurs in two forms which are commonly termed “dry AMD” and “wet AMD”, 
also known as nonexudative AMD and exudative AMD (Figure 1.3). The dry form of AMD is 
characterised by the formation of deposits known as drusen in the retina and a progressive, 
gradual degeneration of sight. The wet form of AMD is characterised by neovascularisation 
from the choroidal layer penetrating through the Bruch’s membrane and into the retina 
where the leaky blood vessels cause significant damage leading to vision loss. 
"Dry" AMD is caused by a progressive degeneration of the retinal layer itself, with the 
specific atrophy of the macula region. With age the RPE cells undergo a number of changes 
(reviewed by Bonilha, 2008) and in AMD they become more pronounced.  A key aspect of 
the disease progression is the formation of drusen plaques, consisting of extracellular 
debris, between Bruch's membrane and the RPE layer. These commonly occur in older 
people without AMD and in healthy individuals appear as hard yellow or white spots. 
However in the case of patients with dry AMD these spots are larger and "softer" with 
irregular shapes and a lack of a clearly defined edge.  Around ten to fifteen percent of cases 
of dry AMD lead to wet AMD (section 1.3.2). 
Although AMD disease progression can be slowed through various treatments there is no 
treatment available which will reverse the degenerative effects and restore the function of 
the retina; treatments will be discussed in section 1.3.5. Further, given our limited 
knowledge it is not possible to prevent progression entirely. A better understanding of the 
disease is thus crucial, however it is multifactorial in nature and, as such, it is difficult to 
elucidate the precise mechanism or mechanisms that lead to the degeneration. 
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Figure 1.3 Degradation of the retina with age and AMD. A is a representation of a young 
eye. B represents an ageing eye, note the small drusen deposits (arrows). C represents an 
eye with nonexudative AMD, please note the larger drusen (arrows) and degrading 
photoreceptors. Finally D represents an eye with exudative AMD, with neovascularisation 
penetrating Bruch's membrane and bleeding into the photoreceptor layer. (Author's figure)  
D 
B 
C 
A 
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1.3.2 Neovascular AMD 
Neovascular AMD is also known as exudative AMD and amongst the general population is 
commonly referred to (and widely known) as "wet AMD". As the name suggests it involves 
the formation of new blood vessels leading to damage in the retinal layer. More specifically 
following a gradual degeneration of the retina, new blood vessels develop and pierce the 
Bruch's membrane and RPE layer before growing into the retina, where blood leaks through 
the thin capillary walls causing extensive damage. 
Dry AMD has no treatments and wet AMD can be treated however the dry form is also far 
less harmful. The vasculogenesis that occurs in wet AMD leads to heavy and rapid damage 
done to significant areas of the macular region leading to rapid and extensive vision loss. 
With both scarring and the blood vessels themselves contributing to the damage. It is 
multifactorial in nature with both environmental influences such as smoking and diet 
(Seddon et al., 2006) as well as genetic factors such as the focus of this study, cystatin C.  
 
1.3.3 Similarities to other diseases 
AMD is an age-related disease which has a significant aggregation component (the 
aforementioned drusen). Studies have shown associated elements with a number of other 
age related diseases; most particularly Alzheimer's disease. 
The link with Alzheimer's disease is interesting as Alzheimer's is fundamentally a disease 
that involves aggregation of proteins into plaques. This is analogous to what happens in 
AMD given the build up of large drusen plaques in the retina which are a key hallmark of 
AMD development. However further links beyond this casual association between the 
diseases are not confirmed. Despite this certain genetic factors found to be risks for AMD, 
such as variant B cystatin C (discussed in section 1.4.5) have been linked with Alzheimer's 
disease and has been demonstrated to have impaired secretion in other cells (Benussi et 
al., 2003). Further a recent study on risk variants for the diseases suggested shared genetic 
mechanisms between the two (Logue et al., 2014). An almost equally recent population 
study in an age-matched cohort found no association between the two (Williams et al., 
2014); however another study found data supporting a possible association between the 
diseases (Rozzini et al., 2014). More recently a clear link has been shown between 
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Alzheimer's Disease and AMD, with the CST3 missense variant leading to the production of 
variant B cystatin C (section 1.4.5) being associated with both diseases in a meta-analaysis 
(Butler et al., 2015). The parallel links between AMD and Alzheimer's disease with respect 
to the presence of amyloid β protein deposition in both senile plaques in the brain and 
drusen in AMD have been reviewed by Ohno-Matsui (2011). In conclusion these similarities 
mean that therapeutic techniques for Alzheimer's disease may be applicable to AMD. 
Aggregation is, in fact, a key factor in a number of neurological diseases which are believed 
to be associated with AMD. Proteins found within drusen associated with AMD are 
common to deposits found in a number of other diseases including atherosclerosis, 
elastosis, amyloidosis and dense deposit disease (Mullins et al. 2000). The evidence for a 
relationship between AMD and atherosclerosis in particular is noteworthy, with a recent 
review noting that although there are several differences in studies between groups of 
patients there is a compelling argument to be made that AMD is associated with 
atherogenesis (Machalińska et al., 2012). It has been demonstrated, for example, that AMD 
is associated with an increased risk of certain subtypes of stroke (Ikram et al., 2012) and a 
weak relationship between carotid plaques and AMD has been identified in population 
studies (Klein et al., 2013).  
 
1.3.4 Factors associated with AMD 
As a multifactorial disease AMD is extremely complex and has a large number of 
contributory factors which are known to influence incidence of the disease. Consequently, 
trying to elucidate and target exactly how AMD arises is a difficult process. Further, 
although the RPE (section 1.2.2) is a crucial tissue involved in AMD it is not the only tissue 
involved in the process and different processes will be affected in each tissue. 
There are a number of genes that are associated with the development of AMD. Examples 
include apolipoprotein E which is involved in cholesterol metabolism and its' ε2 and ε4 
forms are associated with increased risk of AMD (Klaver et al., 1998). In addition, fibulin 5  
is a secreted extracellular matrix protein and missense mutations in this protein are 
implicated in a proportion of AMD cases (Stone et al., 2004). However perhaps the most 
notable is complement factor H (a regulatory protein of the complement system), a variant 
of which is associated with AMD and was first identified by Haines et al. (2005). This has 
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since been widely accepted as a major risk factor in the development of the disease. 
However, some proteins believed to be involved, such as TIMP3, have been eliminated as 
possibilities (De La Paz, 1997). 
In addition to these genetic factors lifestyle choices have also been implicated. Examples of 
these non-genetic factors include the combination of not smoking, having a healthy diet 
and being physically active being associated with a 71% reduced risk for AMD amongst 
women (Mares et al., 2011). Further, increased red meat consumption has been associated 
with early onset AMD (Chong et al., 2009). 
There are a wide variety of factors influencing AMD incidence and consequently a number 
of cellular processes that are connected to the disease. It is therefore difficult to ascertain 
the exact pathogenesis of the disease, with many potential targets which are likely to 
contribute but no apparent overall factor leading to development. The many contributing 
pathways also make it a difficult disease to treat as only the symptoms can be treated and 
not the underlying cause. 
One intracellular factor implicated in AMD is oxidative stress and the associated reactive 
oxygen species (ROS) which is of particular relevance to the RPE. ROS are produced in cells 
as a result of normal cellular functioning, notably from respiration in the mitochondria, 
which results in the production of large amounts of highly reactive oxidants. This can lead 
to inappropriate oxidation of cellular proteins leading to damage. Under normal conditions 
these ROS are unlikely to be harmful as cells have mechanisms by which they control the 
risk of damage. However under disease conditions there can be a build up of ROS which can 
lead to severe damage to crucial intracellular mechanisms and impairment of normal 
function in a non-specific non-directed way. This and other potential mechanisms will be 
briefly discussed in section 1.5. 
 
1.3.5 Treatments for AMD 
Although AMD damage cannot be reversed there are several therapies available to reduce 
the progression and impact of wet AMD. The most common treatment is the use of 
vascular endothelial growth factor (VEGF) inhibitors. VEGFs are signal proteins which lead 
to new blood vessel formation; by therapeutically providing inhibitors for these proteins 
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their levels can be reduced and consequently the rate and extent of formation can be 
reduced. Normally the RPE layer itself maintains a very careful balance of growth hormones 
and inhibitors, however it is apparent that this is insufficient in the case of exudative AMD. 
However this treatment cannot reverse the damage done as the inhibitors merely act to 
slow the disease progression by blocking growth signals to the blood vessels. It is worth 
noting that anti-VEGF agents are increasingly favoured over most other, older therapies 
(Hanout et al., 2013). The available anti-VEGF agents were thoroughly comparatively 
reviewed recently by Solomon et al. (2014). 
Photodynamic therapy (PDT) is a technique developed more than twenty years ago. It 
involves the injection of a light-sensitive drug into the patient and then activating it 
specifically where it is needed using a low-powered laser. For AMD treatment this is 
verteporfin; activation of the molecules by laser induces a phototoxic effect, killing the 
blood vessels. However side effects include the patient having to avoid sunlight. Further, 
although PDT slows disease progression, modern VEGF treatment has also resulted in vision 
improvement. Combination therapy of the two (plus steroids which, although having shown 
no visual improvement in clinical studies, have various other benefits such as inflammation 
inhibition) is the subject of much interest and has been reviewed in recent years (Couch & 
Bakri, 2011; Miller, 2011) but anti-VEGF monotherapy is currently preferred (Lally et al., 
2012). 
An earlier approach was the direct use of laser surgery on the eye. By utilising a laser to 
cauterise inappropriately growing blood vessels it is possible to cut off the blood supply and 
hence cause these vessels to die. This prevents further growth of the blood vessel and 
restricts the damage that it can do to the retina. As with other treatments, however, this 
does not repair any damage done, merely prevents further damage from occurring. 
Further, this treatment is limited to the specific blood vessels treated which can be an 
advantage. However this therapy tends to be less effective than others and therefore is 
only used when others cannot be, with a recent review noting it is "not recommended" for 
subfoveal choroidal neovascularisation (Virgili & Bini, 2007). 
Finally radiotherapy has been experimented with in clinical trials. The use of stereotactic 
radiotherapy has been established in cancer but more recently there have been a number 
of tests for its effect on AMD. In particular Jackson et al. (2014) have been conducting a 
study which indicates that SRT can significantly reduce the amount of injections required.  
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1.4 Cystatin C 
Cystatin C was originally identified in urine samples by Butler & Flynn in 1961 and dubbed 
"gamma trace". It was identified and measured as a plasma and cerebrospinal fluid protein 
with a significant age-related variation in concentration (Löfberg  et al. 1980). However its 
amino acid sequence was not described until 1982 when Grubb and Löfberg identified it as 
a 120 residue chain with a Mr of 13,260 Da and the protein was noted to be localised to the 
pituitary glands and proposed to be a neuroendocrine protein (Grubb & Löfberg, 1982). 
However it was also identified in a wide variety of tissues including the thyroid (Löfberg et 
al., 1983), seminal plasma (Grubb et al., 1983) and alveolar macrophages (Chapman et al., 
1990) to name but a few examples. The function of the protein as a cysteine protease 
inhibitor was finally identified in 1984 by Brzin et al. with its ability to inhibit papain and 
human cathepsins elucidated. In addition its homology with egg white cystatin was noted. 
The name cystatin C was finally proposed by Barrett et al. (1984). Following this the cDNA 
coding for the precursor protein was sequenced by Abrahamson et al. (1987a) and that the 
protein seemed to have an inhibitory effect via two binding sites (Abrahamson et al., 
1987b). The gene coding for the protein, designated CST3, was found to be located in 
chromosome 20 in 1989 (Abrahamson et al.; Saitoh et al.) and the structure of the gene 
completely described a year later (Abrahamson et al., 1990). 
As early as 1983 its potential involvement in disease was noted. Cohen et al. (1983) 
described the involvement of a protein “related to the gastroentero-pancreatic 
neuroendocrine protein, gamma trace” in hereditary cerebral haemorrhage with 
amyloidosis. This similar protein had been purified from amyloid fibrils in three Icelandic 
patients dying from the disease and identified in amyloid deposits by immunofluorescence 
microscopy. Their belief that the protein may not have been just related but actually the 
same protein was later confirmed by Ghiso et al. (1986) who noted the L68Q amino acid 
substitution near a proposed active site for the molecule. However at this stage it was 
unsure whether this was due to natural polymorphism in the protein or a point mutation in 
the coding sequence. By 1987 its involvement was clearly identified with Jensson et al. 
identifying it as a causative agent for the disease, forming amyloid fibril deposits in the 
walls of brain arteries. Today cystatin C’s involvement in what is termed Icelandic type 
hereditary cerebral haemorrhage with amyloidosis is well known; reviewed by Levy et al. in 
2006. However this was just the start in identifying cystatin C’s involvement in aggregation-
related diseases; the protein was also proposed as being involved in Alzheimer’s disease 
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(Coria et al., 1987) and eventually identified as a factor in the development of AMD 
(discussed in section 1.3.5). 
In addition it is well known as a marker for kidney function. As early as 1985 (Simonsen et 
al.) it was considered for this purpose and since then it has been demonstrated to be a 
good measure of glomerular filtration rate. The traditional method of calculating this is the 
use of creatinine which has the disadvantage of being highly heterogeneous across 
populations, varying by muscle mass, exercise and diet; cystatin C by contrast is significantly 
more uniform and therefore more reliable as a marker (Shlipak et al., 2013). 
 
1.4.1 Structure of cystatin C 
The sequence of cystatin C was first established more than twenty years ago and can be 
seen in figure 1.4. The protein is manufactured by the cell as pro-cystatin C with a mature 
120 amino acid cystatin C chain linked to a 26 amino acid targeting sequence at the N-
terminus which is essential for targeting to the endoplasmic reticulum (Paraoan et al., 
2003). 
In the normal course of processing this targeting sequence allows the protein to be 
processed through the secretory pathway and is cleaved to leave just the mature protein to 
be secreted from the cell. Consequently the protein only forms its final shape upon the 
severing of this extra length of amino acids.  
In humans it is translated from the CST3 gene which is located on chromosome 20 
(Abrahamson et al., 1989; Saitoh et al., 1989) and consists of a series of five β-strands with 
a large α-helix lying across the surface of the sheet and a short α-helix (Janowski et al. 
2001) (figure 1.5). 
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Figure 1.4 DNA sequence and primary protein structure of cystatin C. Red text is the 
precursor sequence which is cleaved during processing to produce the mature protein, 
highlighted yellow and pink are link regions, highlighted cyan is the alpha chain, highlighted 
green are the beta chains. The point mutation in the precursor leading to variant B form 
cystatin C is indicated. Sequence information from Abrahamson et al. (1986) and primary 
protein structure from Janowski et al. (2001). 
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Cystatin C has been demonstrated to be capable of dimerisation. More specifically it 
dimerises due to the process of three-dimensional domain swapping (Janowski et al., 2001) 
in which a hinge region allows for partial unfolding of the protein and combining with 
similarly unfolded proteins (Jaskólski, 2001). It has been argued that domain swapping in 
itself is enough for the formation of oligomers (Liu et al., 1998) however this process is 
known to be effected by other factors. In the case of the amyloid-associated L68Q mutant 
cystatin C (highlighted in Figure 1.4) the substitution results in a form of cystatin C that has 
a much greater tendency to dimerise and form aggregates in a manner that is temperature 
dependent (Abrahamson & Grubb, 1994). Further, it has been demonstrated that the 
tendency of this disease-causing form of the protein to form amyloid fibrils can be inhibited 
by preventing domain swapping (Nilsson et al., 2004). In short this provides strong evidence 
that the structure of cystatin C is crucial to its capacity for aggregation and ability to cause 
aggregation-related disease. 
 
 
 
 
Figure 1.5 Secondary and tertiary structure of cystatin C protein (reproduced from 
Janowski et al. 2001). It consists of a series of antiparallel β-sheets (blue) twisted around 
the large α-helix (red/yellow). The active site of the mature protein is circled in red. 
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1.4.2 Mechanism of action and function of cystatin C 
Cystatin C is an active cysteine protease inhibitor found extensively throughout the body. 
Abrahamson et al. (1990) found it to be expressed in every human tissue examined ranging 
from the kidney to the lung to the placenta. Further it is found in almost all bodily fluids 
with the highest level being seen in seminal plasma but high levels also in the cerebrospinal 
fluid and blood plasma (Abrhamson et al., 1986). 
As a member of the cystatin type 2 gene family, cystatin C is well established as an 
extracellular protease inhibitor. Consequently the protein is typically produced within the 
cell and then specifically passed to the secretory pathway (as directed by the signal 
targeting sequence) where it is processed, packaged and secreted to the extracellular 
environment. The essential role of the signal sequence in targeting cystatin C to the 
secretory pathway was demonstrated experimentally by Paraoan et al. (2003); loss of this 
signal sequence led to the protein no longer being targeted to the secretory pathway and 
instead presenting a uniform fluorescence throughout the cell, indicating it is diffused 
throughout the cytoplasm and nucleus. This clearly shows that the loss of the signal 
sequence results in the loss of protein targeting. The combination of its ubiquitous 
expression and its secretion means it is thus a very important regulator of extracellular 
protease activity. 
Cystatin C is believed to have a variety of functions related to the regulation of levels of a 
number of different proteins in various bodily fluids and is implicated in several diseases 
and processes. Furthermore it has been used extensively as a marker for kidney dysfunction 
and there is a great deal of literature available about the use of it as a biomarker. Given its 
extracellular nature and abundance, cystatin C is likely to be significantly involved in 
homeostasis and balance of proteins in extracellular fluid and the modelling of extracellular 
membranes and structures. 
In particular Cystatin C is a potent inhibitor of a number of lysosomal cathepsins (B, H, L and 
S) and papain (Turk & Bode, 1991; Barrett et al., 1984).  Especially cathepsins B, which 
cystatin C inhibits far more strongly than other cystatins (Barrett et al., 1984); despite the 
similarities in sequence between the proteins. 
Of further note is that cystatin C is a tight-binding but reversible inhibitory protein. It acts 
through the two hairpin loops and N terminus as seen in figure 1.5 and fits into the active 
39 
 
site of papain (for example) (Bode et al., 1988). The binding mechanism is functionally 
similar to how small serine inhibitors work, specifically by binding at the protein active site 
thus blocking it from use. However it is worth noting that the mechanism itself is quite 
different  to the mechanism typically observed for small serine inhibitors. 
Specifically in small serine inhibitors the inhibitor binds to the active site of the enzyme in a 
manner much like that of a substrate, with the blocking effect being a direct blockage of the 
active site in a “lock and key” type way (Laskowski Jr. & Kato, 1980). For cystatin C, 
however, the binding sites are dissimilar to a bound substrate, yet it still binds to the active 
site (Bode et al., 1988). Note that this original model was based upon chicken cystatin, 
however later experiments demonstrated that this model for binding was also applicable to 
human cystatin C (Lindahl et al., 1992). 
Therefore, to inhibit cysteine proteases cystatin C does not impersonate a substrate but 
does block the active site itself, preventing the binding of a substrate and therefore 
blocking the activity of the protease. Specifically the N-terminal region binds to the protein. 
 
1.4.3 Cystatin C in the eye 
Cystatin C is found in a wide variety of tissues and fluids in the body. However for the 
purpose of this work the most crucial site of expression is within the eye, where it is found 
in high abundance. Specifically cystatin C has been found to be expressed at extremely high 
levels in the retinal pigment epithelium (top 0.2% of expressed proteins) as well as in the 
ciliary epithelium (Paraoan et al., 2000; Paraoan & Grierson, 2007). 
Cystatin C was originally identified as being expressed in the eye in rats, with cystatin C 
mRNA being detected in total RNA extractions from the sclera and retina (Barka & van der 
Noen, 1994).  In humans it was identified as being significantly expressed in the retina, as a 
result of analysis of expressed sequence tags in the RPE (Paraoan et al., 2000). Cystatin C 
was identified as one of the most abundantly expressed transcripts within the RPE and 
consequently was noted as likely being of great importance to the normal functioning of 
the retina. 
This was later confirmed by the finding that the protein was mainly localised to the RPE in 
rat, mouse and human eyes (Wassélius et al., 2001) and it was suggested that the protein 
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might be involved in regulation of photoreceptor degradation. However cystatin C was 
found to co-localise with the Golgi apparatus and to be processed through the secretory 
pathway under normal conditions and passed out of the cell which was confirmed by the 
detection of cystatin C in cell culture media (Paraoan et al., 2001). 
Within the RPE cystatin C is secreted from the basolateral side of the layer (Paraoan et al., 
2001). With the amount of protein produced combined with its directional secretion it 
seems likely to have a crucial role in protein turnover in this region and consequently on 
the effectiveness of Bruch’s membrane in its protective and supportive role 
Despite the high level of expression in the retina cystatin C isn't totally segregated in the 
eye. It has also been found in a variety of tissues of the anterior eye also particularly in the 
ciliary epithelium (Wassélius et al., 2004), as well as having been documented as being 
taken up by a variety of cell types, many of which have been shown to contain endogenous 
cystatin C suggesting its importance in those tissue types and consequently a potentially 
crucial role in the eye as a whole (Wassélius et al., 2005).  
 
1.4.4 Cystatin C in disease 
Given its ubiquitous expression throughout the body it is to be expected that Cystatin C is 
implicated in different key physiological functions, which in turn may be involved in 
diseases ranging from cancer to neurodegeneration. Furthermore it has also been 
established as a kidney function biomarker (Filler et al., 2005) with applications to 
cardiovascular disease (Angelidis et al., 2013) due to its involvement in modulation of 
atherosclerotic plaque formation along with cathepsins (Bengtsson et al., 2008). Cystatin C 
is known to be involved in such diverse diseases such as Alzheimer's, hereditary 
amyloidosis, Parkinson's disease, and atherosclerosis. Cystatin C has also been linked to a 
number of eye diseases including congenital X-linked retinoschisis (Joshi et al., 2006; 
Drenser et al., 2007) and retinitis pigmentosa (Ahuja et al., 2008). Beyond these, however, 
cystatin C has been most associated with age-related macular degeneration itself; more 
specifically the association of variant form of the protein known as variant B with 
development of exudative AMD. 
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Alzheimer's disease is well established as an aggregation disease with the build up of 
amyloid β forming amyloid deposits in the brain being a characteristic factor. Of note is that 
cystatin C has been found to co-localise with amyloid β in these plaques. It was found that 
overexpression of cystatin C could lead to reduction of the deposition of amyloid β (Kaeser 
et al., 2007) implying a protective role in Alzheimer's disease by binding soluble amyloid β 
(Mi et al., 2007) Further, there have been links drawn between Alzheimer's disease and 
cystatin C polymorphisms; this has been extensively reviewed by Kaur & Levy (2012). 
Although there is evidence to show that certain polymorphisms believed to be involved in 
the pathology of the disease are not, and that the cystatin C deposition is a secondary 
event (Parfitt et al., 1993). 
In addition another major disease cystatin C is known to be involved in the pathology of 
cerebral amyloid angiopathy (Icelandic type). A variant of cystatin C was identified as being 
the major constituent of the fibrils produced in this disease (Ghiso et al., 1986) and this was 
later identified to be a polymorphism resulting in a Leu68Gln variant being produced 
leading to the disease. Interestingly, wild type cystatin C is also sometimes found co-
localised with amyloid beta in cerebral amyloid angiopathy and this increases the severity 
of the disease; furthermore evidence suggests that  cystatin C itself could be involved in 
neuronal cell death by apoptosis (Nagai et al., 2008). 
 
1.4.5 Cystatin C variant B 
In 2002 a study by Zurdel et al. discovered that a variant form of cystatin C led to a nearly 
threefold, statistically significant, increase in the risk of developing exudative AMD.  This 
variant, known as variant B, is the result of a single point mutation within the signal 
sequence leading to an A-25->T amino acid substitution. This small change results in drastic 
changes to how RPE cells handle the produced molecule. A subsequent study by Paraoan et 
al. (2003) demonstrated that cystatin C lacking the leader sequence was not processed as 
normal through the secretory pathway of RPE cells, lending support to the hypothesis that 
the leader sequence is a contributing factor to increased risk of AMD. 
Finally another study by Paraoan et al. (2004) demonstrated that the AMD-associated 
variant similarly suffered from a mistrafficking within the cell. Contrasting with the normal 
secretory pathway processing that wild-type cystatin C undergoes, a large amount of the 
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variant B form does not pass into the secretory pathway. Instead the modified signal 
sequence causes the molecule to be retained within the cell in large amounts, leading to a 
build-up of the protein. However rather than just concentrating within the cytoplasm or 
being efficiently degraded, the variant form has been found to associate with the 
mitochondria within the RPE cells.  
Interestingly a different mutation at the same site artificially created by Ratnayaka et al. 
(2007) resulted in an intermediate effect on the protein. Rather than the Ala25Thr 
substitution of variant B this Ala25Ser mutation led to a distribution to both the Golgi 
apparatus and the mitochondria, with secretion being between variant B and wild type 
cystatin C. The implication being that an amino acid substitution with a less hydrophobic 
amino acid is sufficient change to result in the mistrafficking seen with the variant B. A 
study by Benussi et al. (2003) on the same cystatin C variant in skin fibroblasts identified 
reduced secretion as a result of less efficient cleavage of the signal peptide; with reduced 
cystatin C secretion into conditioned media from B/B homozygous fibroblasts and less 
efficient cleavage of a variant B signal peptide-GFP construct. 
Given the large number of functions of the RPE and the heavy metabolic activity required 
for these processes it is likely that this build-up of cystatin C intracellularly would interfere 
with normal cellular functioning. A breakdown in cell function in an area of the RPE would 
lead to a harmful reduction in the capability of the RPE to maintain the extracellular 
environment and protect the photosensitive cells from damage. This is the primary effect 
observed thus far of the variant B change. Given the association with AMD we believe that 
the increased risk is caused by a combination of the reduced secretion of cystatin C and its 
build-up within the cell. This could potentially have a significant effect on the mitochondria 
given the association, however we do not know how the variant B cystatin C becomes 
associated in this way. However it has been noted that cystatin C expression increases with 
exposure to oxidative stress (Alizadeh et al., 2006). Given that oxidative stress is a hallmark 
of AMD it is possible that the variant B protein interferes with the generation of ROS and 
consequently contributes via this mechanism. 
In short, it is well established that variant B cystatin C is a factor in the development of 
exudative AMD. It is also well established that the variant is retained intracellularly to a 
great extent with a consequent reduction in the amount secreted. What is not know, 
however, is how either of these two events occur and what are their functional 
consequence. This is what we seek to make the first steps towards addressing. 
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1.5 Key intracellular processes investigated 
1.5.1 Overview 
The mislocalisation of the variant B form of cystatin C raises a number of questions over its 
effect on the mitochondria. Given the crucial importance of the mitochondria in normal 
cellular functioning it seems likely that this inappropriate association with a protein that is 
primarily extracellular could result in impairment of such functions.  
For this study we selected a number of important intracellular processes which have been 
associated with the mitochondria or age-related macular degeneration or both. Our 
intention being to see if the inappropriate intracellular retention of the variant B protein 
results in disruption in a specific mechanism or mechanisms and consequently informing 
our knowledge of the process or processes by which the increased risk occurs. 
 
1.5.2 Respiration 
1.5.2A The respiratory process 
The most important function of the mitochondria is the production of energy from glucose 
in the form of adenosine triphosphate (ATP) by the respiratory process. This involves a 
number of ATP producing steps however the majority of ATP is generated through a 
process of oxidative phosphorylation. A series of proton pumps at the inner mitochondrial 
membrane, powered by electrons generated by the Krebs cycle, generate an ionic gradient 
which is used to power ATP synthase, generating ATP (figure 1.6). Consequently this is the 
most crucial process to begin addressing as impairment of the generation of energy would 
lead to drastic effects on the cells. 
Interfering with any part of this process could lead to significant impairment of normal 
cellular function in general for any type of cell. A recently published study by Zhang et al. 
(2014) on ATP production in Alzheimer’s disease used a mouse model to demonstrate 
reduced levels of ATP in the brain of affected mice compared with normal control mice; 
with the effect being more pronounced with the increased age of the mice (and hence the 
maturity of Alzheimer's disease pathology). 
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1.5.2B Respiration in the RPE 
Given the wide variety of processes in the RPE which are a requirement of its ability to 
maintain and support the retina and  to ensure the stability of the surrounding 
environment it is possible that disruption of energy generation could lead to the loss of 
homeostatic balance and damage to the retina. In addition due to AMD being an age-
related disease this question is highly relevant. Impairment of mitochondrial respiration 
with age has been established in other tissues and is believed to be due to interference 
with the electron transfer chain (Navarro & Boveris, 2010). The combination of the ageing 
degeneration of capacity for ATP production (Chistiakov et al., 2014) coupled with 
interference from variant B cystatin C has the potential to result in severe detrimental 
effects on the RPE and early onset of disease. In particular it has been noted that reduction 
in ATP levels in human RPE cells can lead to increased oxidative stress and reduced 
phagocytic and autophagic capacity (Schütt et al., 2012). 
A specific example of the importance of ATP in the RPE in particular is highlighted by 
Bergmann et al. (2004). Proton pumps in the lysosomal membrane are crucial in the 
process of maintaining RPE functions such as degradation of photoreceptor outer 
segments. These pumps are ATP-driven and it was shown that A2-E was able to inhibit 
them, with subsequently observed increased intracellular accumulation of photoreceptor 
outer segments. Given the ATP-driven nature of these pumps it is logical to conclude that a 
reduction in the availability of ATP could result in a similar decrease in phagocytic activity in 
the lysosomes. 
Although there is at this time no specific prior evidence relating variant B, respiration and 
AMD it seems undeniable that interference with the respiratory cycle would be severely 
disruptive to the RPE cells. Given the mitochondrial localisation of variant B it is a critical 
process to address in this study.  
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Figure 1.6 Schematic diagram of the mitochondrial electron transport chain. The majority 
of ATP generated in the mitochondria is via the electron transport chain. Electrons sourced 
from the citric acid cycle (or Kreb's cycle) are passed along the chain, causing H+ ions to be 
pumped out of the matrix and setting up an electrochemical gradient across the inner 
mitochondrial membrane. This gradient thus causes the diffusal of H+ ions back into the 
matrix through ATP synthase, which powers the generation of ATP via oxidative 
phosphorylation of ADP (public domain image, Wikimedia commons).  
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1.5.3 Apoptosis 
Given that age-related macular degeneration is a degenerative disease there is interest in 
the process of apoptosis and its potential association with the development of the disease.  
A recent study on apoptosis by Bhattacharya et al. (2012) identified that p53-dependent 
apoptosis increased in an age dependent manner in human RPE cells via the caspase 3 
pathway (figure 1.7 illustrates the caspase pathways of apoptosis). The study concluded 
that alterations to apoptotic checkpoints in the RPE led to the increase basal rate of 
apoptosis. 
Of particular interest is that JNK inhibition in a mouse model of wet AMD has been shown 
to reduce apoptosis and neovascularisation (Du et al., 2013). Further, a pan-caspase 
inhibitor in the same mouse model also results in reduced choroidal neovascularisation, 
implicating apoptosis in this process. JNK is well establshed as having a role in apoptosis, 
specifically via Bcl2 and Bax ultimately leading to the caspase cascade (Dhanasekaran & 
Reddy, 2008). 
Further, cystatin C has become well established as being involved in the process of 
apoptosis in neuronal cells. It has been implicated in apoptosis activation via a JNK-
dependent pathway via increased levels of active Bax protein (Liang et al., 2011) and more 
recently as a trigger in multiple system atrophy (Suzuki et al., 2014). This supports the 
suggestion that cystatin C variant B may result in inappropriate effects on the apoptotic 
pathways within the cell. 
Preliminary work in our lab suggests activation of the apoptotic pathway in RPE cells 
expressing variant B protein (unpublished data). However it is worth noting that despite 
apoptosis being cited frequently as being involved in AMD, some molecular studies suggest 
that other cell death and degenerative pathways may be more significant (Ardeljan et al., 
2014). Given that caspase 3 has long been identified as being a key part in the normal 
caspase cascade leading to apoptosis (Slee et al., 1999), coupled with the preliminary work 
suggesting its activation, it is crucial to properly examine this part of the apoptotic pathway. 
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Figure 1.7 The caspase dependent apoptotic pathway. There are two primary routes of 
caspase-dependant apoptosis. One is by the extrinsic pathway in which FasL binds at the 
cell membrane, leading to a chain of reactions via caspase 8 which concludes with caspase 
3 activation and the triggering of apoptosis. The intrinsic pathway involves the triggering of 
the release of cytochrome C from the mitochondria which also leads to the activation of 
caspase 3 and triggering of apoptosis. Caspase 3 therefore represents a point at which 
apoptosis  as a whole via these processes can be monitored. (Clarke & Tyler, 2009) 
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1.5.4 Autophagy 
Autophagy is a crucial process in all cells and is required for the turnover of proteins and 
organelles (including mitochondria). Without this recycling process defective proteins and 
misfunctioning organelles could build up within a cell, severely hampering its ability to carry 
out its normal functions. Not only would this result in the loss and lack of replacement of 
those which are damaged, but it can result in the processes being actively interfered with 
due to loss of control and misregulation. 
This is of particular importance to the RPE cells; their function as a support tissue 
necessitates them to carefully modulate their environment and maintain themselves 
intracellularly. They have a number of roles (discussed in chapter 1.2.2) which require them 
to process waste products from the photoreceptors. Autophagy has long been cited as a 
possible key process in the development of AMD (Kaarniranta et al., 2013), with the 
accumulation of lipofuscin being cited as particularly relevant (Blasiak et al., 2014). 
Autophagy has been clearly implicated in the development of drusen, with Atg5 (an 
autophagic maker) being present in drusen of aged eyes (Wang et al., 2009). In short, 
preservation of autophagy results in healthier cells and a slower cellular ageing process; 
whereas dysfunction results in poorer cell function and damage to RPE cells (Kaarnirnanta, 
2010). 
A recent study has firmly established a link between autophagy and oxidative stress; with 
the impairment of autophagy likely to exacerbate oxidative stress, thus contributing to 
development of AMD (Mitter et al., 2014).  It was noted that autophagy appeared to be 
impaired in both animal model eyes and in human donor AMD eyes in comparison with 
control eye specimens, which presented an age-related increase in autophagy. 
This recent development is of great interest to the field of AMD research. However it stands 
in contrast to the way in which cystatin C acts in the brain. Cystatin C has been identified as 
an inducer of autophagy in the brain which acts as a protective mechanism against 
neurodegeneration (Gauthier et al., 2011; Liu et al., 2013). This implies that the 
inappropriate processing of cystatin C resulting from the variant B phenotype (and thus 
deficiency of mature cystatin C) may well be a causative factor in AMD development. 
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1.5.5 Oxidative Stress 
1.5.5A Oxidative stress and ageing 
Oxidative stress is a well established feature of both ageing and age-related diseases. It has 
long been established as a method by which cells are damaged and has been extensively 
linked to the mitochondria. It was believed to be central to the gradual degradation of cells 
over time. Additionally the oxygen supply in the choroid is not autoregulated by the oxygen 
levels of the tissue (Shen et al., 2003). 
Indeed, until recently one of the foremost theories on the process of ageing was based 
heavily on the principle of oxidative damage resulting from mitochondrial by-products. This 
was termed the mitochondrial free radical theory of ageing and was extremely popular as a 
fundamental explanation of why ageing occurs. It has its roots in a paper published by 
Harman in 1956 which postulated that ageing was the result of accumulated oxidative 
damage to cells. This theory was refined and added to following the identification of the 
mitochondria as both a source and target for oxidative stress and the later identification of 
the mitochondrial genome, in particular, being of key importance due to the lack of repair 
mechanisms in mitochondria (Fleming et al, 1982; Miquel & Fleming, 1984; Miquel, 1991). 
The theory states that the accumulation over time of DNA damage within mitochondria 
results in the production of more ROS and a decrease in mitochondrial capability and 
resistance to damage leading to further increases in ROS production and cellular damage 
and loss of respiratory functioning. In short, a vicious cycle of loss of energy production 
leading to increased ROS production as a result of mitochondrial DNA damage leading to 
further loss of energy production (Miquel, 1991 ). 
More recent developments, however, have thrown doubt on this theory. Despite the 
substantial amount of evidence in support of it, questions were raised around the fact that 
the evidence was largely circumstantial (Jacobs, 2003) and that the discussion around the 
hypothesis had become influenced by personal opinions. To quote Jacobs (2003): 
"...opponents of the hypothesis tend to define it in such a narrow and extreme way that it is 
almost self-evidently falsified by generally accepted facts. Conversely, its proponents are 
liable to state the theory in such a vague and general way that it is virtually unfalsifiable 
experimentally." 
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Jacob's 2003 paper reviewing the literature behind the theory to that point and calling into 
question the design of experiments attempting to prove or disprove the theory was in itself 
controversial; with a rebuttal posted shortly afterwards (Pak et al., 2003). However it is an 
issue which remains highly topical, being extensively reviewed to this day and inadequately 
proven neither correct nor incorrect (Sanz & Stefanatos, 2008; Barja, 2013; Edrey & Salmon, 
2014; Shokolenko et al., 2014). To summarise the literature indicates that although the 
mitochondrial free radical theory of ageing may require revisions, and despite the fact that 
it seems unlikely that mitochondrial DNA damage is the central cause for ageing, the 
mitochondria and oxidative stress are still a central featuring of the ageing process and are 
of significant interest. 
Further, oxidative stress is implicated as a factor in a number of age-related diseases such 
as diabetes (Maritim et al., 2003), cancer and neurodegenerative diseases (Thanan et al., 
2014). Conversely it is also known that a lower level of oxidative stress than that which 
causes damage is beneficial for both ageing and resistance to age-related diseases (Yan, 
2014). With a number of processes being regulated by moderate levels of ROS including 
ageing itself (Sena & Chandel, 2012). The explanation for this appears to be that the specific 
level of oxidative stress is critical; a very low basal level maintains homeostasis within the 
cell whilst a moderate level results in adaptation to the stress, however severe oxidative 
stress leads to cellular damage and death (Yan, 2014). 
 
1.5.5B Oxidative stress in the eye and AMD 
Oxidative stress is a major issue in the eye. The significant amount of ROS naturally 
generated by the mitochondria within the cells is coupled with a high level of additional 
stress caused by photo-oxidation given the exposure of the eye to light. This is further 
exacerbated by the high metabolic activity levels in the photoreceptor cells, with a 
consequent high level of oxygen consumption (Shen et al., 2005) resulting in an inherently 
highly oxidised environment. 
For the RPE this can be very damaging. Damage to the RPE and its mitochondria as a result 
of oxidative stress has been documented (Cano et al., 2014) and the ageing process has 
been demonstrated to lead to degradation of mitochondria and weaker antioxidant 
defences even as early as 62 (He & Tombran-Tink, 2010). Oxidative stress has been 
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associated with a variety of eye pathologies including cataracts (Spector, 1995), glaucoma 
(Zanon-Moreno et al., 2008) and AMD. 
AMD in particular has been well known for its association with oxidative stress for many 
years. Fifteen years ago an extensive study of the literature by Beatty (2000) stated: 
"There is no shortage of research into the relationship between oxidative stress and AMD, 
but firm evidence of a causal link is still lacking." 
Since then, additional research has been carried out but with many different factors 
contributing to AMD risk it has proven to be a very complicated disease. It was only 
recently that a study specifically identified that tissue specific induction of oxidative stress 
in the mouse RPE led to retinal degeneration, in a similar manner to that in dry AMD (Mao 
et al., 2014). This is further evidence that a contributing causative effect of  AMD is 
oxidative stress, but is evidence against it being the central cause due to lack of other 
features of the disease such as drusen. 
 However it is noteworthy that the association of age-related structural changes to the RPE 
with oxidative stress and decline in function has been established for a number of years 
(Bonilha, 2008).  With oxidative stress also being implicated in other processes, such as 
apoptosis, with an association with AMD it is an extremely attractive possibility for the 
mechanism of action by which variant B cystatin C could work; despite some reservations in 
recent work as to its involvement as the possible primary causative factor for AMD.  
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1.6 Project aims and objectives 
We hypothesise that the inappropriate localisation and intracellular retention of cystatin C 
leads to detrimental effects in the retina and on the RPE cells in particular. Thus 
contributing to development of AMD. 
This project aims to further the understanding of the effects of variant B cystatin C on 
retinal pigment epithelial cells and the mechanisms by which this occurs. This, in turn, will 
further our understanding of the possible ways in which homozygous variant B cystatin C 
results in an increased risk of exudative age-related macular degeneration. 
We examined a selection of intracellular processes of RPE cells as follows: 
 Assessed the effect of variant B cystatin C on respiration rate and total ATP content 
in the cell. This allows for any impact on energy production or turnover of the ATP 
produced to be identified. 
 Examined autophagy and apoptosis markers upon overexpression of variant B 
cystatin C, these are both crucial degradation processes which involve the 
mitochondria and are implied in AMD disease progression. 
 Tested variant B cystatin C's influence on oxidative stress in cells through levels of 
reactive oxygen species. Given the extensive involvement of oxidative stress with 
the retina and its implied involvement in AMD and the crucial role that 
mitochondria have with respect to the production of reactive oxygen species this 
was a major goal. 
 
In addition we sought to identify possible binding partners of cystatin C intracellularly using 
mass spectrometry. This was done in order to provide insight into possible interacting 
proteins or chaperones. Proteins identified by this study may help explain how and why the 
variant B protein becomes mitochondrially mislocalised and therefore represent an 
excellent starting point for further studies on this process. 
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Chapter 2 
Materials and Methods 
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2.1 Mammalian cell culture 
2.1.1 Mammalian cell lines cultured 
All experiments were carried out using human-derived immortalised cell lines. RPE cell lines 
are well established and are highly suitable as models of the in vivo tissue when properly 
maintained. Cultures chosen are detailed below, figure 2.1 contains representative images. 
ARPE19 – A well established human retinal epithelial cell line developed and characterised 
by Dunn et al. (1996). Origin: Some departmental stocks, some ATCC, Virginia, United 
States. Primarily used for preliminary work. 
D407 – A human retinal epithelial cell line described by Davis et al. (1995). Origin: Gifted by 
Dr. T. Michael Redmond. These were preferred in later experiments over ARPE19 due to 
good morphological similarity to RPE cells in vivo, faster growth and higher transfection 
rates.  
HeLa – well established human tumour cell line. Origin: Departmental stocks. Used rarely as 
a control cell line for some experiments. 
Limitations of cultures used 
The D407 cell line chosen as the primary cell line for experimental work and was utilised 
extensively. However D407 cells  have several limitations noted by Davis et al. (1995).  
Particularly notable is the loss of pigment however this is a common occurrence for RPE 
cells unless they are foetal in origin. Their apical microvilli are also shorter than those of 
RPE cells in vivo. Further, they express S100 protein which has been associated with 
transformed cells (as this is a spontaneously transformed cell line). 
ARPE19 cells were used for some of the preliminary work, they have been characterised 
recently as representing a "pathologic or aged RPE" (Ablonczy et al., 2011). For the purpose 
of attempting to identify the induction of age-related effects through variant B cystatin C 
overexpression it was judged more appropriate to use D407s for the majority of work in 
this study. 
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Figure 2.1 Bright field images of ARPE-19 cells (A) and D407 cells (B). ARPE 19 cells 
typically presented with an elongated morphology until they grew to a high density, at 
which point they would start to form clusters of cobblestone-like areas. In contrast D407s 
readily and rapidly formed a cobblestone, RPE-like layer; however unlike the ARPE19 cells 
they would begin to grow in layers on top of one another after forming a monolayer. Scale 
bars are 100 µm.  
A 
B 
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2.1.2 Maintenance of cultures 
ARPE19 and D407 cells were grown in Dulbecco’s Modified Eagle’s Medium/Nutrient 
Mixture F-12 Ham supplemented with L-glutamine, 15 mM HEPES, and sodium bicarbonate 
(Sigma-Aldrich Company Ltd., Dorset, England) and was supplemented in our laboratory 
with 10% Foetal Calf Serum (Sigma-Aldrich Company Ltd., Dorset, England) to facilitate 
rapid cell growth. 
HeLa cells were grown in Dulbecco’s Modified Eagle’s Medium (Sigma-Aldrich Company 
Ltd., Dorset, England) supplemented with 1% L-glutamine (Sigma-Aldrich Company Ltd., 
Dorset, England) and 10% Foetal Calf Serum (Sigma-Aldrich Company Ltd., Dorset, England). 
All cell cultures were grown at 37oC, 5% CO2 and were split using the following procedure 
(numbers for commonly-used T75 flask, scaled depending on culture vessel). Cells were 
washed 1-3 times with 10 mL phosphate buffered saline (PBS) (Thermo Fisher Scientific Inc., 
Waltham, United States). 2.5 mL Trypsin-EDTA (Sigma-Aldrich Company Ltd., Dorset, 
England) was added to the cells and the flask returned to the incubator until all cells were 
detached. To neutralise the trypsin ~9 mL warmed complete media was added and the cell 
suspension transferred to a 30 mL tube. This was centrifuged at 200 g for 3-5 minutes and 
the supernatant removed, leaving just the cell pellet. The cell pellet was then resuspended 
in 10 mL media. Cells were seeded into flask with pre-warmed media added until total 
volume in flask was 10 mL and gently shaken to ensure cells were distributed across the 
surface before returning to incubator. 
Cell counts, where appropriate, were carried out on a haemocytometer using a microscope. 
Typically this was either for the purpose of loading equal amounts of cells in an experiment 
or for appropriate levels of seeding into plates or flasks. 
Given the extensive use of D407 cells the experimental seeding rate was crucial. 
Throughout this work the rate typically ~350,000 cells per well for a 6 well plate, ~2.5 
million cells for a T75, this resulted in the vessels becoming confluent or close to confluent 
in ~3 days, with a large number of cells even after 2 days. To reduce the rate of splitting for 
general maintenance of cultures non-experimental T75s were routinely seeded at ~1 
million cells or less which reduced the confluence to around every 5 days. Given that a T75 
flask typically yielded between 15 and 20 million cells this would seem to agree with a 
published D407 doubling time of ~24 hours (Papadaki et al., 2010). ARPE19 cells meanwhile 
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were typically seeded for normal growth at around 1.5 million cells per T75 flask and 
typically resulted in around 5-6 million cells per flask by day 5 of growth. This also seems to 
agree with a recently published ARPE-19 doubling time of 55-65 hours (Iloki Assanga et al., 
2013). HeLa cells were typically seeded at ~1 million cells per T75 and, similarly to D407s,  
appeared to have a doubling time of around 24 hours. 
2.1.3 Freezing and thawing cells 
Cells were stored as frozen aliquots in liquid nitrogen to ensure their viability. Freezing cells 
was achieved as follows, the volumes are for a T75 flask and scaled for smaller or bigger 
culture vessels. Cells were washed 1-3 times with 10 mL phosphate buffered saline (PBS), 
following this 2.5 mL Trypsin-EDTA was added and cells were returned to the incubator 
until they were detached. Trypsin was neutralised with the addition of ~9 mL warmed 
complete media and cell suspension was transferred to a 30 mL tube. The cells were 
pelleted in a centrifuge at 1000 rpm for 3-5 minutes. The supernatant was removed and 
discarded and the cell pellet resuspended in 900 µL cold media with 20% FCS. The cell 
suspension was then transferred to a cryovial, 100 µL dimethyl sulfoxide (DMSO) (Sigma-
Aldrich Company Ltd., Dorset, England) was added and the tube sealed. Tubes were frozen 
at a rate of -1oC/minute in a -80oC freezer overnight. The frozen cryovials were transferred 
to liquid nitrogen storage. 
To thaw the cells, the cryogenic vial was removed from the liquid nitrogen, the cap 
loosened and the vial placed into a 37oC water bath to thaw. The cells were transferred to 
fresh flasks containing prewarmed media before overnight incubation at 37oC, 5% CO2. 
Following this the flasks were checked by light microscopy to ensure cells had settled and 
attached and the media was replaced in full with fresh, warmed media. 
 
2.1.4 Transfection 
Transfection was carried out using two types of transfection reagent. FuGENE 6 (Roche 
Applied Science, Indianapolis, United States) was used initially but resulted in relatively 
lower transfection efficiencies. TurboFect  (Thermo Fisher Scientific Inc., Waltham, United 
States) was used later and resulted in a higher transfection efficiency. 
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Transfection methods were as follows (volumes for a 6 well plate, scaled appropriately for 
different sized culture vessels based on manufacturer’s guidelines): 
FuGENE 6 
Cells were seeded at ~ 100,000 cells per well then stored in the incubator until the 
transfection complex was ready to be added. This consisted of 3 µL of FuGENE 6 reagent 
added to 100 µL serum-free medium and mixed. This FuGENE/Media mixture was then 
incubated at room temperature for ~5 minutes. Following this incubation 1 µg plasmid DNA 
was added with the tube again flicked several times to mix and incubated for at least ~15 
minutes at room temperature. Finally the complex was added to the wells and the plate 
gently swirled to ensure distribution throughout the media. The plate was then returned to 
the incubator until cells were to be used. One advantage of FuGENE 6 was that the 
transfection complex could be left on as it was not toxic to the cells. 
TurboFect 
Cells were seeded at ~350 ,000 cells per well the day before transfection with incubation at 
37oC, 5% CO2 overnight (~16-20 hours) in 4 mL medium. This allowed for the cells to settle, 
adhere to the surface of the culture vessel and begin to grow. 
For the transfection complex, 2-6 µg DNA (optimised per batch of DNA) was added to 400 
µL serum-free medium and 6 µL TurboFect to the DNA/media mixture. The tube was flicked 
several times to mix and then incubated for 20 minutes at room temperature. The mixture 
was then added to the cells and the plate returned to the incubator overnight. Unlike 
FuGENE the complex had to be removed if cells were to be kept more than 24 hours as the 
reagent was shown to kill the cells if incubated for longer. 
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2.2 Plasmids 
2.2.1 Plasmid constructs used 
2.2.1A EGFP-based 
The plasmid pEGFP-N3 (Clontech) was the backbone vector for EGFP-cystatin C constructs 
for both wild type cystatin C and the variant B form (figure 2.2). These were previously 
developed and described in Paraoan et al. (2001) and were used extensively throughout 
this work for overexpressing the two forms of the protein within cells. 
The primary advantage of these constructs is the ease by which they can be imaged. Given 
that the EGFP tag is attached to the protein, it is visible with a fluorescent microscope 
(excitation maximum 488 nm, emission maximum 507 nm) thus allowing for the localisation 
within the cell to be easily visualised. 
 
2.2.1B HaloTag-based 
Cystatin C-HaloTag plasmids were produced for both wild type cystatin C and variant B 
cystatin C for the purpose of mass spectrometry experiments; the backbone plasmid for 
these constructs is presented in figure 2.3. HaloTag is a relatively new technology which 
relies upon a proprietary protein tag. This tag is not fluorescent itself but is flexible and 
specific, with the ability to covalently link to a corresponding ligand. As the reactive linker is 
identical for all HaloTag this allows it to be used for a variety of purposes. For this study the 
most relevant aspects are the capability for it to be fluorescently imaged intracellularly by 
the addition of a ligand attached to a fluorescent marker and the ability for it to be pulled 
down from cell lyates in a highly specific way by the addition of the ligand attached to 
agarose beads. 
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Figure 2.2 Plasmid map for pEGFP-N3 plasmid used for EGFP constructs. Cut sites for 
insertion are highlighted in red. Confirmation cut site within the plasmid (with 
corresponding cut in the cystatin C gene) highlighted in blue. (From BD Biosciences 
Clontech pEGFP-N3 protocol sheet PT3054-5) 
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Figure 2.3 Plasmid map for pHTC Halotag plasmid used for Halotag constructs. Cut sites 
for insertion of cystatin C are highlighted in red. (From Promega pHTC HaloTag® CMV-neo 
Vector Product Information sheet, 9PIG771) 
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2.2.2 Bacterial transformation for routine amplification 
50 µL of Competent Library-Efficiency DH5α E. coli and 15-30 ng of plasmid DNA were 
transferred to a chilled 1.5 mL tube on ice and mixed. Following 30 minutes of incubation 
the cells were heat shocked for 1.5 minutes at 42oC. The cells were returned to the ice for 2 
minutes before 350 µL SOC medium (Life Technologies, Thermo Fisher Scientific Inc., 
Waltham, United States) was added. 
The bacteria were incubated at 37oC for 1.5 hours on an orbital shaker at ~200 rpm before 
plating onto LB agar plates containing 50 µg/mL kanamycin sulfate (Sigma-Aldrich Company 
Ltd., Dorset, England) for EGFP constructs or 100 µg/mL ampicillin (Sigma-Aldrich Company 
Ltd., Dorset, England) for HaloTag constructs. Bacteria were plated at either 200 µL of 
culture per plate or 100 µL on one plate and 300 µL on the other to ensure that individual 
colonies could be picked. Plates were then incubated overnight at 37oC before storage at 
4oC. 
 
2.2.3 Plasmid preparation from transformed bacteria 
Plasmid preparations were carried out using QIAGEN kits; the QIAGEN Miniprep Spin kit and 
the QIAGEN Endofree Maxi-prep kit (QIAGEN, Limburg, Netherlands). 
Specifically Miniprep kits were used to extract and confirm the presence of plasmid in the 
bacterial cells and to transfer plasmid from one bacterial strain to another. For this purpose 
10 mL of Luria broth containing appropriate antibiotics was inoculated with a single colony 
of bacteria and incubated overnight with shaking at ~180 rpm at 37oC. DNA was then 
extracted following the manufacturer's instructions. 
Endofree kits were used to produce endotoxin free DNA stocks suitable for our experiments 
in mammalian cells. These kits incorporate an extra endotoxin removal step to ensure that 
the DNA is suitable for tissue culture applications. A single colony of bacteria was 
inoculated into 10 mL of Luria broth containing appropriate antibiotics and the culture was 
incubated for 6-8 hours at 37oC with orbital shaking at ~300 rpm. From this initial starter 
culture 200 µL was inoculated into 100 mL of Luria broth and then incubated overnight at 
37oC with orbital shaking at ~180 rpm. DNA was then extracted following the 
manufacturer's instructions. Quantification was carried out by use of either a Nanodrop 
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(Thermo Fisher Scientific Inc., Waltham, United States) or Qubit with dsDNA kit (Life 
Technologies, Thermo Fisher Scientific Inc., Waltham, United States). 
 
2.2.4 DNA Restriction digestions and agarose gel electrophoresis 
Plasmids were routinely checked by restriction digest followed by agarose gel 
electrophoresis. The restriction enzymes used are detailed in Table 2.1, all were supplied by 
Roche Diagnostics Limited, West Sussex, UK. 
 
Table 2.1 Restriction enzymes used for restriction digest of plasmids. 
Enzyme Site cut Description 
HindIII 5’-A|AGCTT-3’ 
3’-TTCGA|A-5’ 
Site within EGFP plasmid for 
insertion of cystatin C. Used 
for verification. 
BamHI 5’-G|GATCC-3’ 
3’-CCTAG|G-3’ 
Site within EGFP plasmid for 
insertion of cystatin C. Used 
for verification. 
BglII 5’-A|GATCT-3’ 
3’-TCTAG|A-5’ 
Site for this enzyme found 
both within EGFP plasmid 
and within Cystatin C gene. 
Used for verification of 
insert. 
EcoRI 5’-G|AATTC-3’ 
3’-CTTAA|G-5’ 
Site within Halotag plasmid 
for insertion of Cystatin C. 
Used for cloning and 
verification. 
XhoI 5’-C|TCGAG-3’ 
3’-GAGCT|C-5’ 
 
Site within Halotag plasmid 
for insertion of Cystatin C. 
Used for cloning and 
verification. 
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Digests were carried out by mixing 1 µL DNA plasmid, 0.5 µL of the relevant enzyme or 
enzymes, 1 µL of the buffer appropriate to each enzymes and making the volume up to a 
total of 10 µL. This was then incubated at 37oC for 1 hour before a brief heat period at 65oC 
for 10 minutes to inactivate certain enzymes and then held at 4oC before analysis. 
DNA was analysed on a 1% Agarose gel made up in TBE buffer (Appendix 2). The agarose gel 
was prepared by adding 0.5x TBE buffer to molecular grade agarose (Sigma-Aldrich 
Company Ltd., Dorset, England). This was then heated until the agarose had fully dissolved 
and the solution allowed to cool to 55-60oC before the addition of SafeView Nucleic Acid 
Stain (NBS Biologicals Ltd., Cambridgeshire, United Kingdom) in a dilution of 1:10,000 
before pouring the gel. 
DNA samples were prepared for analysis by adding a 1:6 dilution of DNA glycerol loading 
buffer (Appendix 2). DNA marker routinely use was Hyperladder I (Bioline, Massachusetts, 
United States). Gels were run at 100-150 V in 0.5x TBE buffer. Visualisation was carried out 
on a Bio-Rad Laboratories Chemidoc using the same settings as used for ethidium bromide 
visualisation. 
 
2.2.5 DNA sequencing 
Plasmids were also routinely checked by DNA sequencing. DNA sequencing of all constructs 
was carried out commercially. Samples were sent by mail and processed by DNA 
Sequencing & Services, University of Dundee, Scotland. The results were returned in both 
FASTA format and as a colour-coded sequencing trace. Primers used for sequencing 
constructs are presented in Table 2.2. 
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Table 2.2 Sequencing primers used to confirm the integrity of constructs used in 
experiments. 
Primer Sequence Description 
E1 5’-TATAAGCAGAGCTGGTTTAG-3’ Sequencing primer for sequencing of 
EGFP plasmid insert (Laboratory 
stock) 
E2 5’-CGTCGCCGTCCAGCTCGACCAG-3’ Sequencing primer for sequencing of 
EGFP plasmid insert (Laboratory 
stock) 
T7 5’- TAATACGACTCACTATAGGG-3’ 
 
Sequencing primer for sequencing of 
Halotag plasmid insert (provided by 
DNA Sequencing & Services, 
University of Dundee, United 
Kingdom) 
SM1 5’- AGCAGCCAACTCAGCTT-3’ Sequencing primer for sequencing of 
Halotag plasmid insert (designed by 
Samantha McDonnell) 
SM2 5’- TGTCGGATTTGCCCATACCG-3’ Sequencing primer for sequencing of 
Halotag plasmid insert (designed by 
Samantha McDonnell) 
 
2.2.6 Site-directed mutagenesis 
For the purpose of repairing a point mutation, Agilent Technologies' (California, United 
States) QuikChange II Site-Directed Mutagenesis Kit was used. Mutagenesis reactions were 
prepared as per the mutagenesis kit manufacturer's instructions. In brief 1 µL (10ng) of 
construct DNA with 1.25 µL (125 ng) of each mutagenesis primer detailed in table 2.3 were 
used in a total final reaction volume of 50 µL. Reaction mixes were then cycled using a 
thermal cycler with an initial step at 95oC for 30 seconds before twelve cycles consisting of 
a denaturation step at 95oC for 30 seconds, an annealing step at 55oC for 1 minute and an 
elongation step at 68oC for 5 minutes. 
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Table 2.3 Primers used for point mutagenesis of plasmid to repair original EGFP 
constructs. 
Primer Sequence Description 
c275t 5'-ctacttcttggacgtggagctgggccgaa-3' Primer used to cause site 
directed mutagenesis in 
cystatin C insert 
c275t.antisense 5'-ttcggcccagctccacgtccaagaagtag-3' Primer used to cause site 
directed mutagenesis in 
cystatin C insert 
 
Amplification products were cooled on ice for 2 minutes before being incubated with 1 µL 
of Dpn I restriction enzyme at 37oC for 1 hour. This digested the parental plasmids, leaving 
only the repaired plasmid behind. 
Following this 1 µL of DNA from each amplification was added to a 50 µL aliquot of 
supercompetent XL1-Blue Escherichia coli and incubated on ice for 30 minutes prior to a 45 
second heat shock at 42oC in a water bath and returning the cells to ice for a further 2 
minutes. 
Preheated NZY+ broth (Appendix 2) was then added to the heat shocked aliquots and then 
transferred to an orbital incubator at 37oC for one hour. The bacteria were then finally 
plated onto Luria agar containing 100 µg/mL ampicillin to select for growth of transformed 
bacteria. 
 
2.2.7 Production of new plasmid constructs 
For the purpose of mass spectrometry HaloTag® was chosen as a way of producing 
improved samples to traditional methods. HaloTag® is a recently developed, flexible system 
produced by Promega for the purpose of tagging proteins; HaloTag is able to covalently 
bond with a specific ligand which in mass spectrometry is used to specifically pull down the 
target protein and then elute only the interacting proteins. This ensures that the sample is 
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not overwhelmed by excessive amounts of the target protein which was greatly appealing 
for this experiment. 
 
Table 2.4 Primers for amplification of cystatin C. These were used to amplify cystatin C 
wild type and variant B sequences from the EGFP constructs and to add appropriate 
restriction digest sites for ligation. (Designed by and obtained from Dr. Paul Kay): 
Primer Sequence Description 
CysC 
Amplifying 
Plasmid 
(forward) 
5'- AATTAGAATTCATGGCCGGGCCCCTGCGC -3' Primer used to 
amplify cystatin C 
inserts from EGFP 
constructs and add 
Eco RI restriction sites 
CysC 
Amplifying 
Plasmid 
(reverse) 
5'- 
AATTACTCGAGGGCGTCCTGACAGGTGGATTTCGAC 
-3' 
Primer used to 
amplify cystatin C 
inserts from EGFP 
constructs and add 
Xho I restriction sites 
 
Cystatin C was amplified from the EGFP constructs with primers (Table 2.4) constructed to 
add restriction digest sites to allow it to be inserted into the Halotag plasmid. The 
amplification reactions were prepared using Phusion DNA polymerase (New England 
Biolabs) as per manufacturer's instructions. In brief reactions were prepared with 1 µL 
(10ng) of the respective EGFP construct (wild type and variant B), 2.5 µL of each primer 
detailed in table 2.4 (10 µM), 10 µL 5x Phusion HF buffer and 1.5 µL DMSO in a final 
reaction volume of 50 µL. 
The PCR thermal cycling conditions as follows, an initialisation step at 98oC for 30 seconds, 
then 30 cycles consisting of a denaturation step at 98oC for 10 seconds, an annealing step at 
55.7oC for 30 seconds and an elongation step at 72oC for 15 seconds. A final elongation step 
followed these cycles at 72oC for 7 minutes and finally the reaction was held at 4oC. 
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Amplified DNA was treated with the QIAGEN PCR Purification kit before both the Halotag 
template and the PCR cystatin C products were double digested with Xho I and EcoRI 
restriction enzymes in Buffer H in total reaction volumes of 20 µL as described in section 
2.2.4. 
Digested PCR products were ligated into the plasmid overnight at room temperature by 
mixing 1 µg of digested plasmid, 1 µg of digested cystatin C PCR product and 5 µL T4 DNA 
ligase in a final reaction volume of 30 µL. 
Following overnight incubation the DNA was transformed into XL1-Blue competent cells 
(Agilent) and cultured on selective Luria agar containing 100 µg/mL ampicillin at 37oC. 
Selected colonies were picked and cultured in Luria broth overnight, again selected for by 
ampicillin at 37oC, and uptake of the plasmid was confirmed by use of a QIAPrep Spin 
Miniprep kit (Qiagen).  
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2.3 Polyacrylamide gel protein analysis 
2.3.1 Preparation of whole cell lysates 
Samples for western blot analysis were produced from transfected and untransfected cells 
as whole cell lysates. Cells were washed with PBS and Lysis buffer (Appendix 2) was added 
in a volume sufficient to be able to spread over the cells, approximately 1mL for a T75 flask, 
and a cell scraper was used to spread the buffer and detach the cells. 
Lysates were transferred to 1.5 mL tubes and syringed with a 21G or 23G needle 10 times 
to shear the DNA and make the sample less viscous. Samples were quantified for total 
protein content by Qubit® Protein Assay (Life Technologies, Thermo Fisher Scientific Inc., 
Waltham, United States) in order to enable equal loading. 
Loading buffer (Appendix 2) was added to the samples in a 1 in 5 ratio and the samples 
were heated at 95oC for 5 minutes to denature the protein and make it suitable for loading. 
Cell lysates were stored in a freezer at -20oC.  
 
2.3.2 Polyacrylamide gel electrophoresis 
Protein samples were analysed utilising methods based on the basic process of separating 
proteins by their ability to move through a polyacrylamide gel (a function of the length and 
charge of the molecule). Polyacrylamide gels, 15 mm thick, were used to separate protein 
samples. Resolving gel (Appendix 2) was poured between two glass plates and water 
saturated butanol was used to level the top and the gel allowed to set for ~30 minutes 
minimum. 
Butanol was removed from the set gel and rinsed off completely with dH2O. Stacking gel 
(Appendix 2) was then poured on top of the resolving gel and a comb added to form the 
wells, then allowed to set for typically up to one hour. Running buffer (Appendix 2) at 1x 
concentration was used in combination with a Bio-Rad mini-PROTEAN system to separate 
the samples on the gel. 
Protein ladder routinely used was PageRuler Prestained Protein Ladder (Thermo Fisher 
Scientific Inc., Waltham, United States). The maximum volume of sample applied was 50 µl 
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in 10 well gels or 30 µl in 15 well gels. Wells were equally loaded by total protein content of 
sample. The gel was typically run at 80V for 10 minutes to allow the sample to enter and 
pass through the stacking gel and then 120-150V for 1-1.5 hours to separate on the 
resolving gel. 
 
2.3.3 Western blotting 
Western blotting involves transferring proteins to a membrane which can then be dyed 
and/or probed with antibodies and imaged. This is achieved in a similar way to the gel 
separation in that an electrical current is used to make the charged protein pass out of the 
gel and onto the nitrocellulose surface. All buffers can be found in Appendix 2. 
Pieces of nitrocellulose membrane and filter paper were cut to size and soaked in transfer 
buffer along with two sponge pads per gel, the components assembled in a transfer 
cassette  as per figure 2.4. Transfer to the membrane was carried out using transfer buffer 
and a Bio-Rad mini-PROTEAN system. The gel was transferred at 100 V for ~60-90 minutes 
with gentle stirring. 
Following the transfer membranes were routinely checked by staining with Ponceau S 
(Sigma-Aldrich Company Ltd., Dorset, England) for transfer success and the presence of 
protein bands on the nitrocellulose membrane. Ponceau S stain was added to the 
membrane for 2 minutes at room temperature with gentle agitation. Then the excess dye 
was poured off and the membrane washed with dH2O to reveal the bands. Repeated 
washes removed the dye entirely allowing the gel to be further analysed. 
The membrane was washed in wash buffer twice for 5 minutes each with gentle agitation, 
then incubated in blocking buffer for at least 1 hour with gentle agitation at room 
temperature (this could be left longer, if left overnight then incubation was at 4oC). After 
the blocking step the membrane was incubated with antibodies diluted as indicated in table 
2.5 in 10 mL blocking buffer or 10 mL 5% BSA in wash buffer as appropriate (typically 
blocking buffer for monoclonal antibodies and 5% BSA for polyclonal antibodies). The 
membrane was incubated with the antibody with gentle agitation overnight at 4oC. 
Following overnight incubation the membrane was washed three times with wash buffer 
for 5 minutes each time and incubated with secondary antibody (Table 2.5) at the 
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appropriate dilution in 10 mL blocking buffer for 1 hour at room temperature. This was 
followed by another three washes before the membrane was exposed to ECL reagent (GE 
Healthcare Life Sciences, Buckinghamshire, UK) and incubated for 1-2 minutes. Finally the 
membrane was visualised on a Chemi-Doc (Bio-Rad Laboratories Ltd., Hertfordshire, UK). 
 
Table 2.5 Antibodies used in western blotting 
Antibody target Dilution Supplier and code Description 
Cystatin C 1:2000 Millipore ABC20 Rabbit polyclonal antibody 
EGFP 1:2000 Clontech 632380 Mouse monoclonal antibody 
GAPDH 1:20,000 Abcam 8245 Mouse monoclonal antibody 
LC3B 1:500 Cell signalling 3868 Rabbit monoclonal antibody 
Caspase 3 1:1000 Abcam 90437 Rabbit polyclonal antibody 
Anti-rabbit 1:1000 Sigma-Aldrich A0545 Goat polyclonal antibody 
Anti-mouse 1:1000 Sigma-Aldrich  A9044 Rabbit polyclonal antibody 
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Figure 2.4 Transfer cassette for western blotting and details of transfer process. For 
transfer of the proteins and subsequent probing with antibodies a nitrocellulose membrane 
was used. The sponge pads padded the cassette in order to ensure that the gel did not slip. 
Four pieces of filter paper were found to be optimal, protecting the gel and membrane 
during the process. All western blot gels were of 1.5 mm thickness. Alignment with the 
electrical current as shown causes the transfer of the protein from the gel to the 
nitrocellulose membrane. Larger proteins require longer transfer times. (Author's figure) 
 
  
Positive Electrode (+) 
Negative Electrode (-) 
Sponge pad 
Sponge pad 
4 sheets of 
Filter Paper 
4 sheets of 
Filter Paper 
Polyacrylamide gel 
Nitrocellulose 
membrane 
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2.3.5 Coomassie staining 
Coomassie staining is a simple method of visualising proteins on a gel however once the gel 
is stained it cannot be used for further analysis. First the SDS gel was removed from 
between the glass plates and placed into a staining tray. Then covered with 10 mL of 0.5% 
Brilliant Blue R250 (Sigma-Aldrich Company Ltd., Dorset, England) and incubated for 1 hour 
at room temperature with gentle agitation. 
The dye was then removed and the gel washed with 50 mL destaining solution (10% Acetic 
Acid/30% Methanol) for 1 hour. The destain solution was replaced and destaining was 
continued overnight with additional destains the next day as necessary to visualise. 
 
2.3.6 Silver staining 
Silver staining is a much more sensitive method of visualising the proteins on a gel than 
coomassie staining. It was primarily used to verify immunoprecipitation samples during 
optimisation, the Pierce Silver Stain Kit (24612, Pierce, Thermo Fisher Scientific Inc., 
Waltham, United States) was used for this purpose as per manufacturer's instructions. 
In brief, the SDS gel was washed twice for 5 minutes with dH2O. Fixing solution (30% 
ethanol, 10% acetic acid) was then added and the gel fixed for 30 minutes with the solution 
being replaced after 15 minutes. The fixing solution was rinsed off with 10% ethanol (two 
washes for five minutes each) and then with dH2O (two washes, five minutes each). 
Sensitiser solution (50 µL sensitiser in 25 mL dH2O) was added to the gel for 1 minute and 
the sensitiser rinsed off with two 1 minute washes with dH2O. Staining solution (0.5 mL 
enhancer in 25 mL stain) was then added and the gel incubated at room temperature for at 
least 30 minutes (up to overnight). The gel was washed briefly for 20 seconds twice in dH2O 
before developing in 25 mL developer solution with 0.5 mL enhancer until bands appeared. 
Finally when the bands were sufficiently visible the developing mixture was removed and 
the gel rinsed with 5% acetic acid for 1 minute before fixing with fresh 5% acetic acid for 
ten minutes. Gels were then photographed with care taken to ensure that bands could be 
clearly viewed. Developed gels could be stored in dH2O at 4
oC until no longer required with 
no visible degradation of the staining. 
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2.4 Flow cytometry analysis for oxidative stress 
Flow cytometry was performed with CellROX® (Life Technologies, Thermo Fisher Scientific 
Inc., Waltham, United States) dye. CellROX® is an oxidative stress dye that permeates into 
the cells and fluoresces upon reacting with reactive oxygen species. It is not specifically 
localised, instead being distributed throughout the cytoplasm of the cell making it a general 
oxidative stress marker. In its reduced state it is very weakly fluorescent, with the signal 
becoming stronger upon oxidation. 
The dye is highly photostable compared with other oxidative stress dyes meaning it is 
significantly easier to work with, although it is still preferable to protect the dye from light 
where possible. Further there are several forms of the dye with varying excitation and 
emission wavelengths. Labelling can be carried out in complete media, with the dye being 
both live cell compatible and certain forms of it also being suitable for formaldehyde 
fixation. Finally the dye is suitable for flow cytometry, allowing for high throughput assaying 
of cells. 
For these experiments CellROX® Deep Red Reagent was used, which has 
absorption/emission maximum at ~644/665 nm which allows it to be specifically 
distinguished from the EGFP fluorescence of the construct tag. Hence it was possible to pick 
out the fluorescencent and non-fluorescent cells from each sample and take readings from 
each for comparison. 
 
2.4.1 Cell preparation 
Cells were seeded and transfected in 6 well plates and were checked using a fluorescent 
microscope to ensure that the transfection had been successful. CellROX® dye was then 
added to cells at a final concentration of 5 µM and incubated for 30 minutes at 37oC. 
Following this incubation period the medium was removed and the cells washed three 
times with PBS to remove excess dye. Cells were then harvested and pelleted before being 
resuspended in 1 mL chilled PBS/2% FCS and were kept on ice until analysis. 
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2.4.2 Flow cytometry 
A FACSCalibur (BD Biosciences, California, US) was used to analyse the dyed cells. Initially 
controls were used to assess that the cells had taken up the dye and that a fluorescent 
population was present. From there the samples were run through the cytometer and each 
cell processed assessed for EGFP fluorescent signal and the red fluorescent signal of the 
CellROX dye. 
To analyse this dataset, individual transfected cells were explicitly selected as a group 
(eliminating any double or triple cell clumps that had not properly dissociated) and 
compared against populations from other samples and with the untransfected population 
from within the same sample. 
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2.5 Protein pull-down 
Two types of pull-down procedure were carried out during this work. The first was 
immunoprecipitation of the original EGFP cystatin C constructs, the second was pull-down 
of the new Halotag cystatin C. 
 
2.5.1 Cystatin C protein immunoprecipitation 
Immunoprecipitation of the EGFP constructs was achieved by the use of an anti-cystatin C 
antibody and Protein-A agarose beads in order to pull down both the fusion construct and 
the endogenous cystatin C.  
Cells were seeded and transfected on 6 well plates; 23 hours post transfection they were 
imaged to ensure the transfection was successful. The medium was removed and discarded 
and the cells washed with PBS, then an appropriate volume of RIPA buffer (Appendix 2, 
~500 µL for a T75 flask) was added to the cells, which were then incubated on ice for 5 
minutes and scraped to remove them from the culture vessel. 
The cell suspension was transferred to a 1.5 mL tube and syringed with a 27G needle, the 
resulting lysate was cleared by centrifugation for 5 minutes at 14,000g. Cleared supernatant 
was transferred to a fresh tube and 50 µL of cystatin C antibody (sc-73878, Santa Cruz 
Biotechnology, Texas, US) was added before incubation overnight with rocking at 4oC. 
40 µL of Protein A agarose bead slurry was added (9863S, Cell Signalling Technology, 
Massachusetts, US) and returned to 4oC for 1.5 hours with rocking. The beads were then 
extracted by centrifugation at 800g for 2 minutes and the supernatant discarded. Four 
washes using 500 µL RIPA buffer were then carried out, with beads pelleted by 800g 
centrifugation for one minute each time between each wash. 
Finally the protein was eluted from the beads by incubation at room temperature for 30 
minutes in 40 µL elution buffer (western blot lysis buffer was used for this purpose to allow 
immediate loading onto gels). The beads were removed from the sample by a 2 minute 
centrifugation at 800g to leave the eluted proteins in a solution cleared of beads. 
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2.5.2 HaloTag® protein pull-down 
The Promega Halotag Mammalian Pull-Down Kit (Promega) was utilised in order to 
specifically precipitate out proteins interacting with cystatin C Halotag constructs and thus 
minimise contaminants. Due to the nature of Halotag and the covalent bonding to the 
ligand it was possible to just elute the interacting proteins. The method was modified from 
the manufacturer's instructions for optimal extraction of the samples. 
Cells were seeded and transfected in a T75 flask; 24 hours post transfection the media was 
removed from the cells and they were washed with chilled PBS. Following this 10 mL of 
fresh chilled PBS was added and the flasks were gently scraped to detach the cells from the 
culture vessel and the suspension transferred to a 15 mL tube. Cells were pelleted at 200g 
for 5 minutes, the PBS removed and the pellet transferred to a -80oC freezer for at least 30 
minutes. 
The pellets were then thawed and resuspended in 150 µL of lysis buffer and 3 µL of 
protease inhibitor cocktail, then the suspension was passed 10 times through a 27G needle. 
Lysate was then centrifuged at 14,000g for 5 minutes to clear. The cleared lysate was then 
kept on ice for subsequent steps. 
Before the addition of resin the lysate was diluted with 350 µL TBS buffer, this diluted 
lysate was added to Halotag binding resin (prior washed with wash buffer - TBS/0.05% 
IGEPAL CA630) and incubated at 4oC for at least 2 hours up to a maximum of overnight. This 
incubation period was to allow the Halotag ligand to covalently bind with the Halotagged 
cystatin C constructs. 
The samples were then centrifuged at 800g for 2 minutes and the supernatant discarded. 
Then they were washed with 1 mL wash buffer (as above) four times, centrifuging between 
each wash at 800g for 2 minutes and discarding the wash each time. Finally 1 mL of wash 
buffer was added and the beads incubated with gentle agitation at room temperature for 5 
minutes before finally being pelleted at 800g for 2 minutes and this final wash discarded. 
Proteins bound to the cystatin C were eluted with 40 µL of RapiGest (Waters) which was 
added to each sample and incubated at 80oC for 10 minutes. This released the protein and 
the beads were subsequently spun down for 2 minutes at 800g and the protein containing 
supernatant recovered for analysis.
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2.6 Mass Spectrometry 
D407 cells were seeded in T75 tissue culture flasks and incubated overnight (~12-16 hours) , 
then transfected with Halotag-Cystatin C constructs before being returned to the incubator 
for a further 24 hours. Halotagged Cystain C protein was extracted as described in section 
2.5.2  and the proteins bound to the construct eluted with 40 µL RapiGest (Waters). 
Samples were then transferred on ice to the University of Liverpool Proteomics facility 
(Technology Directorate, University of Liverpool, England) to be processed. The samples 
were analysed by Electrospray Ionization Fourier Transform Ion Cyclotron Resonance (ESI-
FTICR) and the results returned as both a mass spectrometry trace and mass spectrometry 
data spreadsheets. 
Data returned included normalised ion abundancies, raw abundancies, spectral counts and 
ANOVA analysis of the results automatically generated, calculated in Progenesis QI for 
proteomics (a standard software package to analyse mass spectrometer outputs). In 
addition the individual Mascot search files were provided. The mass spectrometry runs and 
initial analysis were carried out by Dr Deborah M Simpson of the Centre for Proteome 
Research, University of Liverpool. 
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2.7 Respiration assays 
2.7.1 Oxygen probe measurement of respiration rate 
To assess the effect of cystatin C wild type and variant B on the respiration rate of cells the 
rate at which oxygen is depleted was examined. An oxygen probe was used to achieve this, 
this probe measures the concentration of oxygen within a solution within the chamber, 
thus allowing for the concentration of oxygen at different time points to be measured and 
the rate of depletion calculated. Given that oxygen is consumed by the respiratory process 
this rate allows the rate in the cell to be assessed indirectly by the consumption of oxygen 
without having to extract and assess the mitochondria directly (thus potentially 
compromising the physiological relevance of the data). 
Cells were transfected in 6 well plates; 23 hours post transfection plates were imaged, 24 
hours post transfection cells were washed with PBS, harvested and pelleted. Cells were 
then resuspended in PBS/10 mM potassium orthophosphate/10 mM HEPES buffer, counted 
and kept on ice until use. An Oxytherm oxygen electrode unit (Hansatech Instruments, 
Norfolk, United Kingdom) was prepared according to manufacturer's guidelines and 
allowed to stabilise for 3 minutes before 1 million cells were loaded into the chamber. Four 
minutes later glutamate (2.5 mM) and malate (2.5 mM) were added to supplement 
respiratory activity. Finally after 11 minutes total had passed ADP (1 mM) was added to 
ensure that this was not a limiting factor for the rate of respiration. 
Readings were taken for each sample every second until at least 30 minutes total had 
passed since the initial loading. The gradient of the graph produced for each sample, 
following the additions of supplements, was calculated, indicating the rate at which oxygen 
was being used and hence the rate of respiratory activity. 
 
2.7.2 Total ATP content assay 
To assess the total ATP content of transfected and untransfected cells as a measure of 
normal cell functioning the luciferase-based CellTiter-Glo® kit (Promega) was used. 
Although primarily designed for assaying cell viability it achieves this by a measure of ATP in 
samples, consequently loading equal numbers of cells will allow for relative ATP 
quantification. 
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Cells were seeded and transfected in a 6 well plate , imaging was carried out 23 hours post 
transfection for the purpose of correcting for differing transfection rates; 24 hours post 
transfection the cells were harvested. Cells were resuspended in 1 mL media and counted 
to allow for equal loading onto plates. 
For analysis, 40,000 cells were seeded in triplicate for each sample into a white-bottomed 
96-well plate and the total volume of each well made up to 100 µL with additional media. 
Plates were then equilibrated at room temperature for 30 minutes before the addition of 
100 µL of CellTiter-Glo reagent to each well. 
Two minutes of agitation at room temperature was followed by incubation at room 
temperature for 10 minutes. Finally the luminescence was recorded on a Promega Glomax 
Multi+ plate reader to give relative luminescent levels correlating to relative ATP levels. 
 
2.7.3 Preliminary ATP measurements 
Preliminary analysis involved direct measurement of ATP produced by isolated 
mitochondria. Cells were transfected in a 6 well plate and incubated for 24 hours before 
the fluorescence was checked and the cells harvested. A Miltenyi Biotec Human 
Mitochondrial Isolation kit was used, as per manufacturer's instructions, to extract 
mitochondrial protein (and thus mitochondria) from the samples. In brief cells were lysed in 
the kit's lysis buffer with a 25g needle. Following this the lysates were diluted with 
separation buffer and Anti-TOM22 magnetic microbeads were added for magnetic labelling. 
A Miltenyi Biotec QuadroMACS separator was used for the extraction of the magnetic 
beads from the samples, allowing for four simultaneous extractions to be carried out. 
Columns were prepared and the samples passed through the columns, with washing, 
before the beads, with attached mitochondria, were flushed out as per manufacturer's 
instructions. 
Beads were then spun down at 13,000g for 2 minutes and resuspended in 30 µL ROS buffer 
(125 mM KCl, 10 mM MOPS, 5 mM MgCl2, and 2 mM K2HPO4 (pH 7.44)).  Protein was 
quantified by Qubit® Protein assay (Life Technologies). 
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On a white-bottomed 96 well tissue culture plate 5 µg of total mitochondrial protein was 
suspended in 100 µL of ROS buffer. This was incubated in the plate reader for 5 minutes at 
37oC. Following incubation 0.5 µM rotenone and 5 mM succinate were added to drive 
respiration through complexes I, III and IV and 2.5 mM glutamate and 2.5 mM malate were 
added to stimulate the process. Then 100 µL of luciferase reagent from Roche's ATP 
Bioluminescence Assay Kit CLS II along with 1 mM ADP were added to each well and 
luminescent measurements were taken every twenty seconds for approximately six 
minutes. The rate of ATP production could then be calculated from the increase in 
luminescence signal over time.  
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2.8 Statistics and calculations 
2.8.1 T-test 
Unpaired T-tests were routinely used as a statistical test unless otherwise specified. These 
were calculated automatically using Microsoft Excel's t-test function for ease of data 
manipulation in data spreadsheets. 
T-test P values are reported throughout the results and was the standard way by which 
results were assessed.  It is a highly effective method by which results can be assessed for 
statistical significance in a comparison between two data sets. Given that much of the 
comparisons in the analysis are between the means of independent sets of data it was 
deemed to be suitable.  
 
2.8.2 ANOVA 
ANOVA analysis was carried out automatically on mass spectrometry data by the 
Progenesis QI for Proteomics software. 
In addition an ANOVA was used as a preliminary statistical analysis for some sets of data, 
but these are not presented. ANOVA was typically used as a statistical test to indicated the 
potential for notable results within a sample and consequently as a way to draw attention 
to particularly notable sample sets and was never used alone. 
 
2.8.3 Combining standard deviations 
To combine standard deviations for samples with technical replicates the square root of the 
pooled variances was used. This allowed for variation in technical replicates to be preserved 
in the final variances appropriate and was achieved utilising the following calculation: 
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Chapter 3 
Mitochondrial associated cellular 
mechanisms 
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3.1 Introduction 
The primary focus of this study is what happens to variant B cystatin C within retinal 
pigment epithelium cells, encompassing both the interactions of the variant protein with 
other intracellular proteins and the consequent effects on intracellular mechanisms. The 
mislocalisation to the mitochondria indicates that it is possible that  this variant interferes 
with the normal functioning of the mitochondria. Given the importance of mitochondria 
within the cell this would likely be highly disruptive to the cellular environment. 
As a result, key intracellular mechanisms were selected for examination. In each 
mechanism chosen there is reason to believe that the process either may be impaired by 
the mislocalisation or the process has been implied in the development of AMD. 
 
3.2 Preparation of constructs 
Initial preparation and sequencing of stocks of the previously produced EGFP constructs 
(Paraoan et al., 2004) identified an inappropriate point mutation resulting in a GCG codon 
replacing a GTG codon, and a consequent amino acid change of Valine to Alanine. This 
change resulted in  potential detrimental effects on the protein structure. This mutation 
was present in both the cystatin C wild type and variant B plasmid constructs. 
Both of these amino acids are uncharged and hydrophobic with similar pKa values which 
may initially indicate that this substitution would have no effect. However Alanine is highly 
associated with alpha-helices and Valine with β-sheets, further this base is in the middle of 
the third β-sheet in the protein and thus might be expected to have a disruptive effect on 
the structure of the protein. This is of importance with respect to cystatin C's role as a 
protease inhibitor as the inability to bind with its typical substrates may lead to it being 
ineffective. Furthermore with respect to the variant B form of the protein this could lead to 
interactions which are not seen in vivo and hence result in misleading conclusions regarding 
its involvement in disease. 
Consequently a point mutation repair was carried out on the plasmids in order to revert the 
DNA code to its normal human sequence. Amplification primers were designed to 
substitute the inappropriate base for the correct one using PCR thermal cycling. Bacterial 
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cells were then transformed with the repaired plasmid, selected and subject to miniprep 
plasmid extraction utilising a QIAprep Spin Miniprep kit. 
The repair was confirmed by DNA sequencing of miniprep samples produced from the 
transformed bacteria. This established that the point mutation had been successfully 
reverted and consequently fixed the amino acid substitution error in the protein. Sequence 
readings in this region were clear, with clean peaks demonstrating no ambiguity. The 
substituted base and change in amino acid are illustrated in figures 3.1 and figure 3.2. 
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Figure 3.1 DNA substitution repairs in wild type cystatin C fusion protein.  The sequence 
of cystatin C from Abrahamson (1987a) is presented in A. B is the sequenced cystatin C 
from the pEGFP-N3 vector post-repair. Green highlights the area where the expected 
sequence matches with the sequencing output, which represents the entirety of the 
sequence. Red highlights the area where the substitution repair was completed. The 
underlined codon is that which is modified in the variant B form of cystatin C and in this 
wild type form matches with the Abrahamson sequence. C is the associated sequencing 
spectrum for the region where the repair was carried out, illustrating that the sequence 
peaks for the repair are clear and defined with little to no background from other bases. 
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Figure 3.2 DNA substitution repairs in variant B cystatin C fusion protein.  The sequence of 
cystatin C from Abrahamson (1987a) is presented in A. B is the sequenced cystatin C from 
the pEGFP-N3 vector post-repair. Green highlights the sequence areas where the expected 
sequence matches with the sequencing output, which represents the entirety of the 
sequence. Red highlights the area where the substitution repair was completed. The 
underlined codon is that which is modified in the variant B form of cystatin C and in this 
variant B form does not match with the Abrahamson sequence, instead presenting the 
A25T substitution. C is the associated sequencing spectrum for the region where the repair 
was carried out, illustrating that as for the wild type the sequence peaks for the repair are 
clear and defined with little to no background from other bases. 
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Confirmation of localisation of the repaired construct was also carried out (Figure 3.3). This 
was an essential final step to confirming the similarity of the repaired construct to the 
previous work done on the wild type and variant B protein; ensuring the mitochondrial 
localisation of the variant. 
ARPE19 and D407 cells were seeded into glass-bottomed 35mm dishes  and transfected 
with the repaired plasmid constructs and grown overnight. Following this growth period the 
cells were incubated for 30 minutes at 37oC with Mitotracker Red diluted to 250 nM in 
media. This cell-permeable dye accumulates within mitochondria and fluoresces upon 
exposure to appropriate wavelength light (exciting at a wavelength of 581 nm and emitting 
at 644 nm). 
Cells were imaged using a confocal microscope and fluorescence images taken for both the 
EGFP green channel and Mitotracker red channel. This allowed for the co-localisation of the 
protein to be checked based on overlap of the two different fluorescence patterns, given 
the EGFP tagging of the protein and the Mitotracker accumulation within mitochondria. 
EGFP only transfected cells demonstrated a diffuse green fluorescence present throughout 
the cell as expected. The wild type cystatin C-EGFP construct did not show as diffuse 
fluorescence as the tag alone, instead demonstrating specific localisation; however that 
localisation was not specifically localised with the mitochondria staining. In contrast the 
variant B cystatin C-EGFP construct demonstrated a high degree of localisation with the red 
straining of the mitochondria accumulated red dye. 
Given the confirmation of the plasmid by both restriction digest DNA gel and by sequencing 
and the confirmation of the protein localisation of the variant B protein the repair was 
deemed to be successful. The newly repaired pEGFP-N3 cystatin C wild type and cystatin C 
variant B constructs were subsequently used for the majority of following experiments. 
They were routinely checked by the use of agarose gel electrophoresis and periodically 
tested via DNA sequencing throughout the studies to ensure their integrity. 
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Figure 3.3 Localisation of repaired EGFP cystatin C constructs. A and B are D407 cells. C 
and D are ARPE19 cells. Fusion protein localisation is green whilst the mitochondria are 
visible in red (stained with Mitotracker Red dye), areas of yellow indicate co-localisation.  A 
and C are both transfected with the wild type cystatin C EGFP vector construct and present 
a wild type distribution pattern, that is to say not specifically mitochondrially localised. B 
and D are both transfected with the variant B cystatin C EGFP vector construct and present 
the mitochondrial co-localisation as described in Paraoan et al. (2004). Scale bars are 10 
µm. Typical transfection rates ~25-30% for cystatin C wild type construct and 10-15% for 
variant B construct following transfection optimisation.  
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3.3 Respiration 
Respiration is the most crucial process of the mitochondria. It is absolutely essential for the 
normal functioning of cells as it is the primary source of energy in the cell in the form of 
ATP. This is of particular relevance to the RPE cells given the many different processes that 
are essential for its role within the eye. 
There are a two main ways that the respiration rate can be assessed. Either by analysing 
the amount of ATP produced by the cells/mitochondria directly or by measuring the usage 
of oxygen in a closed system and its rate of depletion. Both of these were attempted. 
 
3.3.1 Preliminary respiratory measurements 
As an initial test for rate of respiration an attempt was made to measure the rate of 
production of ATP from the mitochondria. Standard fluorescence kits were utilised which 
produce a signal based upon the amount of ATP within a sample, allowing for direct 
measurement of the levels and thus a calculation of rate of production. For this purpose 
whole mitochondria were extracted from cells, initially by subcellular fractionation and 
later by the use of magnetic separation. 
The former of these two methods is a well established methodology of separating cellular 
fractions, typically to isolate specific types of organelle by density, and is widely used for 
producing crude purifications. The disadvantage is that it is fairly nonspecific and crude 
method; it does not specifically select out the mitochondria, instead typically leaving a 
series of fractions containing significant amounts of different cellular components with 
around the same density (sometimes along with contaminating elements from other 
fractions). It also requires extensive high speed centrifugation cycles for significant lengths 
of time.  
In comparison magnetic separation is a relatively new technique which relies upon 
antibodies attached to magnetic microbeads to select targets within a cell lysate and from 
there use a powerful magnet to extract the beads out with the target attached. By using 
microbeads with antibodies for a mitochondria specific protein (TOM22) it is possible to 
selectively extract the mitochondria from the lysate intact without relying upon high speed 
centrifugation that is likely to result in significantly more contamination. 
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Untransfected ARPE19 cells and cells transfected with the cystatin C EGFP constructs were 
grown in T75 flasks and mitochondria were extracted using a Miltenyi Biotec MACS 
Mitochondrial extraction kit. Given the selectivity of this kit this results in good recovery of 
intact mitochondria from cells as a high purity fraction attached to the beads from where 
they could be used for functional assays. The extract was quantified by BCA assay and 5 µg 
of protein was loaded per well on a white-bottomed 96 well plate for measurement in a 
luminometer. 
The isolated mitochondria, supplemented with ADP and other key components of 
respiration, were allowed to respire in the presence of luciferin and luciferase enzyme. This 
resulted in a fluorescent signal produced in proportion to the level of ATP present which 
was measured in a plate reader over a short period of time to measure the rate of 
production of ATP. 
No significant difference was detected between the untransfected and cystatin C 
transfected samples or between wild type cystatin C and variant B cystatin C transfected 
cells. This is presented in figure 3.4.  
However this approach had a number of drawbacks. Firstly, following this work an 
improved method of transfection was identified, resulting in significantly better 
transfection rates; consequently any difference is less likely to show up in this dataset than 
in subsequent work. Secondly the extraction method was somewhat inconsistent with 
some samples containing large amounts of protein (used as a measure of relative quantity 
of mitochondria) and some containing very little. Finally the method was extremely volatile 
between readings resulting in a significant amount of variation between samples and even 
between technical replicates of the same sample. It is unknown if this is the result of 
different rate of production, of inconsistent use of the ATP by the mitochondria or of 
variation in the reagent itself. Another possibility was damage to the mitochondria caused 
by the extraction processes.  A further limitation was that mitochondria had to be loaded 
by protein quantification, with any potential contamination from the lysate being retained 
having significant consequences on equal loading. Given that the measured amounts of ATP 
were very small this variation resulted in significant error in the results. 
This preliminary study of ATP generation is valuable as a way of testing for any gross 
changes resulting from the overexpression of variant B protein, but not for identifying 
subtle changes. As a result it was decided that measuring the rate of ATP production 
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directly from mitochondria in this way was not the best way to approach this question and 
that a method utilising higher numbers of transfected cells with a more sensitive and 
consistent assay was needed. 
 
 
Figure 3.4 Preliminary data showing the reduction in rate of ATP production in 
mitochondria from ARPE19 cells transfected with pEGFP-N3 vector or pEGFP-N3 vector 
based cystatin C constructs. Rates were calculated from gradients of ATP concentration 
measurements using a bioluminescence-based ATP detection kit. Triplicate technical 
replicates were taken for each of 4 samples. The EGFP control demonstrated a significant 
difference from the untransfected control (P<0.01). However the wild type cystatin C and 
variant B cystatin C demonstrated no significant difference either from the controls or from 
each other. Typical transfection rates: EGFP - 35%, Wild Type Cystatin C - 15%, Variant B 
Cystatin C - 8%. Error bars show standard deviations.  
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3.3.2 Respiratory rate by oxygen depletion 
The uptake of oxygen by the cells was used as an indirect measurement of the respiration 
rate of the cell (oxygen being a key part of the respiratory process and crucial for 
generation of ATP). An oxygen electrode was used to measure oxygen uptake by a discrete 
number of cells, normalised across samples, and the rate of uptake compared between 
transfected and untransfected, wild type and variant B cystatin C. 
In order to ensure that the cells survived and were active for the short time of the 
experiment it was necessary to use an appropriate buffer that would keep the cells intact 
and also be compatible with the experimental system. Consequently a series of initial tests 
with previously used buffers were attempted, specifically a buffer previously used to assess 
muscle cells within the oxyprobe system. However this resulted in problems in getting the 
system to work as the originally recommended buffers proved to be unsuitable for RPE 
cells. 
Subsequent testing of different buffers showed that PBS supplemented with 10 mM 
potassium orthophosphate and HEPES was a suitable buffer to test respiration in RPE cells. 
This resulted in a stable starting point and effective stable decrease in oxygen level upon 
the addition of cells (figure 3.5). 
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Figure 3.5 Optimisation of oxygen electrode. In A the establishment of a baseline for the 
buffer is illustrated, initially the oxygenation rate is high, however this drops to a stable 
level within a few minutes to around 150-200 nmol/mL. This stable level was maintained 
over a period of hours, confirming that any reduction in oxygen from this baseline would be 
due to the presence of cells. B illustrates the effect of adding D407 with no substrates. The 
rate is slower than with substrates but indicates a clear reduction in the level of oxygen 
present in the chamber.  
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This optimisation demonstrated several key factors. Firstly that the buffer allows the cells 
to survive in the chamber, which is a crucial step in order to conduct this experiment. 
Secondly that even with no supplements the cells were demonstrated to be capable of 
respiration. This can be attributed to reagents for the respiratory process being present 
within the cells already. Thirdly, that this number of cells (approximately 1 million loaded) is 
appropriate for producing a visible oxygen depletion readout over a short period of time. 
Finally that a stable rate of oxygen consumption is produced by the presence of the cells, 
making it suitable for comparative readings between the differentially transfected and 
untransfected cells. It also provides an baseline for the buffer, which is likely to vary 
somewhat, but can be expected to be between approximately 150 and 200 nmol/mL; with 
any significant departure from that baseline being indicative of a problem with the setup on 
any particular reading. 
Trypsin harvested cells, suspended in the optimised buffer, were loaded into the oxygen 
probe chamber following equilibration and stabilisation of the probe. Experimental 
substrates glutamate, malate and ADP were added sequentially and measurements were 
taken over a period of no less than thirty minutes following the final addition to ensure the 
consistency of the decrease in oxygen concentration. 
This was calculated for each sample and normalised to the untransfected control. The rate 
of oxygen consumption (and hence, indirectly, the rate of respiration) was expressed as a 
relative rate to the untransfected for each set of samples (figure 3.6). Overall very small 
differences were detected between the rates and no significant difference was detected 
between any of the samples when normalised to the untransfected control. Hence 
indicating that oxygen consumption is not effected as a result of either transfection or the 
overexpression of EGFP tag or cystatin C fusion protein constructs.  
One advantage of this technique was that it allowed for whole, intact cells to be measured 
over time rather than isolated mitochondria, thus eliminating the difficulties of equal 
mitochondrial loading and improving the relevance of the measurement by using whole 
cells (thus preserving other intracellular processes involved). In addition it crucially allowed 
for the addition of supplements during the experiment, which is not possible with certain 
other systems (Diepart et al., 2010). However there are also disadvantages of this method. 
As the differences themselves were very small this meant that it is quite likely that it was 
below the detection threshold of the sensor for significance. This is exacerbated by the fact 
that at least one study comparing methods of measuring consumption classified the Clark 
96 
 
electrode as being poor for reproducibility of results for cells, despite being a commonly 
used method (Diepart et al., 2010). There is also the fact that Clark-type electrodes 
consume oxygen in the measurement process (Warkentin et al., 2007), potentially effecting 
the results.  
 
 
Figure 3.6 Oxygen consumption rate of D407 cells relative to untransfected control. Rate 
calculated from gradients of oxygen consumption following addition of all substrates. No 
significant difference was identified between any of the rates shown (n = 3). Mean 
transfection rates: EGFP - 44%, wild type cystatin C - 55%, variant B cystatin C - 53%. Error 
bars show standard deviations.  
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3.3.3 Total ATP content of cells 
Total ATP content of transfected and untransfected cells was measured in order to identify 
the overall intracellular level of ATP as a result of overexpression of the fusion proteins. The 
relative amounts of ATP within the cells would indicate whether or not the ATP is being 
maintained within the cell at a normal level. 
Optimisation of the experiment was carried out to ascertain the optimal number of cells to 
use (figure 3.7). Serially diluted cells were loaded into a white bottomed plate in duplicate 
and a Promega CellTiter-Glo ® Luminescent Cell viability assay kit was used according to the 
manufacturer's instructions. From this assay it was determined that approximately 40,000 
cells were ideal for usage, balancing a strong signal with ease of accurate counting for 
loading onto the plate. 
For the full experiment D407 cells were transfected with cystatin C EGFP fusion proteins 
and grown overnight and imaged approximately one hour before the beginning of the 
experiment to ensure the transfection was successful and to check the rates of transfection 
of each sample. 
Cells were harvested utilising trypsin and counted so that a discrete number of cells could 
be loaded into the wells. Cells were diluted in 100 µL media and added to a 96 well white-
bottomed luminescence tissue culture plates plate in triplicate for technical replicates. 
Relative luminescence used as a measure of relative ATP concentrations (figure 3.8). 
Media by itself presented a very low level of luminescence signal, indicating negligible 
background to interfere with the ATP readings from the cells. No significant difference was 
detected between any of the transfected samples, nor was any difference detected 
between treated and untreated cells; indicating that the ATP levels are not significantly 
different under the conditions tested. 
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Figure 3.7 Cell number test for ATP luminescence detection. D407 cells loaded by volume 
after cell counting to identify concentration (n = 2). From this it was decided to load 40,000 
cells per experiment. Higher numbers of cells resulted in higher readings but were more 
difficult to load accurately due to the limited volume of wells necessitating a very high 
concentration, making accurate counting difficult. Lower numbers of cells were easier to 
load but produced a fainter signal. 
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Figure 3.8  Relative luminescence for ATP content of transfected and untransfected D407 
cells. Technical replicates in triplicate, n = 3. No significant difference was identified 
between the relative luminescence levels, and hence the relative levels of ATP in the 
sample, were observed between the experimental samples. Cell-free media resulted in an 
extremely low level of background fluorescence that is unlikely to interfere with results. 
Mean transfection rates for samples were: EGFP - 38%, wild type cystatin C - 31%, variant B 
cystatin C - 24%. Error bars are standard deviations.  
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3.4 Apoptosis 
Prior experiments indicated that the presence of variant B protein might lead to cleavage of 
caspase 3 and consequently the activation of the caspase apoptotic pathway. However the 
visual appearance of transfected cells was healthy, not dying, which seemed to contradict 
this. Caspase 3 is a crucial protein in both primary caspase-based apoptotic pathways and is 
therefore a key point to test for general apoptotic activation. 
Although there was a distinct lack of visible signs of cell death it may simply be that there is 
a very low level of apoptotic activation; which could potentially lead into interference with 
normal cell processes. Consequently western blots were carried out on transfected and 
untransfected samples in an attempt to confirm this prior result. 
D407 cells were transfected with the pEGFP-N3 vectors and grown overnight. Cell lysates 
were taken and the lysates subjected to western blot analysis. Commercially purchased 
Jurkat cell lysates were used as controls for caspase-3 cleavage. Lysates were equally 
loaded by protein content and successful transfer  to the membrane was confirmed by 
Ponceau S staining. 
The transfection of D407 cells, with either construct, and the subsequent expression of 
cystatin C fusion proteins was not found to cause detectable levels of active caspase 3. The 
uncleaved pro-caspase 3 protein was clearly detectable in all samples indicating that 
caspase 3 was indeed present. However cleaved caspase 3 was only detectable in 
chloroquine-treated Jurkat cells (used as a positive control for the active form of the 
protein) and, as such, there is no evidence for cleaved caspase 3 in the samples. 
This indicates that the caspase 3 apoptotic pathway has not been activated by the presence 
of the cystatin C protein. This contradicts the previous preliminary experiments however it 
is consistent with microscope observations of transfected cells compared with 
untransfected cells. Specifically there is no noticeable indications when inspected visually 
which would be expected from increased levels of apoptotic activity (figure 3.10). Note, 
however, that this experiment is specific to the involvement of caspase 3 mediated 
apoptotic activity. 
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Figure 3.9 Caspase 3 probed blot of D407 lysates transfected with EGFP, wild type cystatin 
C fusion protein and variant B cystatin C fusion protein.  Commercially available Jurkat 
control lysates were used as positive and negative controls (9663S, New England Biolabs). 
Lower molecular weight fragments (as seen for the positive control, Jurkat treated with 
cytochrome C to induce apoptosis) indicate the cleavage and thus activation of the 
apoptotic pathway. The samples lacked these low molecular weight fragments showing 
activated caspase 3, instead only presenting uncleaved bands similar to the negative 
control (untreated Jurkat cell lysate). D407 samples normalised to total protein content. 
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Figure 3.10 Bright field images of untransfected and transfected D407 cells. A, D407 cells 
seeded at the same time as B, C and D. B, D407 cells 24 hours post transfection with EGFP 
producing plasmid. C, D407 cells 24 hours post transfection with cystatin C wild type-EGFP 
fusion protein. D, D407 cells 24 hours post transfection with cystatin C variant B-EGFP 
fusion protein. Scale bars are 100 µm. There was no visually apparent effect of the 
transfection upon the cells which may indicate increased apoptosis, no obvious increase in 
dead cells or cell debris. Cells adhered well to the flask and grew to form the monolayer 
with cobblestone appearance characteristic of RPE cells (as can be seen beginning to form 
in patches on each image). 
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3.5 Autophagy 
The autophagic process was assessed by use of an autophagic marker protein,  the B 
isoform of protein Light Chain 3 (LC3B). This is a marker of autophagy due to its presence in 
the membrane of autophagocytes. 
Specifically this protein is found within the cytosol in a particular form known as LC3B-I. 
Through the autophagic process LC3B-I is converted to LC3B-II via lipidation and is 
incorporated into the membranes of autophagic vesicles. As a result of this LC3 has been 
established as a marker for autophagic vesicles and the ratio between the two forms can be 
used as a simple indicator for changes in autophagy. 
D407 cells were transfected with the EGFP plasmid constructs and grown for 24 hours. 
Following transfection, cells were examined by microscope for the successful uptake of 
plasmid, media was removed and the cells lysed for western blotting. SDS-PAGE followed 
by western blot analysis was carried out using an LC3B specific antibody (Cell Signalling 
Technologies, #2775) which detects both forms of the protein (figure 3.11). 
The ratio between the two bands for each sample was calculated as an indicator of levels of 
autophagosomes, which acts as an indicator of disruption to the autophagic process. 
Although it does not indicate if this is due to increased production of autophagic vesicles or 
decreased clearance. These ratios were normalised to the untransfected control ratio in 
each set in order to correct for any variation between sets of samples resulting from any 
slight variations in conditions. 
An increase in the number of autophagic vesicles was detected in transfected cells 
compared to untransfected and mock transfected cells, and for mock transfected cells 
compared to untransfected cells (figure 3.12). As this increase was also detected in the 
EGFP transfected samples and a smaller increase in the mock transfectant it appears that 
this increase is due to the effect of transfection on the cell and is not because of the 
presence of cystatin C, either wild type or variant B. Consequently this implies that under 
the experimental conditions tested there is no effect specific to the variant B protein on the 
number of autophagosomes present. Although this does not provide specific information 
on the rate it does highlight that there appears to be no specific disruption. 
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Figure 3.11  Sample western blot of autophagic marker LC3B in D407 cell lysates. HeLa 
was used as a control cell line, with untreated HeLa acting as a negative control and 
choloroquine-treated HeLa (50 µM of chloroquine overnight) used as a positive control for 
the LC3B-II form of the protein. An increase in the -II form was clearly visible resulting from 
the chloroquine treatment. Readings were taken of both the LC3B-I and LC3B-II bands and 
the ratio between the two calculated. The HeLa samples were valuable only as controls as 
their ratios could not be used to compare with the D407 ratios as LC3B ratios cannot be 
used to compare different cell lines since expression levels can differ greatly. 
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Figure 3.12 LC3B ratios as an autophagy marker for D407 transfected and untransfected 
cells. Ratios were normalised to untransfected sample in each experimental set in order to 
minimise variability between sets resulting from slight variations in conditions. Ratio is 
LC3B-II to LC3B-I, with a higher value indicative of increased numbers of autophagic vesicles 
within the cell.  All samples treated with transfection reagent have statistically significantly 
higher ratios (P < 0.01) than the untransfected samples. EGFP and wild type cystatin C have 
statistically significantly higher ratios (P < 0.05) than the mock transfection, with variant B 
cystatin C close to significance (P = 0.07). Transfection rates were: EGFP - 47%, wild type 
cystatin C - 45%, variant B cystatin C - 24%. Error bars are standard deviations.  
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3.6 Oxidative stress 
Oxidative stress is of great significance for cells in the eye, particularly the RPE. Oxidative 
stress is typically due to the production of reactive oxygen species which are highly reactive 
molecules with the potential to react with intracellular proteins. 
Oxidative stress has a number of potential causes in cells. In particular it can be caused by 
the generation of reactive oxygen species by the mitochondria. The process of respiration 
involves the use of oxygen, resulting in significant amounts of oxygen in the cell 
concentrating at the mitochondria and the subsequent formation of reactive oxygen 
species. This results in the mitochondria themselves being particularly at risk from oxidative 
stress-related damage and, further, that cells with large numbers of mitochondria are at 
greater risk. 
Consequently, analysis of the effect of variant B cystatin C protein on intracellular oxidative 
stress levels through reactive oxygen species measurements was a high priority for this 
study. CellROX® Deep Red dye combined with flow cytometry was the method selected 
after comparison with other techniques. This allowed for the specific selection of 
fluorescent cells, producing meaningful data on any relationship between the expression of 
the proteins and the extent of oxidative stress. It also allowed for a comparison to be drawn 
between the fluorescent cells in a sample and the nonfluorescent cells, thus providing a 
control inherent in each individual sample which helps to correct for any potential variation 
in uptake of the dye. 
For untransfected samples, approximately 10,000 cells were measured. For transfected 
samples a minimum amount of transfected cells was used as a parameter for 
measurement; specifically this was 5,000 cells after 24 hours and 2,000 cells after five days. 
This difference is due to the decrease in transfection over this period of time, necessitating 
a smaller count due to significantly larger amounts of cells needing to be counted in order 
to obtain a sufficient amount of readings. The population of cells following harvesting was 
largely uniform and single celled, although a small population of duplets or clusters was 
also present, these were eliminated from the analysis. Following treatment and harvesting, 
cells were kept on ice suspended in PBS with 2% FCS until they could be analysed. 
Untransfected cells typically clustered with very low levels of green fluorescence and a clear 
red fluorescence indicating that the staining was successful. In transfected samples a 
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substantial untransfected population displayed similar characteristics to that of untreated 
cells however a significant number of cells displayed green fluorescence. 
A low level of increased green autofluorescence was detected in a fraction of a percentage 
(less than 0.1%) of the untransfected cells with corresponding increases in the oxidative 
stress marker, likely cellular debris. For transfected samples a significantly larger 
percentage of the sample displayed strong fluorescent signal. 
Twenty four hours post transfection there is an increase in oxidative stress apparently 
resulting from the transfection reagent (figure 3.13). This can be clearly seen by comparing 
the statistically significantly higher red fluorescent signal of the oxidative stress dye in the 
mock transfectant samples with the low reading in the untransfected sample. The data 
from the plasmid transfectants suggests that the effect only occurs in cells which have been 
treated with the transfection reagent but not taken up a plasmid; although the data for this 
is not statistically significant for all three transfected samples there is a clear pattern visible 
in the readings. 
Five days post transfection (four days growth in normal media with no transfection reagent) 
results in the loss of this increase in oxidative stress for the mock sample over the 
untreated sample. The presence of EGFP likewise displays no effect on the oxidative stress 
of the cell compared to untransfected cells from the same sample. However both wild type 
cystatin C and variant B cystatin C fusion protein transfectants display statistically 
significant increases in oxidative stress over the untransfected cells within the same sample 
(figure 3.14). 
The advantages of this assay were that individual cells were measured to make up a 
population, hence providing large numbers of data points. Further given the difference in 
the wavelengths of the dye there was little chance of cross-contamination of signal. 
However disadvantages included the background level of fluorescence potentially 
interfering with results plus the large drop-off in transfection rate after five days. This 
necessitated a huge number of counts to gain sufficient transfected cell counts for analysis 
meaning the untransfected counts for these are significantly larger than other counts. In 
addition particularly low-fluorescence transfected cells may be mixed with untransfected 
readings. 
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Figure 3.13 Mean oxidative stress in transfected (T) and untransfected (U) D407 cells 
treated with CellROX oxidative stress dye, 1 day post-transfection. Transfections either 
with just EGFP or with EGFP-tagged Wild Type or Variant B cystatin C. By t-test the mock 
transfected cells were statistically significantly more fluorescent, hence having more 
oxidative stress, than the untransfected cells (P < 0.01), as were the untransfected cells 
from the variant B sample compared to transfected cells from the same sample (P < 0.01). 
Approximately 5000 transfected cells were measured for each transfected count and a 
minimum of approximately 5000 untransfected cells for untransfected measurements. 
Error bars show standard deviation. 
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Figure 3.14 Mean oxidative stress in transfected (T) and untransfected (U) D407 cells 
treated with CellROX oxidative stress dye, 5 days post-transfection. By t-test the 
differences between the EGFP transfected and untransfected cells in the same sample are 
insignificant (P=0.2834), the respective differences for Wild Type (P=0.0474) and Variant B 
(P=0.0005) are significant, but the difference between transfected Wild Type and Variant B 
is not significant (P=0.4665). Approximately 2000 transfected cells were measured for each 
transfected count and at least approximately 10,000 cells for untransfected measurements 
(however many more were recorded for the untransfected cells in the transfected samples 
due to loss of transfection by this time). Error bars show standard error. 
 
  
0 
50 
100 
150 
200 
250 
300 
350 
400 
450 
  
C
e
llR
O
X
 d
ye
 f
lu
o
re
sc
e
n
ce
 (
R
FU
) 
Untransfected Mock 
Transfected 
U         T 
EGFP 
U         T 
Wild Type 
U         T 
Variant B 
110 
 
 
 
 
 
 
 
Chapter 4 
Protein-protein interactions: 
mass spectrometry analysis 
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4.1 Introduction 
In addition to the functional tests which were used to assess possible ways in which the 
variant B protein could cause intracellular effects compared with wild type protein it was 
decided that the intracellular protein-protein binding partners of cystatin C would also be 
assessed. This would provide a starting point for additional future work exploring the 
intracellular interactions of variant B cystatin C. 
Of particular interest are interacting proteins with the potential for involvement in how it is 
transported (if at all) to the mitochondria, how the mislocalisation with the mitochondria 
occurs (through any interactions with mitochondrial proteins) and how it might affect 
intracellular processes (thus potentially leading to the development of AMD). In order to 
achieve this, mass spectrometry was selected for the purpose of identifying and analysing 
interacting proteins. 
Mass spectrometry allows for high precision identification of proteins. By utilising 
immunoprecipitation techniques it is possible to specifically select out a target protein and 
its interacting partners from a mixed solution of proteins and then to identify those 
interacting proteins. This has the distinct advantage over western blot screening of IP 
samples in that all of the proteins within a sample can be identified, without having to 
guess at possible interactions and subsequently probe for them. 
For this study both wild type cystatin C and variant B cystatin C fusion proteins have been 
immunoprecipitated, HaloTag with no linked protein was used as a control for nonspecific 
interactions. Mass spectrometry analysis was then performed on the immunoprecipitated 
samples by the University of Liverpool Proteomics service. 
 
4.2 Preparation and optimisation 
4.2.1 Production of new plasmid constructs 
One option for mass spectrometry analysis was to simply use the existing EGFP constructs 
for pull-down and isolation of cystatin C as well as any interacting proteins. However this 
suffered from a number of potential limitations and disadvantages. 
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Firstly, contamination resulting from the denaturing of antibody itself can prove to be a 
problem. The traditional process for protein pull-down necessitates the use of an antibody 
it is typically performed using an antibody for the target in combination with protein A or 
protein G linked to agarose beads. Specifically, incubating a sample (such as a cell lysate) 
with the antibody for the protein desired followed by an incubation with protein A or 
protein G agarose slurry which links to the first antibody and allows the protein to be pulled 
down by centrifugation. However this leads to large amounts of antibody fragments after 
elution as the antibody is released along with the proteins. 
Consequently it is preferable to perform the mass spectrometry with a selection method 
that is directly attached to the beads or column being used. This allows for the elimination 
of the majority of the ligand or antibody in question. Traditionally this has involved either 
using antibody covalently attached to beads or by producing and using a His tag construct 
which is recoverable due to its affinity for certain metal ions (nickel, cobalt and copper, 
with cobalt being the most specific). 
Secondly , contamination from the target protein can disrupt results. When attempting to 
identify proteins bound to a particular target proteins by this method large amounts of the 
target protein remain in the sample. This results in a huge signal for the target protein with 
the potential to interfere with the results. Further, if the target protein is capable of binding 
to itself this is more difficult to identify. 
For the purpose of carrying out mass spectrometry analysis a new cystatin C construct was 
produced. To address the two disadvantages detailed above a new type of tag was 
selected, known as HaloTag® (Promega). HaloTag® is a versatile way to tag proteins at 
either terminus which forms covalent bonds with proprietary ligands which allows it to be 
used as a flexible and highly specific way to select for the protein in question. This results in 
the tagged protein becoming permanently bound to the ligand, thus preventing it from 
detaching upon elution in the process of immunoprecipitation. Consequently ensuring that 
the sample eluted consists only of those proteins that are bound to the target tagged 
protein and not ligand fragments or excessive amounts of tagged protein which may 
overwhelm the sample. 
The new construct was produced by amplifying the cystatin C wild type and variant B genes 
out of the existing EGFP constructs using primers incorporating appropriate restriction 
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digest sites for its insertion into the Halotag plasmid. From there the target plasmid and the 
amplified cystatin C were digested to allow for insertion and ligated together (figure 4.1).  
Transformation into bacteria followed by followed by colony picking on selective media 
allowed for the selection of bacteria containing the appropriate plasmids. Three colonies 
from each transformation were selected from the original agar plates and all three grew 
successfully when streaked onto selective media agar plates. Two of each of these three 
selected colonies for each clone were found to have successfully taken up the plasmid, as 
verified by plasmid extraction and agarose gel electrophoresis demonstrating a clear band 
of DNA present at the correct size (figure 4.2). 
The success of the insert and the integrity of the plasmid was confirmed by restriction 
digest agarose DNA gels and by DNA sequencing. In addition the capability of Halotag 
ligands to bind to the plasmid construct and to confirm expression of the protein construct 
intracellularly was tested using a fluorescent TMR ligand to check for the presence of 
protein within transfected cells compared with untransfected cells. 
HaloTag® only transfection resulted in a cell-wide glow however the plasmid constructs 
presented with a localised glow. Localisation for wild type and variant B constructs was as 
per the EGFP constructs. As with the EGFP tagged protein it was necessary to attach 
Halotag to the C-terminus of the protein to ensure the tag remains following cleavage of 
the targeting sequence at the N-terminus. 
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A 
 
 
B 
GCTAGCAAAGCGATCGCTTCCGAA|TTCCTACCGCGGATATCTAGATTTGGGCCCAATTCCT
GCAGGCGAGCTCTC|GAG 
 
C 
GCTAGCAAAGCGATCGCTTCCGAATTCATGGCCGGGCCCCTGCGCGCCCCGCTGCTCCTGC
TGGCCATCCTGGCCGTGGCCCTGGCCGTGAGCCCCGCGGCCGGCTCCAGTCCCGGCAAGC
CGCCGCGCCTGGTGGGAGGCCCCATGGACGCCAGCGTGGAGGAGGAGGGTGTGCGGCG
TGCACTGGACTTTGCCGTCGGCGAGTACAACAAAGCCAGCAACGACATGTACCACAGCCG
CGCGCTGCAGGTGGTGCGCGCCCGCAAGCAGATCGTAGCTGGGGTGAACTACTTCTTGGA
CGTGGAGCTGGGCCGAACCACGTGTACCAAGACCCAGCCCAACTTGGACAACTGCCCCTTC
CATGACCAGCCACATCTGAAAACGAAAGCATTCTGCTCTTTCCAGATCTACGCTGTGCCTTG
GCAGGGCACAATGACCTTGTCGAAATCCACCTGTCAGGACGCCCTCGAGCCAACCACTGA
GGATCTGTACTTTCAGAGCGATAACGATGGATCCGAAATCGGTACTGGCTTTCCATTCGAC
115 
 
CCCCATTATGTGGAAGTCCTGGGCGAGCGCATGCACTACGTCGATGTTGGTCCGCGCGAT
GGCACCCCTGTGCTGTTCCTGCACGGTAACCCGACCTCCTCCTACGTGTGGCGCAACATCAT
CCCGCATGTTGCACCGACCCATCGCTGCATTGCTCCAGACCTGATCGGTATGGGCAAATCC
GACAAACCAGACCTGGGTTATTTCTTCGACGACCACGTCCGCTTCATGGATGCCTTCATCGA
AGCCCTGGGTCTGGAAGAGGTCGTCCTGGTCATTCACGACTGGGGCTCCGCTCTGGGTTTC
CACTGGGCCAAGCGCAATCCAGAGCGCGTCAAAGGTATTGCATTTATGGAGTTCATCCGCC
CTATCCCGACCTGGGACGAATGGCCAGAATTTGCCCGCGAGACCTTCCAGGCCTTCCGCAC
CACCGACGTCGGCCGCAAGCTGATCATCGATCAGAACGTTTTTATCGAGGGTACGCTGCCG
ATGGGTGTCGTCCGCCCGCTGACTGAAGTCGAGATGGACCATTACCGCGAGCCGTTCCTG
AATCCTGTTGACCGCGAGCCACTGTGGCGCTTCCCAAACGAGCTGCCAATCGCCGGTGAGC
CAGCGAACATCGTCGCGCTGGTCGAAGAATACATGGACTGGCTGCACCAGTCCCCTGTCCC
GAAGCTGCTGTTCTGGGGCACCCCAGGCGTTCTGATCCCACCGGCCGAAGCCGCTCGCCTG
GCCAAAAGCCTGCCTAACTGCAAGGCTGTGGACATCGGCCCGGGTCTGAATCTGCTGCAA
GAAGACAACCCGGACCTGATCGGCAGCGAGATCGCGCGCTGGCTGTCTACTCTGGAGATT
TCCGGT 
 
Figure 4.1 HaloTag® construct insert schematic. A shows the complete map of the 
HaloTag® plasmid used (From Promega pHTC HaloTag® CMV-neo Vector Product 
Information sheet, 9PIG771), the red circle highlights the multiple cloning site. B is the full 
sequence of the multiple cloning site with the EcoRI cutting site highlighted in red and the 
XhoI cutting site highlighted in blue. C is the full sequence for the multiple cloning site and 
HaloTag® sequence with the ligated cystatin C wild type inserted, which is highlighted by 
underlining. Yellow highlights the C-terminal HaloTag® sequence. 
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Figure 4.2 Restriction digest of Halotag constructs to confirm insert. Each sample consists 
of an uncut plasmid for reference and a plasmid cut with EcoRI and XhoI to demonstrate 
the presence of the cystatin insert. Not all plasmids successfully took up cystatin C as can be 
seen in wild type cystatin C sample 2 and variant B cystatin C sample 3 where only the cut 
band of the plasmid is visible with no insert. The cystatin C band is marked with an arrow . 
HaloTag® plasmid cut is provided for reference.  
HaloTag® 
Plasmid 
Cystatin C variant B 
Plasmid constructs 
Wild Type Cystatin C 
Plasmid constructs 
1 2 3 1 2 3 
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4.2.2 Optimisation of protein pull-down 
In order to ascertain the differences and similarities between the interactions of variant B 
cystatin C and wild type cystatin C it was necessary to carry out a protein pull-down. This 
allowed for the specific isolation of cystatin C and any bound proteins from the cell lysates 
and consequently for the identification of said bound proteins through the use of mass 
spectrometry. 
Protein pull-down was carried out utilising a Halotag Mammalian Pull-down kit (Promega). 
Attempts were made to pull-down samples from multiwell tissue culture plates. However 
this resulted in a relatively low amount of protein precipitated from the samples. Hence, 
this proved to be insufficient for our purposes and consequently experiments were scaled 
up significantly. 
Success was eventually achieved utilising T75 flasks. These produced a large pellet of cells 
for lysis and processing. Subsequent protein pull-down of these optimisation samples  
resulted in clear protein bands on SDS polyacrylamide gels detected by silver staining which 
were indicative of successful pull-down of proteins. The method proved to be highly 
effective resulting in a sufficient amount of interacting proteins  for mass spectrometry 
analysis. 
Initially the kit was used as recommended by the manufacturer, however the elution buffer 
contained within the kit was SDS-based. This was judged to be inappropriate for use in a 
mass spectrometer as it would interfere with the column and contaminate results, 
potentially damaging the machine. 
An alternative elution buffer, RapiGest (Waters) was tested. The results of this in 
comparison with SDS elution were clearly visible on silverstained SDS gels (figure 4.3). This 
resulted in a significantly lower amount of protein being visible, with significantly fainter 
bands present compared with SDS elution. However bands were still present for both 
samples  indicating that both methods were successful in eluting protein from the beads. 
Despite the lower quantity of elution of protein with RapiGest compared with an SDS buffer 
it was decided that it is nevertheless preferable to carry it out directly in RapiGest. This is 
due to the fact that SDS elution would require the sample to be cleaned of SDS, the most 
likely method of which would be to run the sample on an SDS-PAGE gel and extract from 
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said gel. By doing this there would not only be an extra, lengthy, step in the processing of 
the sample before the mass spectrometry itself but it is also likely that a significant amount 
of protein would be lost in the process. Furthermore it was possible that certain proteins 
would be lost due to the relatively small amounts of the protein in the sample in the first 
place. The consequent loss of protein through the extra steps would likely result in more 
lost in the extra step than gained through the more efficient elution from beads by using 
this buffer. As a result, although not as efficient, RapiGest elution was the best option 
available. 
 
 
 
 
Figure 4.3 Silver stain of Halotag protein pull-downs with different elution buffers. T75 
lysed and HaloTag pulled-down before resin separated into two tubes for elution by two 
different methods. Each lane is therefore approximately half a T75 of pulled down protein. 
SDS elution was more successful than RapiGest elution, however both methods presented 
bands for both of the constructs. 
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SDS Elution 
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4.2.3 Preliminary mass spectrometry 
An effective extraction and elution technique for the HaloTag® constructs utilising a mass 
spectrometry appropriate elution buffer was thus established. Following this a preliminary 
mass spectrometry analysis run was attempted. This was to simultaneously provide a 
starting point for mass spectrometry analysis and to ensure that the overall technique was 
capable of producing effective mass spectrometry results. 
The backbone HaloTag® plasmid by itself was usedas a control for nonspecific binding of 
Samples were analysed by the University of Liverpool Proteomics facility and results were 
returned as spectral counts with associated Mascot searches for each data file (courtesy of 
Dr Deborah Simpson). 
Mascot searches were compared to identify proteins unique to either the wild type cystatin 
C or variant B cystatin C as an initial mass spectrometry analysis (given the n=1 nature of 
this preliminary run and the sole utilisation of spectral counts it cannot be used by itself to 
draw conclusions on differences). These are presented in Table 4.1 with details of potential 
involvement in aspects of interest to this study. 
This preliminary run confirmed the validity of the methods used and, more importantly, 
confirmed that results could be obtained even with the lower protein concentration 
resulting from RapiGest elution. Consequently the decision was made to continue with full 
mass spectrometric analysis of lysates. 
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Table 4.1 Preliminary mass spectrometry analysis by spectral counting, unique proteins. A 
complete list of all proteins identified in the preliminary mass spectrometry as only being 
present in either variant B cystatin C pulled-down samples or wild type cystatin C 
immunoprecipitated samples. Proteins which were found to be present in both were 
excluded, as were those proteins for which spectra were identified in the HaloTag®-only 
control. Included are accession numbers, name and a brief overview of potential relevance 
to this study.  
 
Accession Protein Potential relevance to AMD/cystatin 
C/mitochondria 
Cystatin 
specific to 
P02774 Vitamin D-binding 
protein 
Unknown, found on cell surfaces and 
associates with immunoglobulin and IgG 
on lymphocytes. 
Variant B 
P38646 Stress-70 protein, 
mitochondrial 
Implicated in cell proliferation and 
ageing. May act as a chaperone. 
Variant B 
P05141 ADP/ATP 
translocase 2 
Involved in exchange of ADP from 
cytoplasm with ATP in mitochondria 
across inner membrane. 
Variant B 
P35232 Prohibitin DNA synthesis inhibitor, involved in 
cellular proliferation. May be involved in 
regulating mitochondrial respiration and 
ageing. 
Variant B 
P02647 Apolipoprotein A-1 Involved in protein aggregation. 
Associated with Alzheimer's disease. 
Variant B 
P53634 Dipeptidyl 
peptidase 1 
Protease. Strongly inhibited by cystatin 
C. 
Variant B 
    
P07360 Complement 
component 8 
Unknown. Involved in complement 
cascade. 
Note: Many other complement 
components detected in both. Likely to 
not be highly relevant. 
Wild Type 
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P01023 Alpha-2-
Macroglobulin 
Unknown. Inhibits proteinases by a 
unique mechanism – a stretch of 
peptides containing cleavage sites for 
different proteinases. Protein becomes 
trapped when cleaves the site. 
Entrapped enzyme remains active 
against low molecular weight substrates. 
Wild Type 
P01019 Angiotensinogen Unknown. Regulator of blood pressure, 
body fluid and electrolyte homeostasis. 
Serine endopeptidase inhibitor. 
Wild Type 
P0C0S5 Histone H2A.Z Unknown. Chromatin structural protein. 
Note: Other histones detected in both. 
Likely to not be highly relevant. 
Wild Type 
Q6NXT2 Histone H3.3C Unknown. Chromatin structural protein. 
Note: Other histones detected in both. 
Likely to not be highly relevant. 
Wild Type 
P08779 Keratin type I 
cytoskeletal 16 
Unknown. Structural component of 
cytoskeleton. 
Note: Other keratins detected in both. 
Likely to not be highly relevant. 
Wild Type 
P02538 Keratin type II 
cytoskeletal 6A 
Unknown. Structural component of 
cytoskeleton. 
Note: Other keratins detected in both. 
Likely to not be highly relevant. 
Wild Type 
P00739 Haptoglobin-related 
protein 
Unknown. Homologous to serine 
proteases but has no enzymatic activity. 
Wild Type 
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4.3 Protein interaction analysis 
Following the demonstrated success of the method triplicate samples were produced and 
treated as for the preliminary experiment, using RapiGest buffer for elution, and 
transferred to the University of Liverpool Proteomics facility for analysis. 
Data was returned as both spectral counts and as raw and normalised abundances 
subjected to ANOVA analysis. Mascot (Matrix Science) and Progenesis QI (Nonlinear 
Dynamics) had been used to analyse the mass spectrometry raw output. The processing of 
samples through mass spectrometry and the subsequent analysis of the raw data through 
these programs was done by Dr Deborah Simpson of the Centre for Proteome Research, 
University of Liverpool. 
Of the two analysis methods, ion abundance is more sensitive than spectral counting (Milac 
et al., 2012). However both have been used in the examination of the dataset and selection 
of proteins for discussion. 
Full details of normalised abundances are presented in Appendix Table 1 along with ANOVA 
p-values, complete spectral counts are presented in  Appendix Table 2 with confidence 
scores for reliability of identification. In total 185 proteins were identified as being present 
in the samples and those with the most significant differences were chosen as a set for 
further analysis. 
 
4.3.1 Significant results by ANOVA analysis 
From ANOVA analysis of the full mass spectrometry data set eight proteins appeared to 
have significant differences either against the control or between the wild type and variant 
B. These are presented in Table 4.2 with their normalised abundances in each sample. 
Individual unpaired t-test values for each of the three pull-downs are presented in Table 
4.3. 
The first three proteins listed were expected to be significant binding partners, and help to 
validate the approach by their presence. Cathepsins B and L along with dipeptidyl peptidase 
1, also known as cathepsin C, are known inhibitory targets for cystatin C and their presence 
indicates the effective pull-down of cystatin C bound proteins. Each of them demonstrated 
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a statistically significant, or close to statistically significant, higher presence in normalised 
abundancy in cystatin C transfected samples compared with the HaloTag control samples. 
Further, spectral counts were uniformly zero for the control samples but counts were 
present for cystatin C samples. There was no identified difference between wild type and 
variant B cystatin C samples for cathepsins B and L in either spectral counts or normalised 
abundance. However a significant difference was detected for dipeptidyly peptidase I in the 
spectral counts, with a higher level detected for wild type cystatin C. 
It is worth noting that for the cathepsins in each case the wild type value from set 2 that is 
particularly low. Eliminating that value as a potential outlier brings all three to P < 0.05 
significance level in normalised abundance, demonstrating a statistically significantly higher 
level of abundance in the wild type samples. 
The fourth protein is 78 kDa glucose-regulated protein, individual t-testing indicates this is  
significantly increased  in variant B cystatin C binding compared to the control plasmid. 
Spectral counting indicated a significant increase for both wild type and variant, as well as a 
close to significant difference between the two with wild type cystatin C being higher. As 
for the cathepsins, eliminating the single lowest abundance from the wild type dataset 
resulted in a statistically significant difference in abundances between the two. 
Cystatin C itself is also present on this list. Given that the fusion protein should not be able 
to detach from the bead based ligand it seems likely this is the result of the formation of 
dimers. There is a statistically significant difference (P<0.01) in spectral counts between 
wild type cystatin C and the control, but no other differences. 
Prohibitin displays a very strong statistically significant normalised abundancy increase (P < 
0.01) in variant B cystatin C compared with wild type cystatin C. Further there is a close to 
significant increase in binding to variant B over the control. 
Both leucyl-cystinyl aminopeptidase and stress-70 protein display a similar normalised 
abundancy pattern to the cathpsins with respect to differences in variant B and wild type 
cystatin C binding. Namely elimination of an apparent outlier (all from the same set, 
notably) of wild type cystatin C readings results in statistically significant higher levels in the 
wild type form (P < 0.05).  
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Table 4.2 ANOVA significant results of mass spectrometry Halotag pull down ion abundances for Halotag, Wild Type Cystatin C-Halotag fusion and 
Variant B Cystatin C-Halotag fusion transfected D407. Table shows those proteins with an ANOVA P-value of <0.05. These are the normalised ion 
abundances from the mass spectrometry output. 
  
Accession Protein Halotag Normalised abundance Wild Type Normalised abundance Variant B Normalised abundance 
ANOVA 
(P=) 
P07711;Q5NE16 Cathepsin L1 13113.03 48227.11 40417.78 3533291 734520.6 4277290 1098944 1036262 2798111 0.000793 
P07858 Cathepsin B 86042.56 62776.73 73531.79 4362367 1006305 4940636 1435178 615334.4 2405779 0.001136 
P53634 Dipeptidyl peptidase 1 27491.31 157320.1 52984.53 8593620 1301101 11220991 852512.1 285743.6 1178349 0.00384 
P11021;O95399 
78 kDa glucose-regulated 
protein 
78167.37 294317.7 55676.82 7384152 911581.5 14463609 979188 637926.2 1398130 0.010751 
P01034 Cystatin-C 76287.66 151379.5 86871.38 5340401 1911358 37207228 341471.9 289242.5 2858737 0.011564 
P35232 Prohibitin 39491.17 60223.67 36007.04 41333.37 26046.57 35478.42 68523.07 60103.76 80632.52 0.021159 
Q9UIQ6 
Leucyl-cystinyl 
aminopeptidase 
39372.51 53683.88 44553.74 3754831 99494.74 2320624 43164.89 82493.12 68016.2 0.033988 
P38646 
Stress-70 protein, 
mitochondrial 
22874.29 67301.2 20673.51 900229.3 99261.2 720731.3 122446.6 242889.6 37965.08 0.048722 
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Table 4.3 Individual T-test values for paired comparisons between differently transfected cells for ANOVA indicated significant proteins (Table 4.2). 
Cathepsins found in wild type and variant B transfected samples are significantly or close to significantly higher than those found in the Halotag control 
sample. Prohibitin displays a very statistically significant difference between wild type and variant B cystatin C and a close to significant difference between 
variant B cystatin C and the control. Confidence score for the mass spectrometry result is included, indicative of reliability of identification of protein in 
question. 
Accession Protein 
Mass Spectrometry 
Confidence Score 
Halotag-Wild Type T-
test (P=) 
Halotag-Variant B T-
test (P=) 
Wild Type-Variant B 
T-test (P=) 
P07711;Q5NE16 Cathepsin L1 645.5 0.059456919 0.049304905 0.380727736 
P07858 Cathepsin B 784.36 0.051830837 0.052599005 0.21662346 
P53634 Dipeptidyl peptidase 1 1143.68 0.078935255 0.058378623 0.10322176 
P11021;O95399 78 kDa glucose-regulated protein 2620.78 0.129978739 0.02070666 0.168435252 
P01034 Cystatin-C 1210.91 0.260533842 0.280220256 0.292267756 
P35232 Prohibitin 199.85 0.27987545 0.063515872 0.008851566 
Q9UIQ6 Leucyl-cystinyl aminopeptidase 1265.14 0.131358 0.200991494 0.134066929 
P38646 Stress-70 protein, mitochondrial 1072.19 0.092001209 0.187372088 0.153761031 
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4.3.2 Other notable protein readings 
Presented here are several observations on proteins that were not detected as significant 
by ANOVA analysis but may be of potential interest. The complete data set can be seen in 
Appendix 1, for complete ion abundance data and spectral count data. 
Despite the significant difference in binding for prohibitin there was no detected 
corresponding difference between wild type cystatin C and variant B cystatin C in 
normalised abundances for prohibitin-2 (P = 0.11). Nor was there any detectable difference 
in level from the control sample. 
A close to significant difference was detected between the wild type and variant B samples 
for voltage-dependent anion-selective channel protein 1, with variant B seeming to bind 
more strongly (P = 0.067). Removal of an apparent outlier (approximately three times 
higher than either of the other two) also resulted in a significant difference between the 
variant B sample and the HaloTag® control sample (P < 0.05). 
Heat shock protein beta-1 is nearly absent in spectral counts from the control and variant B 
samples, however it is clearly present in the wild type samples. Removal of an apparent 
outlier (as for cathepsin) brings normalised abundance differences between wild type and 
variant B samples close to significance (P = 0.062). 
Finally, calmodulin-like protein 3 is close to significantly higher in wild type samples over 
variant B samples (P = 0.063). Removing an apparent outlier from each of the control and 
wild type results in the wild type being significantly higher than either (P < 0.01). 
4.3.3 Summary 
Mass spectrometry analysis produced a wealth of data on potential intracellular binding 
partners for cystatin C. The presence of cathepsins, well known cystatin C targets, served to 
support the integrity of the dataset. 
In particular prohibitin is a stand out result from this dataset, with a significantly higher 
amount of this protein bound to variant B cystatin C compared with either the control or 
wild type cystatin C. With its high binding capability and very high significance it appears to 
be an excellent candidate for future studies. 
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Chapter 5 
Discussion 
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5.1 Overview of results 
This study sought to address two major investigative lines, both of them relating to variant 
B cystatin C. First was the aim of examining some of the major intracellular processes which 
may be influenced by the presence of the variant B protein. Second was the nature of 
variant B interactions within the cell, specifically proteins it binds to and how they may 
relate to RPE cellular mechanisms implicated in AMD pathology. 
In the first instance the processes examined were respiration, apoptosis, autophagy and 
oxidative stress. Respiration was assessed by total ATP content and by oxygen depletion 
utilising an oxygen probe to give an indirect measure of the respiratory rate of the cells. 
Autophagic change was assessed by quantification of relative levels of the two forms of the 
autophagy related protein LC3B, a change being indicative of a change in the number of 
autophagosomes and consequently disruption to the normal rate of autophagy. Apoptosis 
was assessed by the activation of caspase-3, a crucial protein in the caspase cascade and 
the cleavage of which is necessary for activation, based on preliminary data indicating 
cleavage.  
Oxidative stress was measured by flow cytometry and use of the CellROX® oxidative stress 
indicator dye. This allowed for cell-wide levels of reactive oxygen species (ROS) to be 
assessed in large populations of cells, indicating the level of oxidative stress. A statistically 
significant increase in ROS was detected 5 days post transfection in D407 cells transfected 
with wild type cystatin C and variant B cystatin C as evidenced by increased fluorescence of 
the indicator dye.  
In the second instance the protein interactions were assessed by mass spectrometry of 
protein pull-downs. The proteins specifically bound to cystatin C (both wild type and variant 
B) constructs were isolated and assessed for significant differences in rate of binding to the 
two forms of the protein as well as compared to a background level of nonspecific binding. 
A number of significant proteins were identified as binding partners specifically for wild 
type cystatin C, variant B cystatin C or both. Some of these, such as prohibitin, are of 
particular interest and may prove to be starting points for very valuable future work. 
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5.2 Respiration 
5.2.1 Overexpression of EGFP or cystatin C-EGFP fusion protein does not significantly 
affect the rate of respiration  
It was of significant importance to check whether the simple act of overexpressing cystatin 
C would result in changes by itself. The constructs available all overexpress the fusion 
proteins by means of the CMV promoter in order to guarantee large amounts of the protein 
in question in an attempt to trigger any effects associated with their expression. This 
overexpression results in a significant amount of cystatin C being present within the cell, in 
excess of normal physiological conditions. 
Oxygen is used at a specific rate in the respiratory process as the final acceptor for the 
electrons from the electron transport chain. Consequently it can be used as an indirect 
measure of the respiratory process. Specifically by measuring the decreasing level of 
oxygen within a chamber it is possible to indirectly compare the relative rate of respiration 
between samples. 
This oxygen probe data for the overexpression of wild type cystatin C, chapter 3.3.2, 
presented no significant change in the rate of depletion of oxygen, indicating no increase or 
decrease in rate of respiration, compared with untransfected samples. Consequently 
neither the vector itself, nor the overexpression of cystatin C causes an effect on the rate of 
production of ATP. 
This was an expected outcome given the nature of the constructs. The wild type form of 
cystatin C enters the secretory pathway and is passed out of the cell (Paraoan et al., 2001), 
it is not known for being specfically mitochondrially localised and as such it seemed unlikely 
that even high levels of the protein would result in blocking of this specific process. Further, 
the EGFP protein by itself is distributed throughout the cytoplasm upon expression; again, 
giving no reason to expect any effect upon the mitochondria. 
It is worth noting that, although this data indicates that cystatin C has no direct regulatory 
involvement in the respiratory process in cells, there is some evidence in published studies 
to suggest that there is an indirect link between cystatin C and the respiratory processes. 
More specifically it has been noted that growing cancer cells in hypoxic conditions (1% 
oxygen) leads to the down-regulation of cystatin C and an elevated level of cathepsin B, 
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with the effect being greater in metastatic tumour cells (Wickramasinghe et al., 2005), 
linking cystatin C with hypoxia-enhanced tumour progression. Consequently it is possible 
that disruption of respiration, and thus alteration of normal oxygen levels, could result in 
the normal cellular responses being altered by the presence of the variant B gene, given the 
apparent link between oxygen levels and cystatin C expression. 
 
5.2.2 Rate of respiration is not significantly altered by variant B cystatin C 
Given the association with the mitochondria the respiratory process was one possibility by 
which the protein could interfere with normal cellular processes; with the protein 
mislocalisation having the potential for interactions  with one or more of the proteins 
involved in the process such as ATP synthase or part of the electron transport chain. 
Alternatively, assuming no direct interaction with the proteins, the increased concentration 
of protein around the mitochondria might itself interfere with the process. 
The reduction of ATP production capacity in the presence of an age-related protein has 
precedent in the form of A2E, a well established component of lipofuscin which is itself a 
hallmark of ageing (Lamb & Simon, 2004). Recent studies have established that growing 
cells in the presence of A2E inhibits the production of ATP (Saadat et al., 2014). 
Using this method no significant difference was identified in the rate of respiration between 
cells transfected with wild type protein or variant B protein. Further, as for the wild type 
cystatin C and EGFP proteins, no significant difference was found between transfected and 
untransfected cells. This indicates two major points. 
Firstly it indicates that the variant B cystatin C protein does not interfere with the 
respiratory process. This is key, as it provides evidence against respiration being the a major 
source of disruption in the RPE, or indeed in other cells, contributing to disease resulting 
from variant B cystatin C. Given the high energy requirements of RPE cells it would be 
expected that degradation of respiration would result in significant negative effects on the 
cells. The apparent lack of such effects is unsurprising and supportive of a more subtle 
effect on the cellular functions. 
Secondly, it suggests that variant B cystatin C does not bind with part of the respiratory 
pathway to an extent sufficient to have a detrimental effect to the process. The variant B 
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protein is highly mitochondrially located, however it is not known how this occurs. If it were 
to be via the proteins of the respiratory process it might be expected that there would be a 
detrimental effect on the normal functioning of this process given the presence of the 
variant B protein. Since this is evidently not the case it suggests that this is unlikely to be 
the primary way by which variant B protein associates with the mitochondria. 
In summary these results indicate that although reduced ATP production is a feature of 
ageing in cells, variant B cystatin C does not appear to induce a change on the respiratory 
process of RPE cells. Nor does it seem that binding to parts of the respiratory pathway the 
cause of variant B's mislocalisation to the mitochondria.  
 
5.2.3 Total cellular ATP content is not significantly altered by cystatin C wild type or 
cystatin C variant B overexpression 
In addition to the rate of ATP production, data on the total ATP content of cells was 
presented in chapter 3.3.3. Although the rate of production is important and more 
informative with respect to the effect of variant B cystatin C protein given its mitochondrial 
localisation it was also desirable to take distinct measurements of cellular ATP content. This 
allows for the overall state of ATP within the cell to be monitored. More specifically 
although the oxygen depletion may indicate whether or not it is being produced at the 
same rate, only direct ATP measurements can inform whether it is also being consumed at 
the same rate. 
Overall no significant difference was demonstrated between any of the treated samples or 
the controls, indicating that the ATP content within the cells is stable. These findings 
support the previous observation that there is no change in rate whilst simultaneously 
indicating that there is no effect on the usage of ATP, or at least not one that could be 
detected with luciferase assay. 
Given the variety of cellular processes that use ATP this is crucial. Further it has recently 
been established that a decrease in the cellular levels of ATP (such as occurs with ageing) 
can result in increase vulnerability of the cells to damage (Schütt  et al., 2012). As the levels 
are not altered as the result of cystatin C variant B protein expression this provides 
evidence to help rule this out as a method of action.  
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5.3 Apoptosis 
5.3.1 Caspase 3 is not activated by the presence of cystatin C variant B 
Despite indications of involvement of cystatin C in apoptosis from the literature, the variant 
B cystatin C protein does not appear to result in increased levels of caspase 3 activation. 
The RPE cells were not noticeably unhealthy from visual inspection of transfected cells and 
were not dying off in a way that suggested a pro-apoptotic role for the variant. 
Further there was no indication of activation of the caspase 3 protein as a result of the 
overexpression of cystatin C or of the expression of variant B cystatin C. Cleavage of pro-
caspase 3 to its active form is a crucial linked step in the process of activation of the 
apoptotic pathway by both intrinsic and extrinsic pathways. If there were any activation of 
the apoptotic machinery through these pathways it would therefore be expected to result 
in the activation of caspase-3.  
Overall these results seem to preclude the involvement of variant B cystatin C in the 
induction of apoptosis as a key process by which it could be acting. It is unknown why 
preliminary results indicated that this might be the case but the results presented here 
appear to be more expected in light of the variant B involvement in AMD as a progressive 
degenerative disease rather than an acute disease involving mass cell death. 
To clarify AMD is characterised by the degradation of the retina with a build up of deposits 
and neovascularisation through Bruch's membrane and into the photoreceptor layer, 
largely limited to the macular region. It does not involve mass cell death of RPE cells and 
consequently it would seem unlikely that mass triggering of apoptosis as a result of a faulty 
gene product would be the cause.  
Although this experiment indicates that there is no activation of caspase-3 in this incidence 
it does not contradict indications that apoptosis may be a contributory process for the 
progression of degenerative disease. This experiment has focussed specifically on whether 
variant B triggers apoptosis in a healthy cell line, however it may be that apoptosis is a late 
event in such degeneration and thus is outside the scope of this experiment. 
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5.4 Autophagy 
5.4.1 Levels of autophagosomes are not changed by the presence of variant B cystatin C 
Our data indicates that cystatin C does not appear to induce autophagic change in the RPE 
cells of the eye. However this method of autophagy detection has its limitations. Optimally 
for autophagy the autophagic flux should be measured. Although LC3B ratios can inform 
that there is a change in autophagy it provides no information specific to the rate (and, 
indeed, may miss a rate change if both production and clearance are changed to the same 
degree). 
However this result is indicative that there is no disruption to the overall process as a whole 
which would lead to increased numbers or a build up of autophagosomes. Consequently 
this suggests that variant B does not influence autophagy within RPE cells. 
This is perhaps somewhat surprising. Autophagy is a crucial process in the RPE, disruption 
of which has been associated with processes such as damage by A2E (Saadat et al., 2014) 
and increased susceptibility to oxidative stress (Mitter et al., 2014). Further, cystatin C has 
recently been implicated in having a protective role in autophagy in neuronal cells (Tizon et 
al., 2010; Gauthier et al., 2011) . 
It may be theorised that although there is no overall change in levels of autophagosomes 
indicating the disruption of specific stages of the process resulting in autophagy imbalance, 
there may be an effect on the rate of the process as a whole, without creating an imbalance 
within said process. Given the implication of cystatin C in mTOR signalling by Tizon et al. 
(2010) it cannot be ruled out that disruption of normal cystatin C levels could lead to effects 
upon autophagy overall, without changing the number of autophagosomes. 
Given the lack of flux data autophagy cannot totally be ruled out as a contributory process. 
However the data presented here indicate that its involvement is less likely than the 
literature on cystatin C and autophagy would imply. Consequently although it is not to be 
ruled out, this study suggests that autophagy may not be the most valuable line of 
investigation. 
  
134 
 
5.5 Oxidative stress 
5.5.1 Overexpression of wild type cystatin C and variant B cystatin C results in an increase 
in oxidative stress within the cell 
The overexpression of cystatin C results in a significant increase in oxidative stress in the 
D407 RPE cell line over untransfected cells. This effect was not observed with either mock 
transfected cells or EGFP only transfected cells, consequently indicating that the effect is 
due specifically to cystatin C and not in response to the transfection reagent or to the EGFP 
tag (or, by association, by the simple act of protein overexpression with this vector). 
There was no indication of a significant difference between the variant B and wild type 
forms of the protein. This seems to indicate that the presence of cystatin C within the cell is 
sufficient in itself to cause the increase in oxidative stress; which implies that this is a 
simple artefact of overexpression of cystatin C. 
However, it is important to note is that the plasmid constructs lead to the overexpression 
of the proteins in question. As a result there is a far higher concentration of even the wild 
type protein compared with in vivo conditions. Hence this simple explanation may not be 
indicative of what is occurring. 
More specifically, the high level of expression results in a high concentration of cystatin C 
intracellularly; from western blots on cell lysates it is known that there is a large amount of 
cystatin C fusion protein within the cells even with the wild type cystatin C construct as a 
result of the CMV promoter. Consequently even without the mitochondria specific 
localisation it seems highly possible that the very high levels of wild type cystatin C have 
resulted in a build up within the cell, the secretory mechanisms unable to clear the protein 
as effectively. 
This results in a potential explanation and avenue worthy of further examination. 
Specifically that the intracellular accumulation of cystatin C over time can result in 
increased levels of oxidative stress. In the case of variant B cystatin C its impaired secretion 
results in this accumulation occurring more rapidly and increasing risk of degeneration 
resulting in the association with AMD as reported by Zurdel et al. (2001). 
Although speculative, this hypothesis matches both the oxidative stress results in this study 
and with literature on both cystatin C variant B and with oxidative stress in relation to 
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ageing and AMD. There is evidence throughout the literature to suggest that cystatin C has 
a protective role in oxidative stress induced cell death in neuronal cells (Nishio et al., 2000; 
Nishiyama et al., 2005) and that it is regulated by oxidative stress in the RPE (Alizadeh et al., 
2006) suggesting its role as an oxidative stress response. Consequently the suggestion that 
inappropriate cellular processing and retention within the cell of cystatin C, such as in the 
case of variant B cystatin C, could result in disruption ofoxidative stress regulation is highly 
plausible. 
Further work is needed to confirm or refute this hypothesis. However it represents an 
intriguing proposal with the potential to go some way to explaining how variant B cystatin C 
leads to increased levels of oxidative stress in RPE cells. A process which has been 
implicated in AMD. 
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5.6 Mass Spectrometry 
5.6.1 General observations on results 
One of the immediately obvious patterns in the mass spectrometry data is the significant 
number of different keratins within the sample. Which may lead to the conclusion that 
keratins are of particular importance, however that would be in error. Keratins are a very 
common contaminant of mass spectrometry samples, typically resulting from skin and hair. 
More specifically dust in a laboratory is likely to be keratin and it can settle from the 
atmosphere onto glassware and plasticware consequently resulting in contamination. Every 
effort was made in this procedure to avoid this form of contamination, minimising it, 
however this results in the keratins present in the sample being unlikely to be of any 
experimental interest. 
Variation between replicate samples is difficult to avoid, even with every care being taken 
to ensure that samples have been produced identically. Indeed, due to inherent variability 
in the process samples measured multiple times on an instrument in the same way each 
time can vary noticeably. Samples were run sequentially through the same column on the 
same day in order to minimise any difference however there is still a significant amount of 
variation, enough to call into question certain individual readings. This means that it has 
been essential to individually examine proteins of interest to check for outliers and to 
compare individual values. A limitation of this is that this analysis may miss a potential 
protein of interest, although care has been taken to select a number of the most crucial 
results for discussion.  
Finally, both the spectral counts and normalised abundances are of value for analysis. 
Although the normalised abundance is the more sensitive of the two (Milac et al., 2012) the 
spectral counts are also useful both for comparison and to draw attention to proteins which 
have been overlooked in abundance, as determined by ANOVA analysis, due to outlying 
values. 
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5.6.2 Cathepsins are bound at an increased level by wild type cystatin C compared with 
variant B cystatin C 
Cathepsins are well established as inhibitory targets for cystatin C, in particular cathepsins 
B, H, L and S (Barret, 1986; Turk & Bode, 1991) as well as dipeptidyl peptidase I, also known 
as cathepsin C (Nicklin & Barrett, 1984). Cathepsins are proteases which have been linked 
with aggregation based age related diseases including age related macular degeneration 
(Im & Kazlauskas, 2007) and  Alzheimer's disease (Kaur & Levy, 2012; Yamashima, 2013). As 
a specific example, cathepsin B is known to degrade human amyloid-β in mice, amyloid-β 
being a key  (Wang et al., 2012). 
Mass spectrometry confirms the interaction of wild type cystatin C protein with cathepsins 
B, L and C; this serves both as a confirmation that the fusion protein can effectively bind to 
its normal target and demonstrates that the mass spectrometry process is working 
appropriately. Further, the variant B form of the protein also binds to the cathepsins to a 
statistically significant extent, demonstrating that despite the difference in amino acid 
sequence it is still capable of activity. Which is to be expected as the secretion is only 
reduced as a result of the mutation, not eliminated (Paraoan et al., 2004) and the change is 
within the targeting sequence, not within the mature protein. 
After removing an apparent outlier there is also a statistically significant difference in the 
level of binding to cathepsins between variant B cystatin C and wild type cystatin C.  It is 
difficult to say, however, whether this difference is due to an instability in binding (which 
seems unlikely as the amino acid change is in the targeting sequence, not in the mature 
protein) or due to its misassociation with other proteins and the mitochondria. This 
reduced binding seems to be consistent with the expected characteristics of the fusion 
proteins. Specifically wild type cystatin C passes through normal processing pathways 
within the cell and binds with cathepsins. Variant B cystatin C passes through this route at a 
reduced level as a result of its retention and localisation to the mitochondria. 
Consequently although the level is reduced it seems unlikely that this is a result of 
disrupted ability of the mature form of each protein to bind. Instead it is more likely that 
the difference in level of binding is simply due to more wild type cystatin C being processed 
appropriately and thus more cystatin C is present in locations where it can bind with 
cathepsins than variant B cystatin C which has reduced processing given the mislocalisation. 
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5.6.3 Prohibitin 
5.6.3A Overview 
Prohibitin is a widely expressed protein known to be translated from chromosome 17q21 
(Sato et al., 1992). It consists of a 272 amino acid protein chain which associates with 
prohibitin-2 protein. It has been found in a wide variety of species, with homologues of the 
gene present in mammals, Drosophila, C. elegans, plants and yeast (Coates et al., 1997). 
Originally the protein was thought to be of significance in cellular proliferation as a 
suppressor protein and in tumour suppression as well as potential roles in cell senescence 
(Nuell et al., 1991; Liu et al., 1994; McClung, 1995). However it was later demonstrated that 
its antiproliferative activity appears to be localised to the 3' UTR of the gene and 
consequently it is believed that the RNA, rather than the protein, acts as a regulatory 
element. The protein itself has been implicated in processes such as apoptosis (Fusaro et 
al., 2003) and as a molecular chaperone (Nijtmans et al., 2000) 
Prohibitin was found to be mitochondrially localised, originally this was identified using 
immunofluorescence on tagged protein expressed in hamster kidney cells as far back as 
1995 (Ikonen et al.). It is found in the mitochondria as a large complex consisting of two 
subunits with a ring-like structure located at the mitochondria's inner membrane, targeted 
there by noncleavable targeting sequences in the N-terminal of the proteins (Tatsuta et al., 
2005). It seems to be of importance in both the production of new mitochondria and the 
normal metabolic functions of mitochondria as well as acting as a molecular scaffold 
(Nijtmans et al., 2000; Tatsuta et al., 2005). 
In addition prohibitin has become known as being involved in oxidative stress. Most 
relevant for our purposes is the recent discovery of its involvement in oxidative stress in the 
eye. More specifically it has been found that prohibitin is translocated between 
mitochondria and the nucleus and consequently it seems to be an early signalling event for 
oxidative stress in the RPE and the retina (Lee et al., 2010).  
As a result of the above, prohibitin seems a plausible candidate for involvement with 
variant B cystatin C protein. Its involvement with the mitochondria, as well as numerous 
processes implicated in the disease, make it highly relevant to this study. 
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5.6.3B Variant B Cystatin C interacts with Prohibitin protein significantly more than wild 
type cystatin C does 
From the mass spectrometry analysis it is apparent that the variant B form of cystatin C 
interacts with prohibitin to a statistically significantly higher level than the wild type form. 
This is the singular most striking result from the whole of the mass spectrometry dataset, 
with a very strong statistical significance level. 
This presents numerous implications for the understanding of variant B cystatin C. Firstly, as 
a mitochondrial-associated protein the high level of binding of the variant to it immediately 
suggests that this is a possible cause of the mitochondrial localisation. In addition it has 
been established that prohibitin can be found and bind to proteins within the nucleus 
(Wang et al., 2002; Fusaro et al., 2003). This, combined with its mitochondrial specific 
targeting sequence, raises the intriguing possibility that it is the binding of variant B cystatin 
C with this protein that leads to the mitochondrial targeting resulting from the mutation. 
This hypothesis is speculative, but it provides a potential explanation for both the 
mistrafficking to the mitochondria and its apparent retention there. 
 
5.6.3C Variant B Cystatin C does not interact with Prohibitin-2 at a significant level 
In contrast with its partner protein, the mass spectrometry data does not indicate a 
statistically significant difference between the interactions of variant B cystatin C and wild 
type cystatin C with respect to their interaction with prohibitin-2. The lack of binding 
suggests that the binding is specific to the prohibitin subunit and may even inhibit the 
formation of the complex. This is a potential explanation for a way in which variant B 
protein disrupts normal cellular functioning however there is no additional data available to 
draw a conclusion from these observations. 
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5.6.4 Voltage-dependent anion-selective channel protein 1 
Voltage-dependent anion-selective channel protein 1 is a protein found in the outer 
mitochondrial membrane and also in the plasma membrane of cells (Lawen et al., 2005).  In 
mitochondria it provides a channel through which small molecules can diffuse (Colombini, 
1979) and is the major pore-forming protein (Lawen et al., 2005). In particular it is a major 
pathway through which metabolites including ADP/ATP, succinate and citrate are 
exchanged (Benz, 1994). 
The higher rate detected in binding of the variant B cystatin C and wild type cystatin C as 
well as the statistically significant difference from the HaloTag® control suggests that this 
may be another mitochondrial protein responsible for variant B's localisation. Extensive 
binding of cystatin C to a crucial pore protein such as this might be assumed to block its 
function. However our findings on respiration suggest that this is unlikely, as restricted 
exchange of crucial metabolites would be expected to lead to a disruption of the 
respiratory process. 
Interestingly VDAC has recently been implicated in superoxide diffusion from the 
mitochondrial intermembrane space and consequently in the role of oxidative stress in 
relation to the mitochondria. Specifically dihydroetheidium oxidation was observed to be 
slowed in muscle fibre cells following antimycin A treatment when VDAC inhibitors were 
present (Sakellariou et al., 2013). Further it has been demonstrated that reduced levels of 
VDAC1 result in significantly reduced levels of lipid peroxidation in a VDAC1 +/- mouse 
model in comparison to VDAC1 +/+ mice (Manczak et al., 2013); which appears to be 
further evidence of VDAC1's involvement in increasing levels of reactive oxygen species 
within the intracellular environment. 
Taken together with the above oxidative stress data this is highly suggestive of an effect of 
intracellularly retained cystatin C having an effect on oxidative stress through its 
mitochondrial association. 
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5.6.5 Other mass spectrometry implicated cystatin C binding partners 
5.6.5A 78 kDa glucose-regulated protein 
This protein is believed to be involved in correct folding of proteins via interaction with 
DNAJC10 (Uniprot P11021) in the endoplasmic reticulum. Consequently the statistically 
significant binding rate with wild type cystatin C is easy to understand as, presumably, the 
interaction comes about through the processing steps. Although it does not seem 
significant with respect to the effect of variant B cystatin C this result supports the wild type 
cystatin C construct being properly processed by the secretory pathway and thus is perhaps 
noteworthy as an additional point of evidence in favour of the quality of the mass 
spectrometry dataset. 
 
5.6.5B Leucyl-cystinyl aminopeptidase 
Significantly binds to wild type cystatin C. Also known as oxytocinase it is involved in the 
release of N-terminal amino acids (Uniprot Q9UIQ6). It is believed to be the angiotensin IV 
receptor in the brain (Gard, 2008) with angiotensin IV having links with Alzheimer's disease 
through being a potential treatment target (Wright & Harding, 2008). 
 
5.6.5C Mitochondrial stress-70 protein 
A heat shock protein localised to mitochondria but also found in the endoplasmic 
reticulum, plasma membrane and cytoplasmic vesicles. Plays a role in cell proliferation, 
stress response and maintenance of the mitochondria (NCBI Gene database). The mass 
spectrometry data indicates it binds significantly with wild type cystatin C which is unusual 
given its mitochondrial localisation, however given that it is also found in parts of the 
secretory pathway it is difficult to determine how significant this finding is. 
 
5.6.5E Heat shock protein beta-1 
Also known as HSP27 (Uniprot P04792)  and appears to be significantly bound to wild type 
cystatin C. Known to be involved in stress resistance and actin organisation and has been 
implicated as a mediator of oxidative injury to the RPE cells (Pons et al., 2010) and is highly 
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expressed in the RPE (Strunnikova et al., 2001). May be involved in coping with the stress of 
the internal overexpression of cystatin C. 
 
5.6.5F Calmodulin-like protein 3 
Believed to compete with calmodulin for cellular substrates, calmodulin is a messenger 
protein for the transduction of calcium signals and is involved in control of a number of 
enzymes and ion channels. Implicated in Alzheimer's disease (Min et al., 2013). Appears to 
bind significantly with wild type cystatin C but the effect of this on intracellular processes 
and how this relates to the RPE cells is unknown.  
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5.7 Future work 
For each of the two main lines of work in this study, one result stands out in particular from 
the rest as being particularly worthy of further investigation. The most promising step 
onwards from the mass spectrometry results is for additional follow up work to be carried 
out on the subject of prohibitin's potential interaction with variant B cystatin C. Following 
analysis of the mass spectrometry results an attempt was made to confirm the prohibitin 
result using western blot analysis, as well as to measure the relative levels of prohibitin in 
transfected cell lysates. Unfortunately due to time limitations it was not possible to 
optimise and complete these experiments in time for this study. However this is a key step 
to further future work. It may be necessary to carry out an ELISA to quantify the level of 
prohibitin, there are a number of commercial prohibitin ELISA kits that could fulfil this 
purpose. 
Voltage-dependent anion-selective channel protein 1 appears to also be a protein of 
interest and would also benefit from additional experiments. Papers published within the 
past few years link this protein to Alzheimer's disease and to oxidative stress, therefore it 
seems quite possible that it is also involved with variant B cystatin C mediated AMD. 
However prohibitin appears to be the better candidate of the two (if one is to be chosen) 
for immediate follow up research given its potential to be both the cause of the 
mitochondrial targeting and the reason for its localisation there whilst also being linked to 
oxidative stress in the RPE. 
In addition to the above, immunofluorescence in live cells could be used to monitor the 
localisation of cystatin C with these potential bound proteins. This is significantly simplified 
due to the work done in this study to create the HaloTag® construct. As HaloTag® itself is 
not intrinsically fluorescent there is great flexibility in experimental design, meaning that 
producing good quality images should be possible. In the case of prohibitin in particular this 
will provide information about where in the cell variant B cystatin C is bound to prohibitin 
and whether prohibitin is acting as an anchor to the mitochondria or variant B cystatin C is 
being transported there by prohibitin, or perhaps both. An more informative approach 
might be to attempt to monitor fluorescence via a time course. 
Following this there are a number of experiments that could be carried out. The 
interactions between prohibitin and prohibitin 2 as a result of the presence of cystatin C 
variant B would be a valuable piece of information. Ideally the effect of cystatin C variant B 
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on mitochondrial biogenesis would be measured, given the that prohibitin is implicated in 
the process. Perhaps through visualisation and measurement of mitochondria using 
mitochondrial dyes on samples (Medeiros, 2008). 
Assuming that prohibitin is indeed confirmed as a binding partner for variant B cystatin C it 
would be valuable to use protein interaction modelling in an attempt to specifically identify 
how this interaction occurs. If it is due to the targeting sequence of variant B cystatin C this 
would explain exactly why this amino acid substitution results in the mislocalisation. 
For the functional assays the oxidative stress measurements are of greatest interest and 
warrant additional work. The great importance of oxidative stress in AMD pathology 
coupled with the link between variant B, mitochondria and AMD suggests that this could be 
a method of action for the variant B protein if it can be verified. 
Unfortunately the constructs used to date all rely on the CMV promoter which massively 
overexpresses the protein. This is an effective way to exaggerate a response for 
measurement, however it means the protein is present at non-physiological levels 
compared in vivo RPE cells. The consequence being in this case that potentially the level of 
wild type cystatin C within the cell is inadvertently leading to a phenotype similar to that of 
variant B cystatin C being retained within the cell. 
The solution to this is the production of constructs utilising the normal promoter for human 
cystatin C. By expressing with the normal promoter and regulatory elements it is expected 
that cystatin C would be produced at normal cellular levels for RPE cells and thus this would 
be a much more accurate reflection of the effects in vivo. One disadvantage of this 
approach, however, is that effects may be masked by the endogenous cystatin C. 
In addition, this construct could be used to examine other processes perhaps  to re-
examine those already studied here but under a physiologically-relevant concentration. 
Given the low level of response likely from low levels of protein it is likely even more 
sensitive assays would be needed.  Nevertheless a plasmid construct with the human 
promoter would be a very valuable research tool and would be an excellent next step. 
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5.8 Concluding remarks 
A number of progressive steps in our understanding of variant B cystatin C have resulted 
from this study. Firstly, the apparent increase in oxidative stress resulting from high levels 
of intracellular cystatin C is of potentially great importance to the understanding of variant 
B cystatin C's effect on RPE cells. If this is indeed the method of action for variant B cystatin 
C then it once again raises the question of to what extent is oxidative stress a central cause 
of AMD and ageing in general. Verifying that this occurs as a result of cystatin C intracellular 
build up is an extremely important next step. 
In addition two mitochondrial based proteins which appear to interact with variant B 
cystatin C have been identified, opening up new lines of investigation with the potential to 
push forward our understanding of this mislocalisation. If a variant B cystatin C protein 
interaction at the mitochondria were to be confirmed this will provide a clear avenue of 
further investigation for the  effects of variant B on the RPE cells and the integration of that 
into the larger picture of AMD pathogenesis. 
Finally a potential explanation for how variant B cystatin C's mislocalisation to the 
mitochondria occurs in the form of prohibitin has been identified. If this is validated as the 
pathway (or at least a pathway) by which variant B is mislocalised then the long standing 
question of precisely how the single base mutation in the targeting sequence of cystatin C 
causes intracellular retention and mitochondrial mislocalisation may finally be answered. 
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Appendix Table 1: Complete ion abundance data for mass spectrometry experiment. ANOVA values for significance are included. 
Accession Protein Halotag Normalised abundance Wild Type Normalised abundance Variant B Normalised abundance 
ANOVA 
(P=) 
P07711;Q5NE16 
Cathepsin L1 OS=Homo 
sapiens GN=CTSL PE=1 SV=2 
13113.03 48227.11 40417.78 3533291 734520.6 4277290 1098944 1036262 2798111 0.000793 
P07858 
Cathepsin B OS=Homo 
sapiens GN=CTSB PE=1 SV=3 
86042.56 62776.73 73531.79 4362367 1006305 4940636 1435178 615334.4 2405779 0.001136 
P53634 
Dipeptidyl peptidase 1 
OS=Homo sapiens GN=CTSC 
PE=1 SV=2 
27491.31 157320.1 52984.53 8593620 1301101 11220991 852512.1 285743.6 1178349 0.00384 
P11021;O95399 
78 kDa glucose-regulated 
protein OS=Homo sapiens 
GN=HSPA5 PE=1 SV=2 
78167.37 294317.7 55676.82 7384152 911581.5 14463609 979188 637926.2 1398130 0.010751 
P01034 
Cystatin-C OS=Homo sapiens 
GN=CST3 PE=1 SV=1 
76287.66 151379.5 86871.38 5340401 1911358 37207228 341471.9 289242.5 2858737 0.011564 
P35232 
Prohibitin OS=Homo sapiens 
GN=PHB PE=1 SV=1 
39491.17 60223.67 36007.04 41333.37 26046.57 35478.42 68523.07 60103.76 80632.52 0.021159 
Q9UIQ6 
Leucyl-cystinyl 
aminopeptidase OS=Homo 
sapiens GN=LNPEP PE=1 SV=3 
39372.51 53683.88 44553.74 3754831 99494.74 2320624 43164.89 82493.12 68016.2 0.033988 
169 
 
P38646 
Stress-70 protein, 
mitochondrial OS=Homo 
sapiens GN=HSPA9 PE=1 
SV=2 
22874.29 67301.2 20673.51 900229.3 99261.2 720731.3 122446.6 242889.6 37965.08 0.048722 
P10620 
Microsomal glutathione S-
transferase 1 OS=Homo 
sapiens GN=MGST1 PE=1 
SV=1 
1641.517 3141.681 433.8308 10914.03 1798.646 2841.203 12411.44 20345.96 6111.78 0.058656 
P62937;Q9Y536 
Peptidyl-prolyl cis-trans 
isomerase A OS=Homo 
sapiens GN=PPIA PE=1 SV=2 
29470.73 162034.3 12643.23 292088.5 97330.7 263163.1 315751.9 498830.2 152595 0.07311 
P05141;P12235 
ADP/ATP translocase 2 
OS=Homo sapiens 
GN=SLC25A5 PE=1 SV=7 
9393.296 39520.21 13843.83 145886.5 32156.45 67251.9 38041.04 92643.51 63980.06 0.080526 
P27348 
14-3-3 protein theta 
OS=Homo sapiens 
GN=YWHAQ PE=1 SV=1 
0 20706.29 0 2856.544 1263.53 1177.183 0 0 0 0.082311 
P08107;P17066;P48741 
Heat shock 70 kDa protein 
1A/1B OS=Homo sapiens 
GN=HSPA1A PE=1 SV=5 
7479.263 29820.18 4588.248 254641.1 24926.59 151876.9 26550.67 65418.14 10251.86 0.094093 
P06899;Q6DN03 
Histone H2B type 1-J 
OS=Homo sapiens 
GN=HIST1H2BJ PE=1 SV=3 
245.1087 2899.985 380.4734 2616.036 25814.98 2339.599 123.3444 152.0741 1849.241 0.10787 
170 
 
P53999 
Activated RNA polymerase II 
transcriptional coactivator 
p15 OS=Homo sapiens 
GN=SUB1 PE=1 SV=3 
532.7164 1707.237 35.01324 2937.899 5459.864 1685.558 6111.674 12202.11 1039.289 0.124139 
P11142;P54652 
Heat shock cognate 71 kDa 
protein OS=Homo sapiens 
GN=HSPA8 PE=1 SV=1 
75182.39 235862.4 39617.75 1519797 155003.8 786293.8 135869.4 323164.2 66244.67 0.126988 
P62979 
Ubiquitin-40S ribosomal 
protein S27a OS=Homo 
sapiens GN=RPS27A PE=1 
SV=2 
155769.6 246037.2 40204.98 649273.1 334605 612750.7 82389.5 521172.7 109571 0.147286 
Q99623 
Prohibitin-2 OS=Homo 
sapiens GN=PHB2 PE=1 SV=2 
30298.4 64060.42 31402.53 43260.65 24924.31 28322.11 96167.18 38163.75 70684.28 0.165195 
P31151 
Protein S100-A7 OS=Homo 
sapiens GN=S100A7 PE=1 
SV=4 
0 171.4909 0 160.8923 166.4249 21031.89 0 0 488.73 0.171072 
Q15149 
Plectin OS=Homo sapiens 
GN=PLEC PE=1 SV=3 
1727.877 15092.12 541.861 8798.345 120412.7 11130.47 3437.309 7242.767 1855.088 0.173123 
P23396 
40S ribosomal protein S3 
OS=Homo sapiens GN=RPS3 
PE=1 SV=2 
24620.44 91909.58 13473.82 394026.6 89002.09 70539.27 115645.2 219705.2 48929.75 0.178646 
P12236 
ADP/ATP translocase 3 
OS=Homo sapiens 
GN=SLC25A6 PE=1 SV=4 
4217.865 9195.174 4589.295 52767.26 5581.639 10046.29 16882.42 25974.56 15182.11 0.188879 
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P62249 
40S ribosomal protein S16 
OS=Homo sapiens GN=RPS16 
PE=1 SV=2 
11865.3 11898.78 4949.291 40992.88 39464.68 8171.663 23403.1 50393.92 15593.7 0.189398 
P22314 
Ubiquitin-like modifier-
activating enzyme 1 
OS=Homo sapiens GN=UBA1 
PE=1 SV=3 
9.665088 1212.953 0 141.5592 636.5612 3.198 2749.157 8714.175 349.511 0.2036 
Q06830;P32119;Q13162 
Peroxiredoxin-1 OS=Homo 
sapiens GN=PRDX1 PE=1 
SV=1 
144872.8 231173.1 135787.2 309433.2 110144.7 203966.5 243880.6 288676.1 362547.5 0.209532 
A8MT79 
Putative zinc-alpha-2-
glycoprotein-like 1 OS=Homo 
sapiens PE=5 SV=2 
2896.413 4525.868 2524.937 4446.255 9383.985 22808.24 3778.97 28742.47 7448.632 0.221211 
P21796 
Voltage-dependent anion-
selective channel protein 1 
OS=Homo sapiens GN=VDAC1 
PE=1 SV=2 
14616 72965.27 23301.79 37358.05 25176.97 47344.92 51902.55 65224.53 86685.09 0.222051 
P06748 
Nucleophosmin OS=Homo 
sapiens GN=NPM1 PE=1 SV=2 
11372.25 31949.59 20361.11 27868.83 194008.8 67152.13 15039.27 83673.06 18390.76 0.227452 
P84095 
Rho-related GTP-binding 
protein RhoG OS=Homo 
sapiens GN=RHOG PE=1 SV=1 
483.5288 7328.744 992.581 25731.42 846.2422 13003.81 0 24795.77 0 0.228527 
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Q8NC51 
Plasminogen activator 
inhibitor 1 RNA-binding 
protein OS=Homo sapiens 
GN=SERBP1 PE=1 SV=2 
358.3373 1093.083 0 2268.619 1331.332 2000.049 984.067 3407.9 1054.015 0.229626 
P07437;A6NKZ8;A6NNZ2;Q
13885;Q9BUF5;Q9H4B7 
Tubulin beta chain OS=Homo 
sapiens GN=TUBB PE=1 SV=2 
20800.08 133209.6 10379.49 650494.6 52869.02 80925.95 110260 255439.5 104260.9 0.235618 
P62913 
60S ribosomal protein L11 
OS=Homo sapiens GN=RPL11 
PE=1 SV=2 
5020.837 29654.06 3145.072 65063.15 53135.43 10502.11 20538.64 42587.06 12411.1 0.242398 
P04792 
Heat shock protein beta-1 
OS=Homo sapiens GN=HSPB1 
PE=1 SV=2 
19868.11 113933.4 3033.569 204276.6 63841.02 160007 55391.6 81426.75 11965.35 0.246318 
Q08211 
ATP-dependent RNA helicase 
A OS=Homo sapiens 
GN=DHX9 PE=1 SV=4 
0 682.7522 0 1016.908 11053.31 0 2901.396 12533.72 425.837 0.247831 
P62888 
60S ribosomal protein L30 
OS=Homo sapiens GN=RPL30 
PE=1 SV=2 
4257.212 10560.23 2341.326 6144.587 24108.8 10867.94 10394.13 19381.69 6434.29 0.260156 
P61978 
Heterogeneous nuclear 
ribonucleoprotein K 
OS=Homo sapiens 
GN=HNRNPK PE=1 SV=1 
3132.741 25100.79 971.9891 21463.29 15637.07 26927.3 29709.15 85925.56 4873.354 0.266266 
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P27482 
Calmodulin-like protein 3 
OS=Homo sapiens 
GN=CALML3 PE=1 SV=2 
960.7899 84307.5 2738.187 44016.62 12494.79 54986.75 4989.855 5222.784 3835.266 0.285151 
P62847 
40S ribosomal protein S24 
OS=Homo sapiens GN=RPS24 
PE=1 SV=1 
5073.946 9157.179 2860.024 3136.422 1854.097 0 12018.56 6139.535 2040.283 0.288213 
P60660;P14649 
Myosin light polypeptide 6 
OS=Homo sapiens GN=MYL6 
PE=1 SV=2 
11149.72 36550.49 6835.172 23800.85 6778.879 8479.292 6093.078 8747.523 2741.108 0.290053 
P62826 
GTP-binding nuclear protein 
Ran OS=Homo sapiens 
GN=RAN PE=1 SV=3 
10445.95 17961.89 2402.434 29265.26 16870.28 5708.014 21725.66 62419.21 14447.84 0.292968 
P10809 
60 kDa heat shock protein, 
mitochondrial OS=Homo 
sapiens GN=HSPD1 PE=1 
SV=2 
37350.48 66434.41 23919.51 104997.2 58268.29 227482.7 41123.83 195472.1 33581.87 0.295966 
P52597 
Heterogeneous nuclear 
ribonucleoprotein F 
OS=Homo sapiens 
GN=HNRNPF PE=1 SV=3 
8267.865 27194.76 1302.397 6983.572 24541.33 5961.129 46233.86 51344.79 11365.8 0.297689 
P10599 
Thioredoxin OS=Homo 
sapiens GN=TXN PE=1 SV=3 
13650.61 37740.69 6719.273 74121.18 20447.47 52042.63 10265.46 43718.98 21538.24 0.30109 
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P09211 
Glutathione S-transferase P 
OS=Homo sapiens GN=GSTP1 
PE=1 SV=2 
0 19277.34 46.13795 1636.873 1431.456 3464.013 8505.175 25609.23 823.8745 0.306923 
P23528;Q9Y281 
Cofilin-1 OS=Homo sapiens 
GN=CFL1 PE=1 SV=3 
 
6634.527 65469.18 1248.369 108995.2 20454.09 102909.5 4167.226 70063.04 8908.491 0.31484 
Q71UM5 
40S ribosomal protein S27-
like OS=Homo sapiens 
GN=RPS27L PE=1 SV=3 
736.453 4563.391 590.1875 8982.777 4453.93 3027.23 3277.199 5939.755 546.8993 0.322134 
Q00839 
Heterogeneous nuclear 
ribonucleoprotein U 
OS=Homo sapiens 
GN=HNRNPU PE=1 SV=6 
14990.55 18616.81 8271.909 14884.28 76009.78 21253.33 17887.64 34015.32 17794.25 0.32766 
P01876;P01877 
Ig alpha-1 chain C region 
OS=Homo sapiens GN=IGHA1 
PE=1 SV=2 
66.54413 61437.61 1369.187 4.72617 0 3726.004 278.4505 553.6813 190.4825 0.327777 
P13639 
Elongation factor 2 OS=Homo 
sapiens GN=EEF2 PE=1 SV=4 
243.5559 18716.73 138.5916 10423.14 3872.681 18768.43 62.65754 10644.71 306.8015 0.3292 
P49411 
Elongation factor Tu, 
mitochondrial OS=Homo 
sapiens GN=TUFM PE=1 SV=2 
9742.697 5588.227 1234.161 30663.94 5120.173 10669.3 5400.737 14222.45 13288.8 0.331268 
P06702 
Protein S100-A9 OS=Homo 
sapiens GN=S100A9 PE=1 
SV=1 
2067.364 57554.1 4848.434 3408.474 1133.391 642.8835 885.2019 2273.055 13834.02 0.335502 
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P14324 
Farnesyl pyrophosphate 
synthase OS=Homo sapiens 
GN=FDPS PE=1 SV=4 
96.38554 984.0768 0 363.4856 342.179 569.5343 1388.981 3126.383 86.77479 0.359523 
P09651;Q32P51 
Heterogeneous nuclear 
ribonucleoprotein A1 
OS=Homo sapiens 
GN=HNRNPA1 PE=1 SV=5 
2242.632 18877.84 2400.424 5525.261 62586.75 12117.28 1125.025 25181.18 280.4879 0.365303 
P80723 
Brain acid soluble protein 1 
OS=Homo sapiens GN=BASP1 
PE=1 SV=2 
12327.93 8362.618 7286.852 28633.12 9385.827 21438.68 1939.989 30757.18 2739.034 0.366128 
P61353 
60S ribosomal protein L27 
OS=Homo sapiens GN=RPL27 
PE=1 SV=2 
1909.413 1085.983 91.62424 901.3417 3852.167 869.1463 3067.026 3072.597 1172.556 0.368767 
P08195 
4F2 cell-surface antigen 
heavy chain OS=Homo 
sapiens GN=SLC3A2 PE=1 
SV=3 
 
391.0046 1752.731 1277.137 8271.972 481.0362 1520.28 2625.718 10668.16 1845.617 0.370272 
P67936 
Tropomyosin alpha-4 chain 
OS=Homo sapiens GN=TPM4 
PE=1 SV=3 
252.5539 4579.481 0 6638.003 711.4677 759.4386 0 3633.434 0 0.372536 
P60174 
Triosephosphate isomerase 
OS=Homo sapiens GN=TPI1 
PE=1 SV=3 
3165.724 24508.6 18.81876 14045.74 6742.03 6628.407 2.602118 9364.669 170.1631 0.374694 
176 
 
P05090 
Apolipoprotein D OS=Homo 
sapiens GN=APOD PE=1 SV=1 
2816.893 5727.335 2945.705 3333.823 130789.6 2503.882 4604.506 2184.671 534.3652 0.378556 
P31944 
Caspase-14 OS=Homo 
sapiens GN=CASP14 PE=1 
SV=2 
4906.257 7900.542 832.8636 13084.5 2050.713 52519.21 8758.059 11210.49 12662.07 0.384554 
P62263 
40S ribosomal protein S14 
OS=Homo sapiens GN=RPS14 
PE=1 SV=3 
2727.655 8302.627 243.3454 9411.487 10376.53 2887.308 9300.896 15266.35 2176.115 0.390748 
Q8NHW5 
60S acidic ribosomal protein 
P0-like OS=Homo sapiens 
GN=RPLP0P6 PE=5 SV=1 
5436.534 6458.15 1411.768 4671.192 10255.2 5241.744 10032.82 26944.21 3371.657 0.394854 
Q07021 
Complement component 1 Q 
subcomponent-binding 
protein, mitochondrial 
OS=Homo sapiens GN=C1QBP 
PE=1 SV=1 
9078.38 22206.35 3235.061 68611.6 9560.322 52240.08 6564.714 65212.99 8315.135 0.398124 
P61604 
10 kDa heat shock protein, 
mitochondrial OS=Homo 
sapiens GN=HSPE1 PE=1 SV=2 
6739.212 19096.77 0 43172.5 14551.5 60542.9 77.89647 51337.46 146.1069 0.398934 
P26373 
60S ribosomal protein L13 
OS=Homo sapiens GN=RPL13 
PE=1 SV=4 
10338.08 10562.39 3148.34 8662.245 31878.02 3108.51 22512.42 26961.51 10471.05 0.402434 
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P49207 
60S ribosomal protein L34 
OS=Homo sapiens GN=RPL34 
PE=1 SV=3 
1819.8 5616.845 286.3723 3121.448 2022.631 1820.933 6233.019 6402.552 2124.724 0.407152 
P07737 
 
Profilin-1 OS=Homo sapiens 
GN=PFN1 PE=1 SV=2 
 
 
26961.97 121406.3 1303.885 49181.99 60096.36 19019.5 113664.2 334842.1 27684.14 0.408074 
Q00325 
Phosphate carrier protein, 
mitochondrial OS=Homo 
sapiens GN=SLC25A3 PE=1 
SV=2 
7071.125 18819.97 9941.442 44403.4 7537.672 42831.11 16791.26 41920.6 14213.43 0.414779 
P60709;A5A3E0;P0CG38;P
0CG39;P62736;P68032;Q6
S8J3;Q9BYX7 
Actin, cytoplasmic 1 
OS=Homo sapiens GN=ACTB 
PE=1 SV=1 
401348.1 1953730 572655.6 1922138 957543.5 1375907 506634.5 1225998 679480.5 0.415423 
P62701;P22090 
40S ribosomal protein S4, X 
isoform OS=Homo sapiens 
GN=RPS4X PE=1 SV=2 
1457.84 5890.872 282.0348 2823.683 7602.5 707.4862 7116.985 9160.099 2301.909 0.422125 
P62857 
40S ribosomal protein S28 
OS=Homo sapiens GN=RPS28 
PE=1 SV=1 
11059.83 11922.6 13765.26 33287.41 11703.02 23794.85 9938.27 30059.18 9958.472 0.424428 
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P07910;O60812 
Heterogeneous nuclear 
ribonucleoproteins C1/C2 
OS=Homo sapiens 
GN=HNRNPC PE=1 SV=4 
4074.201 11667.58 1750.584 5141.099 172959.6 8437.719 3097.848 12790.72 12842.36 0.425924 
P36578 
60S ribosomal protein L4 
OS=Homo sapiens GN=RPL4 
PE=1 SV=5 
2362.119 4118.333 1460.461 2047.396 7623.146 354.7611 5455.221 11736.33 2651.7 0.428325 
P43307 
Translocon-associated 
protein subunit alpha 
OS=Homo sapiens GN=SSR1 
PE=1 SV=3 
260.4053 2186.581 1808.172 7558.485 357.9385 0 4233.107 1552.53 3008.035 0.4436 
P00338;P07864 
L-lactate dehydrogenase A 
chain OS=Homo sapiens 
GN=LDHA PE=1 SV=2 
16664.91 115136.1 2687.722 49607.02 67065.22 38362.23 141829.2 356046.4 12968.7 0.44495 
P45880 
Voltage-dependent anion-
selective channel protein 2 
OS=Homo sapiens GN=VDAC2 
PE=1 SV=2 
25877.63 95260.99 36281.23 79523.78 27589.69 46828.6 65727.87 61315.97 108887.5 0.445276 
P30041 
Peroxiredoxin-6 OS=Homo 
sapiens GN=PRDX6 PE=1 
SV=3 
 
 
1651.658 3492.913 0 7001.628 3187.642 455.5918 3136.161 10486.73 831.8769 0.450808 
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Q71U36;A6NHL2;Q13748;
Q6PEY2;Q9BQE3;Q9H853;
Q9NY65 
Tubulin alpha-1A chain 
OS=Homo sapiens 
GN=TUBA1A PE=1 SV=1 
373.5554 13735.16 592.4726 44122.03 8203.964 1385.242 11766.08 23254.9 1136.386 0.472955 
P06576 
ATP synthase subunit beta, 
mitochondrial OS=Homo 
sapiens GN=ATP5B PE=1 SV=3 
19425.95 37605.08 14872.18 43301.08 18279.83 62815.81 21745.72 36689.39 20921.04 0.474901 
Q15366 
Poly(rC)-binding protein 2 
OS=Homo sapiens GN=PCBP2 
PE=1 SV=1 
1191.138 7758.481 892.8504 5791.138 3298.22 8855.575 7884.038 14276.1 1144.96 0.480621 
P07339 
Cathepsin D OS=Homo 
sapiens GN=CTSD PE=1 SV=1 
1629.477 7784.662 147.3561 5149.49 1910.249 8604.697 3162.118 5205.398 1850.577 0.490568 
P02795 
Metallothionein-2 OS=Homo 
sapiens GN=MT2A PE=1 SV=1 
689.9888 2596.554 390.3806 6916.828 663.4322 730.9614 211.0675 6685.829 0 0.497726 
Q9NQ39 
Putative 40S ribosomal 
protein S10-like OS=Homo 
sapiens GN=RPS10P5 PE=5 
SV=1 
2498.518 7035.834 3184.254 19681.32 7489.932 4033.077 6469.173 19365.37 2630.515 0.498639 
P01834 
Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 
6698.851 806784.5 12122.91 12953.67 9096.575 13563.39 10128.99 14447.26 5702.405 0.499237 
P08779;O76013;P35900;Q
7Z3Y9;Q8N1A0;Q99456 
Keratin, type I cytoskeletal 16 
OS=Homo sapiens GN=KRT16 
PE=1 SV=4 
125026.3 599418.8 984697.5 130458.2 37737.3 131975.3 30922.44 6738021 244082.8 0.506047 
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P07195 
L-lactate dehydrogenase B 
chain OS=Homo sapiens 
GN=LDHB PE=1 SV=2 
3046.033 11001.4 15.00021 17095.79 12874.32 2067.125 53172.54 120395.2 240.6979 0.512072 
Q07020 
60S ribosomal protein L18 
OS=Homo sapiens GN=RPL18 
PE=1 SV=2 
19733.87 30072.5 10580.05 17706.16 44386.48 26052.6 27111.27 59060.38 17845.3 0.516548 
P63244 
Guanine nucleotide-binding 
protein subunit beta-2-like 1 
OS=Homo sapiens 
GN=GNB2L1 PE=1 SV=3 
 
 
 
1551.193 9931.967 1678.968 14960.98 4047.999 6672.025 17633.27 38628.25 1293.234 0.51998 
P56134 
ATP synthase subunit f, 
mitochondrial OS=Homo 
sapiens GN=ATP5J2 PE=1 
SV=3 
807.9087 3159.532 3169.689 4501.577 1076.231 0 0 835.6917 517.7817 0.521545 
P50914 
60S ribosomal protein L14 
OS=Homo sapiens GN=RPL14 
PE=1 SV=4 
5876.198 13819.55 1149.515 5385.463 18036.49 77.86273 12147.71 20782.82 6539.508 0.525109 
P58107 
Epiplakin OS=Homo sapiens 
GN=EPPK1 PE=1 SV=2 
0 3453.648 0 0 46789.19 9091.431 0 717.3711 0 0.526173 
181 
 
P63313;P62328 
Thymosin beta-10 OS=Homo 
sapiens GN=TMSB10 PE=1 
SV=2 
23868.98 26125.81 92.97859 42556.9 22969.9 11972.37 1064.096 35588.5 679.3189 0.528163 
P06454 
Prothymosin alpha OS=Homo 
sapiens GN=PTMA PE=1 SV=2 
18142.65 27937.88 266.9306 52397.24 20873.81 10527.19 449.8733 51977.36 1325.289 0.53063 
P14174 
Macrophage migration 
inhibitory factor OS=Homo 
sapiens GN=MIF PE=1 SV=4 
10066.68 54659.69 0 10234.79 6663.247 4782.534 22836.77 35757.75 9271.517 0.538645 
P25705 
ATP synthase subunit alpha, 
mitochondrial OS=Homo 
sapiens GN=ATP5A1 PE=1 
SV=1 
7687.852 64209.52 10179.84 60049.3 26886.67 48474.09 56595.39 116291.5 8715.265 0.53875 
P06733;P09104;P13929 
Alpha-enolase OS=Homo 
sapiens GN=ENO1 PE=1 SV=2 
28387.61 219189 10378.08 225835 52236.8 133274.5 10156.21 262590.2 12282.86 0.542443 
P02787 
Serotransferrin OS=Homo 
sapiens GN=TF PE=1 SV=3 
7702.333 427471.1 10408.13 14044.93 9315.036 10087.34 7964.094 14995.64 12010.22 0.546749 
P46781 
40S ribosomal protein S9 
OS=Homo sapiens GN=RPS9 
PE=1 SV=3 
936.6739 5538.217 1685.502 2457.664 14288.61 0 3587.775 5810.468 5936.071 0.547514 
P05387 
60S acidic ribosomal protein 
P2 OS=Homo sapiens 
GN=RPLP2 PE=1 SV=1 
28941.27 41479.41 17539.35 93423.33 69486.42 16906.97 33189.22 80257.65 35721.22 0.549169 
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P67809 
Nuclease-sensitive element-
binding protein 1 OS=Homo 
sapiens GN=YBX1 PE=1 SV=3 
29104.21 27814.39 708.2476 32309.05 34289.42 13413.7 26583.68 53153.2 10720.73 0.555374 
P01024 
Complement C3 OS=Homo 
sapiens GN=C3 PE=1 SV=2 
288.8026 22785.59 262.4533 374.5839 387.4936 129.8754 536.2411 1388.435 183.1002 0.556237 
P05787;P41219;Q9NSB2 
Keratin, type II cytoskeletal 8 
OS=Homo sapiens GN=KRT8 
PE=1 SV=7 
56816.26 76031.42 130976.5 92059.94 1003372 75296.89 152862.5 317300.7 80579.09 0.56276 
Q02543 
60S ribosomal protein L18a 
OS=Homo sapiens 
GN=RPL18A PE=1 SV=2 
2121.809 7853.826 1028.439 1869.95 9267.594 1871.917 4424.423 11780.31 3370.751 0.571105 
P04075 
Fructose-bisphosphate 
aldolase A OS=Homo sapiens 
GN=ALDOA PE=1 SV=2 
1096.848 17471.61 28.46111 5667.587 3625.861 10396.37 4265.032 13591.01 265.1161 0.57518 
P11940;Q13310 
Polyadenylate-binding 
protein 1 OS=Homo sapiens 
GN=PABPC1 PE=1 SV=2 
1558.714 8375.323 401.3618 2840.421 2652.093 83.08612 11820.35 21058.62 403.9738 0.581635 
P01040 
Cystatin-A OS=Homo sapiens 
GN=CSTA PE=1 SV=1 
40725.67 18192.86 7288.105 35814.88 10864.33 162392.2 27613.55 69229.96 22216.42 0.582273 
P62854 
40S ribosomal protein S26 
OS=Homo sapiens GN=RPS26 
PE=1 SV=3 
4878.606 16275.42 881.5713 5026.293 24180.55 0 11488.58 18888.64 1836.998 0.590484 
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P52272 
Heterogeneous nuclear 
ribonucleoprotein M 
OS=Homo sapiens 
GN=HNRNPM PE=1 SV=3 
830.964 8751.501 232.7231 2810.502 4960.433 3047.123 1224.993 6026.763 322.5909 0.600057 
P05109 
Protein S100-A8 OS=Homo 
sapiens GN=S100A8 PE=1 
SV=1 
1396.355 102872.8 3861.255 3598.724 12714.44 17954.13 582.3346 4240.464 7953.874 0.602569 
P02538 
Keratin, type II cytoskeletal 
6A OS=Homo sapiens 
GN=KRT6A PE=1 SV=3 
20491.93 466684.9 26902.18 17231.9 10401.13 38038.5 17234.57 314479.7 15820.24 0.604325 
P61204 
ADP-ribosylation factor 3 
OS=Homo sapiens GN=ARF3 
PE=1 SV=2 
2367.579 10552.16 3673.112 24158.51 4840.484 2271.675 14872.35 17984.94 3907.449 0.607161 
P49327 
Fatty acid synthase OS=Homo 
sapiens GN=FASN PE=1 SV=3 
0 401.7261 0 0 0 0 0 10852.16 0 0.609864 
P39023 
60S ribosomal protein L3 
OS=Homo sapiens GN=RPL3 
PE=1 SV=2 
 
20179.67 8184.007 4957.924 8987.695 12750.92 17908.41 11128.26 30030.24 10254.13 0.611026 
Q5VTE0;Q05639 
Putative elongation factor 1-
alpha-like 3 OS=Homo 
sapiens GN=EEF1A1P5 PE=5 
SV=1 
112144.4 412166.9 73970.76 534362.5 193367.9 220420.7 299041.7 674546 95133.82 0.613994 
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P10412;P16401 
Histone H1.4 OS=Homo 
sapiens GN=HIST1H1E PE=1 
SV=2 
27545.82 52912.74 7402.685 42354.49 143536.8 15941.64 59993.74 35341.3 22184.68 0.625423 
P63104;P31946 
14-3-3 protein zeta/delta 
OS=Homo sapiens 
GN=YWHAZ PE=1 SV=1 
1472.992 92383.51 738.4746 15160.38 5135.734 22309.96 1136.585 16774.55 1165.305 0.629559 
P05783 
Keratin, type I cytoskeletal 18 
OS=Homo sapiens GN=KRT18 
PE=1 SV=2 
24576.93 74024.65 100180.8 68676.76 544200.8 49888.73 90672.6 144697.2 34130.77 0.631979 
P0CG05;A0M8Q6;B9A064;
P0CF74 
Ig lambda-2 chain C regions 
OS=Homo sapiens GN=IGLC2 
PE=1 SV=1 
1164.994 286471.1 3465.277 2654.196 1015.606 23238.53 2587.999 4815.269 785.6186 0.637634 
Q8TF72 
Protein Shroom3 OS=Homo 
sapiens GN=SHROOM3 PE=1 
SV=2 
76986.94 61357.16 241747.3 60204.6 149584 4445.949 88473.13 12793.43 193243.8 0.639565 
P15924 
Desmoplakin OS=Homo 
sapiens GN=DSP PE=1 SV=3 
18801.19 90955.64 22653.06 41356.89 30639.71 156048.5 7477.322 94659.72 26147.94 0.64436 
P68371;P04350;Q3ZCM7 
Tubulin beta-4B chain 
OS=Homo sapiens 
GN=TUBB4B PE=1 SV=1 
4618.243 23070.81 776.7972 93453.58 5544.078 8354.55 15814.1 56595.09 0 0.651163 
Q14240 
Eukaryotic initiation factor 
4A-II OS=Homo sapiens 
GN=EIF4A2 PE=1 SV=2 
2548.159 10989.92 337.1176 10398.54 5804.373 17408.82 22702.59 44010.35 176.7467 0.654634 
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P40926 
Malate dehydrogenase, 
mitochondrial OS=Homo 
sapiens GN=MDH2 PE=1 SV=3 
1523.516 5643.847 30.67288 3961.957 578.8155 3840.861 569.1368 410.3102 1232.411 0.657407 
P13647;P12036;Q3SY84;Q
7RTS7;Q8N1N4 
Keratin, type II cytoskeletal 5 
OS=Homo sapiens GN=KRT5 
PE=1 SV=3 
413683 3937016 488241.9 391047.3 142925 1081675 163574.7 2108789 420446.5 0.685838 
Q01105 
Protein SET OS=Homo 
sapiens GN=SET PE=1 SV=3 
 
2861.33 5634.572 0 15164.88 331.7298 2994.625 0 19737.76 205.1547 0.692603 
Q6UWP8 
Suprabasin OS=Homo sapiens 
GN=SBSN PE=2 SV=2 
345.9268 270.8905 1.519573 1240.296 0 11417.14 963.7798 489.8891 636.9261 0.695154 
P02545 
Prelamin-A/C OS=Homo 
sapiens GN=LMNA PE=1 SV=1 
3018.527 45461.41 604.2104 7850.691 13391.43 14664.21 9467.699 12563.26 793.4076 0.699725 
P27797 
Calreticulin OS=Homo sapiens 
GN=CALR PE=1 SV=1 
1192.036 7712.166 100.5758 2580.641 2026.206 5846.044 6455.253 5827.351 252.7025 0.701805 
P14618 
Pyruvate kinase PKM 
OS=Homo sapiens GN=PKM 
PE=1 SV=4 
10748.6 75509.63 4852.821 59629.69 10431.19 71195.93 32037.48 128631.3 8934.718 0.705312 
P62241 
40S ribosomal protein S8 
OS=Homo sapiens GN=RPS8 
PE=1 SV=2 
13888.75 16250.76 6787.4 6164.958 48131.6 797.0242 15150.91 33028.96 6469.94 0.713601 
Q9NZT1 
Calmodulin-like protein 5 
OS=Homo sapiens 
GN=CALML5 PE=1 SV=2 
8406.135 20745.07 6014 7029.994 10318.11 9272.46 7630.094 11954.81 19567.56 0.714545 
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P07900;Q58FG0 
Heat shock protein HSP 90-
alpha OS=Homo sapiens 
GN=HSP90AA1 PE=1 SV=5 
21019.14 47817.02 4445.832 43552.82 28961.39 20390.58 114867.1 235021.3 3530.226 0.715104 
P08238;P14625;Q12931;Q
14568;Q58FF6;Q58FF7;Q5
8FF8;Q58FG1 
Heat shock protein HSP 90-
beta OS=Homo sapiens 
GN=HSP90AB1 PE=1 SV=4 
41521.21 169098.9 13615.85 130119.3 71851.6 63033.97 311576.4 639716.5 9534.223 0.728856 
P08729 
Keratin, type II cytoskeletal 7 
OS=Homo sapiens GN=KRT7 
PE=1 SV=5 
23280.59 53992.57 123935.2 44906.93 833311.9 39746.02 61344.4 125216.6 57415.39 0.730575 
P01857 
Ig gamma-1 chain C region 
OS=Homo sapiens GN=IGHG1 
PE=1 SV=1 
8801.351 467659.5 7951.57 13612.72 15529.91 23605.49 13268.27 24006.16 6782.882 0.731568 
Q5D862 
Filaggrin-2 OS=Homo sapiens 
GN=FLG2 PE=1 SV=1 
25719.3 4377.761 21244.5 35758.98 5783.139 52408.35 8856.693 56159.14 33708.16 0.736403 
Q09666 
Neuroblast differentiation-
associated protein AHNAK 
OS=Homo sapiens 
GN=AHNAK PE=1 SV=2 
 
 
 
2904.817 27721.94 3747.15 5926.702 5373.386 10775.62 13106.53 18450.4 5435.196 0.736814 
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Q9H299 
SH3 domain-binding glutamic 
acid-rich-like protein 3 
OS=Homo sapiens 
GN=SH3BGRL3 PE=1 SV=1 
3097.22 10066.28 772.144 845.145 3984.025 1265.775 2747.309 3215.829 1235.886 0.755944 
P04264;P14136 
Keratin, type II cytoskeletal 1 
OS=Homo sapiens GN=KRT1 
PE=1 SV=6 
7423208 4515086 7433954 18168975 3790973 15476437 2732453 29096210 12138436 0.75666 
P22528 
Cornifin-B OS=Homo sapiens 
GN=SPRR1B PE=1 SV=2 
10657.89 68705.62 27356.95 9017.234 13910.02 38882.64 11685 35199.05 25571 0.761439 
P31947 
14-3-3 protein sigma 
OS=Homo sapiens GN=SFN 
PE=1 SV=1 
924.247 74450.71 549.4839 1076.331 612.6374 20620.52 138.5136 2316.762 2639.381 0.762458 
Q5QNW6;Q96A08 
Histone H2B type 2-F 
OS=Homo sapiens 
GN=HIST2H2BF PE=1 SV=3 
760.478 4445.975 232.3265 513.5778 52045.58 788.9898 563.865 2184.215 3474.237 0.763936 
P61313 
60S ribosomal protein L15 
OS=Homo sapiens GN=RPL15 
PE=1 SV=2 
3503.387 5714.089 1427.433 2056.115 9058.696 2636.095 4745.326 8504.931 2550.601 0.766472 
P84098 
60S ribosomal protein L19 
OS=Homo sapiens GN=RPL19 
PE=1 SV=1 
9065.292 17386.33 2402.36 6039.592 22037.71 6091.797 15255.84 26783.25 4607.735 0.771892 
P05386 
60S acidic ribosomal protein 
P1 OS=Homo sapiens 
GN=RPLP1 PE=1 SV=1 
11015.78 33544.88 10858.37 22407.79 31025.93 2480.73 41541.94 51001.01 5963.199 0.772699 
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P62269 
40S ribosomal protein S18 
OS=Homo sapiens GN=RPS18 
PE=1 SV=3 
11966.33 33729.73 18572.21 48386.09 69173.34 6202.017 66856.88 13555.08 44102.57 0.773293 
P61247 
40S ribosomal protein S3a 
OS=Homo sapiens GN=RPS3A 
PE=1 SV=2 
2881.599 5120.366 619.9012 2985.944 3103.45 0 9244.09 9100.004 0 0.77942 
Q71DI3;Q6NXT2 
Histone H3.2 OS=Homo 
sapiens GN=HIST2H3A PE=1 
SV=3 
4388.865 112550.8 3297.113 3390.002 365064.9 7602.819 3057.545 2877.722 36995.27 0.800062 
P12273 
Prolactin-inducible protein 
OS=Homo sapiens GN=PIP 
PE=1 SV=1 
2158.034 9179.554 13797.89 12653.84 93322.87 0 2607.488 3986.798 4815.484 0.800156 
P02647 
Apolipoprotein A-I OS=Homo 
sapiens GN=APOA1 PE=1 
SV=1 
14311.65 10378.71 14145.1 7112.624 13772.92 13215.11 14655.41 8503.208 13497.4 0.801811 
P00558 
Phosphoglycerate kinase 1 
OS=Homo sapiens GN=PGK1 
PE=1 SV=3 
4008.709 40544.61 7250.183 18455.13 10039.11 5047.955 12625.64 37174 8047.947 0.804669 
Q04695;Q9C075 
Keratin, type I cytoskeletal 17 
OS=Homo sapiens GN=KRT17 
PE=1 SV=2 
125803.2 5845811 201455.7 131431.3 703295.2 164032.2 140255.9 1198750 121878.3 0.805953 
P0C0S8;P0C0S5;P16104;Q8
IUE6 
Histone H2A type 1 OS=Homo 
sapiens GN=HIST1H2AG PE=1 
SV=2 
25031.24 66147.68 19891.1 27759.74 2041711 9318.63 17380.13 24358.42 135516.3 0.807671 
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P08670;P17661 
Vimentin OS=Homo sapiens 
GN=VIM PE=1 SV=4 
22918.43 106483.9 20117.72 17560.03 514558 27432.11 16797.4 66753.18 34166.33 0.80971 
Q86YZ3 
Hornerin OS=Homo sapiens 
GN=HRNR PE=1 SV=2 
122244.7 64468.22 106605.5 1128266 14679.55 25930.83 42987.26 325298.8 333359.7 0.813217 
P20930 
Filaggrin OS=Homo sapiens 
GN=FLG PE=1 SV=3 
2698.692 365.5888 874.9889 5679.155 255.9236 7314.339 121.5561 2757.68 4299.466 0.81408 
P04406 
Glyceraldehyde-3-phosphate 
dehydrogenase OS=Homo 
sapiens GN=GAPDH PE=1 
SV=3 
55906.18 226887.3 37108.67 171400.9 65860.63 50515.39 138131.7 303116.8 38367.95 0.838443 
P04259 
Keratin, type II cytoskeletal 
6B OS=Homo sapiens 
GN=KRT6B PE=1 SV=5 
2507.352 367922.1 39268.18 3284.98 49679.51 16850.71 897.3722 397521.9 3040.705 0.840814 
P32969 
60S ribosomal protein L9 
OS=Homo sapiens GN=RPL9 
PE=1 SV=1 
1309.008 1588.781 33.18558 586.1056 4679.631 1689.072 4476.501 19479.02 0 0.846589 
P62805 
Histone H4 OS=Homo sapiens 
GN=HIST1H4A PE=1 SV=2 
3848.651 74773.82 7019.555 6363.047 948587.1 6268.303 5473.953 15910.27 80823.97 0.847091 
P02533 
Keratin, type I cytoskeletal 14 
OS=Homo sapiens GN=KRT14 
PE=1 SV=4 
193056.1 1955687 329664 281183.4 116630.6 589917.6 87283.16 2981932 267688.3 0.848782 
Q01469;A8MUU1 
Fatty acid-binding protein, 
epidermal OS=Homo sapiens 
GN=FABP5 PE=1 SV=3 
18012.9 76813.97 16865.42 18644.29 4808.732 235026.5 7017.771 44044.41 14823.78 0.86254 
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P62917 
60S ribosomal protein L8 
OS=Homo sapiens GN=RPL8 
PE=1 SV=2 
5081.717 30496 1150.857 6891.367 12530.19 5881.426 8934.193 15331.15 4802.554 0.864042 
P35908;Q7Z794;Q9NY12 
Keratin, type II cytoskeletal 2 
epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 
2984712 968491.8 1314173 1634245 615762.1 2228992 701661.7 2515707 3182074 0.866968 
P68363;P68366 
Tubulin alpha-1B chain 
OS=Homo sapiens 
GN=TUBA1B PE=1 SV=1 
13911.5 40506.74 3868.38 158004.2 36791.43 2749.39 32900.08 94724.78 3751.137 0.873579 
P62753 
40S ribosomal protein S6 
OS=Homo sapiens GN=RPS6 
PE=1 SV=1 
2921.725 12258.03 994.2008 1977.526 13879.55 2699.157 9823.868 19705.91 970.6267 0.876743 
P13645;Q2M2I5;Q7Z3Y7;Q
7Z3Y8;Q7Z3Z0 
Keratin, type I cytoskeletal 10 
OS=Homo sapiens GN=KRT10 
PE=1 SV=6 
6259208 2718063 4178041 3889563 1162828 17004314 2139016 15043749 6437534 0.888102 
P02768 
Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 
44583.34 1831823 43685.77 96105.55 132177.8 65761.94 64014.96 428187.7 24607.51 0.889284 
P62258 
14-3-3 protein epsilon 
OS=Homo sapiens 
GN=YWHAE PE=1 SV=1 
217.3708 6382.742 221.6579 5710.076 3.830082 588.1143 1982.067 6178.039 0 0.908319 
P46777 
60S ribosomal protein L5 
OS=Homo sapiens GN=RPL5 
PE=1 SV=3 
546.6267 2017.195 428.5844 103.5458 11379.6 1155.419 801.9743 2578.33 1023.638 0.915129 
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P35579 
Myosin-9 OS=Homo sapiens 
GN=MYH9 PE=1 SV=4 
9071.562 67019.56 8963.336 30052.37 12382.2 33919.59 21859.35 33766.72 10006.08 0.915708 
P43243 
Matrin-3 OS=Homo sapiens 
GN=MATR3 PE=1 SV=2 
97.2118 538.3257 0 0 7126.344 0 592.6074 598.0563 0 0.916634 
P06744 
Glucose-6-phosphate 
isomerase OS=Homo sapiens 
GN=GPI PE=1 SV=4 
48.99844 14145.94 336.7758 3301.665 1538.335 0 4638.143 24414.88 0 0.922983 
P14923 
Junction plakoglobin 
OS=Homo sapiens GN=JUP 
PE=1 SV=3 
4595.261 17305.98 8493.698 11672.82 4154.028 28187.35 2983.452 20381.24 10802.39 0.929144 
P22531;P22532;P35326;Q9
6RM1 
Small proline-rich protein 2E 
OS=Homo sapiens 
GN=SPRR2E PE=2 SV=2 
21009.65 119250.5 17405.85 28432.34 5211.722 495161.9 12689.97 45621.56 31413.47 0.930886 
Q5T749 
Keratinocyte proline-rich 
protein OS=Homo sapiens 
GN=KPRP PE=1 SV=1 
31231.93 13013.56 20721.04 43418.62 5102.596 100450.7 8470.032 76524.55 28711.55 0.932265 
Q02878 
60S ribosomal protein L6 
OS=Homo sapiens GN=RPL6 
PE=1 SV=3 
8878.81 36929.11 3982.445 9162.326 23007.35 4376.562 16764.46 21764.96 5715.915 0.935026 
P61626 
Lysozyme C OS=Homo 
sapiens GN=LYZ PE=1 SV=1 
8502.997 6345.146 12078.92 9764.04 2079.935 52947.44 3482.597 28288.74 18027.42 0.938852 
Q02413 
Desmoglein-1 OS=Homo 
sapiens GN=DSG1 PE=1 SV=2 
15660.97 11692.87 9869.008 18601.2 4308.103 42725.27 8280.715 28297.91 10978.8 0.945703 
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P07355;A6NMY6 
Annexin A2 OS=Homo 
sapiens GN=ANXA2 PE=1 
SV=2 
9529.432 109926.5 16669.45 23831.14 18106.68 75118.09 19589.64 47262.77 33388.74 0.952358 
P47929 
Galectin-7 OS=Homo sapiens 
GN=LGALS7 PE=1 SV=2 
13147.89 450977.1 9743.681 19463.48 4392.767 256844.9 14740.58 20916.29 52204.98 0.953288 
P81605 
Dermcidin OS=Homo sapiens 
GN=DCD PE=1 SV=2 
111809.2 206853.6 317877.7 185714.4 429345.9 132552.5 112249.3 303902.5 265801.4 0.965283 
P01859 
Ig gamma-2 chain C region 
OS=Homo sapiens GN=IGHG2 
PE=1 SV=2 
0 297517 230.336 1457.426 876.7175 115.55 100.0228 3836.654 129.6759 0.98862 
P31949 
Protein S100-A11 OS=Homo 
sapiens GN=S100A11 PE=1 
SV=2 
5110.838 26112.9 1525.049 9276.506 3579.061 5141.155 2293.57 10059.24 6199.379 0.98909 
P35527 
Keratin, type I cytoskeletal 9 
OS=Homo sapiens GN=KRT9 
PE=1 SV=3 
5635874 3685903 4766344 22308840 3364919 1490963 1695094 8030866 9989666 0.991245 
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Appendix Table 2: Complete spectral count data for mass spectrometry experiment.  
Accession Protein 
Confidence 
score 
Halotag Spectral Count Wild Type Spectral Count Variant B Spectral Count 
P07711;Q5NE16 
Cathepsin L1 OS=Homo 
sapiens GN=CTSL PE=1 SV=2 645.5 0 0 0 9 3 9 8 8 9 
P07858 
Cathepsin B OS=Homo 
sapiens GN=CTSB PE=1 SV=3 784.36 0 0 0 9 8 12 8 7 10 
P53634 
Dipeptidyl peptidase 1 
OS=Homo sapiens GN=CTSC 
PE=1 SV=2 1143.68 0 0 0 17 14 15 9 3 8 
P11021;O95399 
78 kDa glucose-regulated 
protein OS=Homo sapiens 
GN=HSPA5 PE=1 SV=2 2620.78 0 5 0 35 23 39 21 13 21 
P01034 
Cystatin-C OS=Homo sapiens 
GN=CST3 PE=1 SV=1 1210.91 0 0 0 19 12 23 8 1 16 
P35232 
Prohibitin OS=Homo sapiens 
GN=PHB PE=1 SV=1 199.85 1 2 3 2 0 1 5 1 5 
Q9UIQ6 
Leucyl-cystinyl 
aminopeptidase OS=Homo 
sapiens GN=LNPEP PE=1 SV=3 1265.14 0 0 0 17 2 18 0 0 0 
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P38646 
Stress-70 protein, 
mitochondrial OS=Homo 
sapiens GN=HSPA9 PE=1 
SV=2 1072.19 0 0 0 16 6 12 4 9 0 
P10620 
Microsomal glutathione S-
transferase 1 OS=Homo 
sapiens GN=MGST1 PE=1 
SV=1 28.73 0 0 0 1 0 0 0 0 0 
P62937;Q9Y536 
Peptidyl-prolyl cis-trans 
isomerase A OS=Homo 
sapiens GN=PPIA PE=1 SV=2 319.29 1 6 0 3 2 1 7 6 0 
P05141;P12235 
ADP/ATP translocase 2 
OS=Homo sapiens 
GN=SLC25A5 PE=1 SV=7 
 216.31 0 1 1 0 1 2 1 1 1 
P27348 
14-3-3 protein theta 
OS=Homo sapiens 
GN=YWHAQ PE=1 SV=1 157.56 0 1 0 0 0 0 0 0 0 
P08107;P17066;P48741 
Heat shock 70 kDa protein 
1A/1B OS=Homo sapiens 
GN=HSPA1A PE=1 SV=5 701.23 0 1 0 3 1 3 1 2 0 
P06899;Q6DN03 
Histone H2B type 1-J 
OS=Homo sapiens 
GN=HIST1H2BJ PE=1 SV=3 216.99 0 0 0 0 1 0 0 0 0 
195 
 
P53999 
Activated RNA polymerase II 
transcriptional coactivator 
p15 OS=Homo sapiens 
GN=SUB1 PE=1 SV=3 75.6 0 0 0 0 0 0 0 1 0 
P11142;P54652 
Heat shock cognate 71 kDa 
protein OS=Homo sapiens 
GN=HSPA8 PE=1 SV=1 1084.76 2 2 1 10 6 7 5 6 0 
P62979 
Ubiquitin-40S ribosomal 
protein S27a OS=Homo 
sapiens GN=RPS27A PE=1 
SV=2 204.67 3 2 1 3 4 2 4 1 2 
Q99623 
Prohibitin-2 OS=Homo 
sapiens GN=PHB2 PE=1 SV=2 219.67 3 3 3 2 2 3 4 3 5 
P31151 
Protein S100-A7 OS=Homo 
sapiens GN=S100A7 PE=1 
SV=4 44.96 0 0 0 0 0 1 0 0 0 
Q15149 
Plectin OS=Homo sapiens 
GN=PLEC PE=1 SV=3 543.17 0 1 0 0 11 0 0 0 0 
P23396 
40S ribosomal protein S3 
OS=Homo sapiens GN=RPS3 
PE=1 SV=2 356.31 2 1 0 6 5 2 5 6 2 
P12236 
ADP/ATP translocase 3 
OS=Homo sapiens 
GN=SLC25A6 PE=1 SV=4 202.83 0 0 1 0 0 0 1 1 1 
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P62249 
40S ribosomal protein S16 
OS=Homo sapiens GN=RPS16 
PE=1 SV=2 54.53 1 1 0 1 1 1 1 1 1 
P22314 
Ubiquitin-like modifier-
activating enzyme 1 
OS=Homo sapiens GN=UBA1 
PE=1 SV=3 47.35 0 0 0 0 0 0 1 1 0 
Q06830;P32119;Q13162 
Peroxiredoxin-1 OS=Homo 
sapiens GN=PRDX1 PE=1 
SV=1 350.39 5 5 6 5 3 4 6 4 8 
A8MT79 
Putative zinc-alpha-2-
glycoprotein-like 1 OS=Homo 
sapiens PE=5 SV=2 34.96 1 0 0 0 0 1 0 0 0 
P21796 
Voltage-dependent anion-
selective channel protein 1 
OS=Homo sapiens GN=VDAC1 
PE=1 SV=2 211.38 0 3 1 0 0 1 2 2 2 
P06748 
Nucleophosmin OS=Homo 
sapiens GN=NPM1 PE=1 SV=2 157.99 0 1 0 0 3 1 0 1 0 
P84095 
Rho-related GTP-binding 
protein RhoG OS=Homo 
sapiens GN=RHOG PE=1 SV=1 74.95 0 0 0 1 0 0 0 0 0 
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Q8NC51 
Plasminogen activator 
inhibitor 1 RNA-binding 
protein OS=Homo sapiens 
GN=SERBP1 PE=1 SV=2 29.1 0 0 0 1 0 0 0 0 0 
P07437;A6NKZ8;A6NNZ2;Q
13885;Q9BUF5;Q9H4B7 
Tubulin beta chain OS=Homo 
sapiens GN=TUBB PE=1 SV=2 840.05 1 1 0 2 2 1 3 1 0 
P62913 
60S ribosomal protein L11 
OS=Homo sapiens GN=RPL11 
PE=1 SV=2 110.4 0 0 0 1 2 0 0 2 0 
P04792 
Heat shock protein beta-1 
OS=Homo sapiens GN=HSPB1 
PE=1 SV=2 315.84 0 1 0 3 2 5 1 1 0 
Q08211 
ATP-dependent RNA helicase 
A OS=Homo sapiens 
GN=DHX9 PE=1 SV=4 
 
 57.52 0 0 0 0 1 0 0 1 0 
P62888 
60S ribosomal protein L30 
OS=Homo sapiens GN=RPL30 
PE=1 SV=2 48.31 1 1 0 0 1 0 0 1 0 
P61978 
Heterogeneous nuclear 
ribonucleoprotein K 
OS=Homo sapiens 
GN=HNRNPK PE=1 SV=1 187.71 0 0 0 0 1 0 2 3 0 
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P27482 
Calmodulin-like protein 3 
OS=Homo sapiens 
GN=CALML3 PE=1 SV=2 176.92 0 3 0 0 0 1 0 0 0 
P62847 
40S ribosomal protein S24 
OS=Homo sapiens GN=RPS24 
PE=1 SV=1 36.11 0 1 0 0 0 0 1 1 0 
P60660;P14649 
Myosin light polypeptide 6 
OS=Homo sapiens GN=MYL6 
PE=1 SV=2 93.31 0 2 1 2 1 0 1 0 1 
P62826 
GTP-binding nuclear protein 
Ran OS=Homo sapiens 
GN=RAN PE=1 SV=3 83.1 0 0 0 1 1 1 2 2 0 
P10809 
60 kDa heat shock protein, 
mitochondrial OS=Homo 
sapiens GN=HSPD1 PE=1 
SV=2 363.43 0 3 0 5 3 3 4 6 0 
P52597 
Heterogeneous nuclear 
ribonucleoprotein F 
OS=Homo sapiens 
GN=HNRNPF PE=1 SV=3 82.54 0 0 0 0 0 0 1 1 0 
P10599 
Thioredoxin OS=Homo 
sapiens GN=TXN PE=1 SV=3 32.36 0 0 0 1 0 0 0 0 0 
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P09211 
Glutathione S-transferase P 
OS=Homo sapiens GN=GSTP1 
PE=1 SV=2 59.2 0 1 0 0 0 0 0 1 0 
P23528;Q9Y281 
Cofilin-1 OS=Homo sapiens 
GN=CFL1 PE=1 SV=3 
 
 86.37 0 1 0 0 0 0 0 1 0 
Q71UM5 
40S ribosomal protein S27-
like OS=Homo sapiens 
GN=RPS27L PE=1 SV=3 29.45 0 0 0 0 1 0 0 0 0 
Q00839 
Heterogeneous nuclear 
ribonucleoprotein U 
OS=Homo sapiens 
GN=HNRNPU PE=1 SV=6 178.67 0 0 0 0 3 1 0 1 1 
P01876;P01877 
Ig alpha-1 chain C region 
OS=Homo sapiens GN=IGHA1 
PE=1 SV=2 150.58 0 2 0 0 0 0 0 0 0 
P13639 
Elongation factor 2 OS=Homo 
sapiens GN=EEF2 PE=1 SV=4 54.99 0 1 0 0 0 1 0 1 0 
P49411 
Elongation factor Tu, 
mitochondrial OS=Homo 
sapiens GN=TUFM PE=1 SV=2 77.94 0 0 0 2 0 1 1 2 0 
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P06702 
Protein S100-A9 OS=Homo 
sapiens GN=S100A9 PE=1 
SV=1 63.61 0 2 1 0 0 0 0 0 1 
P14324 
Farnesyl pyrophosphate 
synthase OS=Homo sapiens 
GN=FDPS PE=1 SV=4 29.79 0 0 0 0 0 0 0 1 0 
P09651;Q32P51 
Heterogeneous nuclear 
ribonucleoprotein A1 
OS=Homo sapiens 
GN=HNRNPA1 PE=1 SV=5 166.46 0 2 0 1 2 0 0 2 0 
P80723 
Brain acid soluble protein 1 
OS=Homo sapiens GN=BASP1 
PE=1 SV=2 73.85 0 0 0 2 0 2 0 1 0 
P61353 
60S ribosomal protein L27 
OS=Homo sapiens GN=RPL27 
PE=1 SV=2 42.6 1 0 0 0 0 0 0 1 0 
P08195 
4F2 cell-surface antigen 
heavy chain OS=Homo 
sapiens GN=SLC3A2 PE=1 
SV=3 
 60.35 0 0 0 0 0 0 0 1 0 
P67936 
Tropomyosin alpha-4 chain 
OS=Homo sapiens GN=TPM4 
PE=1 SV=3 58.68 0 0 0 1 0 0 0 0 0 
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P60174 
Triosephosphate isomerase 
OS=Homo sapiens GN=TPI1 
PE=1 SV=3 67.55 0 2 0 1 0 0 0 1 0 
P05090 
Apolipoprotein D OS=Homo 
sapiens GN=APOD PE=1 SV=1 84.21 0 0 0 0 2 0 0 0 0 
P31944 
Caspase-14 OS=Homo 
sapiens GN=CASP14 PE=1 
SV=2 107.46 0 0 0 0 0 2 0 0 0 
P62263 
40S ribosomal protein S14 
OS=Homo sapiens GN=RPS14 
PE=1 SV=3 38.82 0 0 0 0 1 0 1 0 0 
Q8NHW5 
60S acidic ribosomal protein 
P0-like OS=Homo sapiens 
GN=RPLP0P6 PE=5 SV=1 42.38 0 0 0 0 1 0 1 0 0 
Q07021 
Complement component 1 Q 
subcomponent-binding 
protein, mitochondrial 
OS=Homo sapiens GN=C1QBP 
PE=1 SV=1 131.41 0 2 0 2 0 2 0 3 0 
P61604 
10 kDa heat shock protein, 
mitochondrial OS=Homo 
sapiens GN=HSPE1 PE=1 SV=2 91.1 0 0 0 1 1 2 0 1 0 
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P26373 
60S ribosomal protein L13 
OS=Homo sapiens GN=RPL13 
PE=1 SV=4 71.1 0 0 0 0 2 0 1 2 0 
P49207 
60S ribosomal protein L34 
OS=Homo sapiens GN=RPL34 
PE=1 SV=3 45.29 0 0 0 0 1 0 1 1 0 
P07737 
Profilin-1 OS=Homo sapiens 
GN=PFN1 PE=1 SV=2 
 
 
 234.11 0 3 0 2 1 0 4 3 0 
Q00325 
Phosphate carrier protein, 
mitochondrial OS=Homo 
sapiens GN=SLC25A3 PE=1 
SV=2 42.43 0 1 0 1 0 1 0 1 0 
P60709;A5A3E0;P0CG38;P
0CG39;P62736;P68032;Q6
S8J3;Q9BYX7 
Actin, cytoplasmic 1 
OS=Homo sapiens GN=ACTB 
PE=1 SV=1 1302.01 8 14 9 12 9 10 9 8 9 
P62701;P22090 
40S ribosomal protein S4, X 
isoform OS=Homo sapiens 
GN=RPS4X PE=1 SV=2 52.87 0 1 0 0 1 0 1 1 0 
P62857 
40S ribosomal protein S28 
OS=Homo sapiens GN=RPS28 
PE=1 SV=1 82.27 0 1 0 0 0 1 0 2 0 
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P07910;O60812 
Heterogeneous nuclear 
ribonucleoproteins C1/C2 
OS=Homo sapiens 
GN=HNRNPC PE=1 SV=4 229.73 0 0 0 0 5 0 0 1 0 
P36578 
60S ribosomal protein L4 
OS=Homo sapiens GN=RPL4 
PE=1 SV=5 27.48 0 0 0 0 1 0 0 1 0 
P43307 
Translocon-associated 
protein subunit alpha 
OS=Homo sapiens GN=SSR1 
PE=1 SV=3 50.78 0 0 0 1 0 0 0 0 0 
P00338;P07864 
L-lactate dehydrogenase A 
chain OS=Homo sapiens 
GN=LDHA PE=1 SV=2 328.54 0 5 0 1 3 0 5 5 0 
P45880 
Voltage-dependent anion-
selective channel protein 2 
OS=Homo sapiens GN=VDAC2 
PE=1 SV=2 263.79 2 2 3 2 3 1 4 2 3 
P30041 
Peroxiredoxin-6 OS=Homo 
sapiens GN=PRDX6 PE=1 
SV=3 
 
 30.93 0 0 0 1 0 0 0 0 0 
204 
 
Q71U36;A6NHL2;Q13748;
Q6PEY2;Q9BQE3;Q9H853;
Q9NY65 
Tubulin alpha-1A chain 
OS=Homo sapiens 
GN=TUBA1A PE=1 SV=1 766.63 0 1 0 1 1 0 0 1 0 
P06576 
ATP synthase subunit beta, 
mitochondrial OS=Homo 
sapiens GN=ATP5B PE=1 SV=3 78.68 1 1 2 0 1 2 1 1 1 
Q15366 
Poly(rC)-binding protein 2 
OS=Homo sapiens GN=PCBP2 
PE=1 SV=1 40.28 0 1 0 1 0 0 1 1 0 
P07339 
Cathepsin D OS=Homo 
sapiens GN=CTSD PE=1 SV=1 42.11 0 0 0 0 0 1 0 0 0 
P02795 
Metallothionein-2 OS=Homo 
sapiens GN=MT2A PE=1 SV=1 38.88 0 0 0 1 0 0 0 0 0 
Q9NQ39 
Putative 40S ribosomal 
protein S10-like OS=Homo 
sapiens GN=RPS10P5 PE=5 
SV=1 65.03 0 1 0 1 1 0 1 1 0 
P01834 
Ig kappa chain C region 
OS=Homo sapiens GN=IGKC 
PE=1 SV=1 366.96 0 5 0 0 1 0 0 0 0 
P08779;O76013;P35900;Q
7Z3Y9;Q8N1A0;Q99456 
Keratin, type I cytoskeletal 16 
OS=Homo sapiens GN=KRT16 
PE=1 SV=4 2566.41 4 11 14 3 0 3 0 24 5 
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P07195 
L-lactate dehydrogenase B 
chain OS=Homo sapiens 
GN=LDHB PE=1 SV=2 266.08 0 0 0 0 0 0 2 4 0 
Q07020 
60S ribosomal protein L18 
OS=Homo sapiens GN=RPL18 
PE=1 SV=2 111.5 1 0 0 0 1 0 1 2 0 
P63244 
Guanine nucleotide-binding 
protein subunit beta-2-like 1 
OS=Homo sapiens 
GN=GNB2L1 PE=1 SV=3 
 
 
 74.99 0 1 0 0 0 1 1 2 0 
P56134 
ATP synthase subunit f, 
mitochondrial OS=Homo 
sapiens GN=ATP5J2 PE=1 
SV=3 34.48 0 0 0 1 0 0 0 0 0 
P50914 
60S ribosomal protein L14 
OS=Homo sapiens GN=RPL14 
PE=1 SV=4 55.85 1 0 0 0 1 0 1 1 0 
P58107 
Epiplakin OS=Homo sapiens 
GN=EPPK1 PE=1 SV=2 186.01 0 0 0 0 2 0 0 0 0 
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P63313;P62328 
Thymosin beta-10 OS=Homo 
sapiens GN=TMSB10 PE=1 
SV=2 56.95 0 1 0 2 1 0 0 2 0 
P06454 
Prothymosin alpha OS=Homo 
sapiens GN=PTMA PE=1 SV=2 172.65 0 3 0 2 2 0 0 2 0 
P14174 
Macrophage migration 
inhibitory factor OS=Homo 
sapiens GN=MIF PE=1 SV=4 62.76 1 0 0 1 0 0 1 1 1 
P25705 
ATP synthase subunit alpha, 
mitochondrial OS=Homo 
sapiens GN=ATP5A1 PE=1 
SV=1 353.95 0 2 0 3 3 2 3 4 0 
P06733;P09104;P13929 
Alpha-enolase OS=Homo 
sapiens GN=ENO1 PE=1 SV=2 410.48 1 5 0 5 1 3 0 5 0 
P02787 
Serotransferrin OS=Homo 
sapiens GN=TF PE=1 SV=3 579.73 0 13 0 0 0 0 0 0 0 
P46781 
40S ribosomal protein S9 
OS=Homo sapiens GN=RPS9 
PE=1 SV=3 43.65 0 0 0 0 1 0 1 0 0 
P05387 
60S acidic ribosomal protein 
P2 OS=Homo sapiens 
GN=RPLP2 PE=1 SV=1 110.97 1 0 0 1 3 0 1 1 1 
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P67809 
Nuclease-sensitive element-
binding protein 1 OS=Homo 
sapiens GN=YBX1 PE=1 SV=3 148.56 2 2 0 2 2 1 1 3 0 
P01024 
Complement C3 OS=Homo 
sapiens GN=C3 PE=1 SV=2 83.75 0 2 0 0 0 0 0 0 0 
P05787;P41219;Q9NSB2 
Keratin, type II cytoskeletal 8 
OS=Homo sapiens GN=KRT8 
PE=1 SV=7 1242.71 2 4 3 2 16 2 7 8 3 
Q02543 
60S ribosomal protein L18a 
OS=Homo sapiens 
GN=RPL18A PE=1 SV=2 38.05 0 1 0 0 1 0 0 1 0 
P04075 
Fructose-bisphosphate 
aldolase A OS=Homo sapiens 
GN=ALDOA PE=1 SV=2 44.62 0 1 0 0 0 0 0 0 0 
P11940;Q13310 
Polyadenylate-binding 
protein 1 OS=Homo sapiens 
GN=PABPC1 PE=1 SV=2 74.01 0 1 0 0 0 0 0 2 0 
P01040 
Cystatin-A OS=Homo sapiens 
GN=CSTA PE=1 SV=1 102.86 2 0 0 1 1 3 1 2 1 
P62854 
40S ribosomal protein S26 
OS=Homo sapiens GN=RPS26 
PE=1 SV=3 28.01 0 1 0 1 1 0 0 1 0 
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P52272 
Heterogeneous nuclear 
ribonucleoprotein M 
OS=Homo sapiens 
GN=HNRNPM PE=1 SV=3 33.17 0 0 0 0 1 0 0 0 0 
P05109 
Protein S100-A8 OS=Homo 
sapiens GN=S100A8 PE=1 
SV=1 73.83 0 1 1 0 0 0 0 0 1 
P02538 
Keratin, type II cytoskeletal 
6A OS=Homo sapiens 
GN=KRT6A PE=1 SV=3 1928.01 1 3 1 1 0 0 0 1 1 
P61204 
ADP-ribosylation factor 3 
OS=Homo sapiens GN=ARF3 
PE=1 SV=2 38.44 0 0 0 0 0 0 0 1 0 
P49327 
Fatty acid synthase OS=Homo 
sapiens GN=FASN PE=1 SV=3 39 0 0 0 0 0 0 0 1 0 
P39023 
60S ribosomal protein L3 
OS=Homo sapiens GN=RPL3 
PE=1 SV=2 
 54.47 0 0 0 0 0 0 0 1 0 
Q5VTE0;Q05639 
Putative elongation factor 1-
alpha-like 3 OS=Homo 
sapiens GN=EEF1A1P5 PE=5 
SV=1 385.21 3 8 1 5 4 4 6 5 4 
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P10412;P16401 
Histone H1.4 OS=Homo 
sapiens GN=HIST1H1E PE=1 
SV=2 115.86 3 2 0 0 3 0 2 0 2 
P63104;P31946 
14-3-3 protein zeta/delta 
OS=Homo sapiens 
GN=YWHAZ PE=1 SV=1 218.97 0 3 0 1 0 0 0 0 0 
P05783 
Keratin, type I cytoskeletal 18 
OS=Homo sapiens GN=KRT18 
PE=1 SV=2 564.7 0 0 4 1 9 0 5 4 0 
P0CG05;A0M8Q6;B9A064;
P0CF74 
Ig lambda-2 chain C regions 
OS=Homo sapiens GN=IGLC2 
PE=1 SV=1 230.15 0 4 0 0 0 0 0 0 0 
Q8TF72 
Protein Shroom3 OS=Homo 
sapiens GN=SHROOM3 PE=1 
SV=2 30.43 1 1 1 1 1 1 1 1 1 
P15924 
Desmoplakin OS=Homo 
sapiens GN=DSP PE=1 SV=3 304.75 1 6 1 2 1 5 0 3 2 
P68371;P04350;Q3ZCM7 
Tubulin beta-4B chain 
OS=Homo sapiens 
GN=TUBB4B PE=1 SV=1 784.15 0 0 0 1 0 0 0 1 0 
Q14240 
Eukaryotic initiation factor 
4A-II OS=Homo sapiens 
GN=EIF4A2 PE=1 SV=2 74.44 0 0 0 1 0 0 2 1 0 
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P40926 
Malate dehydrogenase, 
mitochondrial OS=Homo 
sapiens GN=MDH2 PE=1 SV=3 31.05 0 1 0 0 0 0 0 0 0 
P13647;P12036;Q3SY84;Q
7RTS7;Q8N1N4 
Keratin, type II cytoskeletal 5 
OS=Homo sapiens GN=KRT5 
PE=1 SV=3 2089.03 14 23 15 9 3 12 7 19 12 
Q01105 
Protein SET OS=Homo 
sapiens GN=SET PE=1 SV=3 
 50.97 0 0 0 1 0 0 0 0 0 
Q6UWP8 
Suprabasin OS=Homo sapiens 
GN=SBSN PE=2 SV=2 41.22 0 0 0 0 0 1 0 0 0 
P02545 
Prelamin-A/C OS=Homo 
sapiens GN=LMNA PE=1 SV=1 171.79 0 3 0 0 1 0 1 1 0 
P27797 
Calreticulin OS=Homo sapiens 
GN=CALR PE=1 SV=1 30.31 0 1 0 0 1 1 1 0 0 
P14618 
Pyruvate kinase PKM 
OS=Homo sapiens GN=PKM 
PE=1 SV=4 166.69 0 3 0 1 1 1 1 2 0 
P62241 
40S ribosomal protein S8 
OS=Homo sapiens GN=RPS8 
PE=1 SV=2 94.36 1 0 0 0 2 0 0 1 0 
Q9NZT1 
Calmodulin-like protein 5 
OS=Homo sapiens 
GN=CALML5 PE=1 SV=2 31.01 0 1 0 0 1 0 0 0 1 
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P07900;Q58FG0 
Heat shock protein HSP 90-
alpha OS=Homo sapiens 
GN=HSP90AA1 PE=1 SV=5 763.65 0 2 0 0 0 0 3 3 0 
P08238;P14625;Q12931;Q
14568;Q58FF6;Q58FF7;Q5
8FF8;Q58FG1 
Heat shock protein HSP 90-
beta OS=Homo sapiens 
GN=HSP90AB1 PE=1 SV=4 970.68 1 4 0 2 3 2 8 7 0 
P08729 
Keratin, type II cytoskeletal 7 
OS=Homo sapiens GN=KRT7 
PE=1 SV=5 1202.7 1 1 8 2 14 0 3 5 1 
P01857 
Ig gamma-1 chain C region 
OS=Homo sapiens GN=IGHG1 
PE=1 SV=1 307.25 0 3 0 0 0 0 0 0 0 
Q5D862 
Filaggrin-2 OS=Homo sapiens 
GN=FLG2 PE=1 SV=1 165.55 1 0 1 2 0 2 1 2 2 
Q09666 
Neuroblast differentiation-
associated protein AHNAK 
OS=Homo sapiens 
GN=AHNAK PE=1 SV=2 
 
 
 63.72 0 2 0 0 0 0 0 1 0 
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Q9H299 
SH3 domain-binding glutamic 
acid-rich-like protein 3 
OS=Homo sapiens 
GN=SH3BGRL3 PE=1 SV=1 28.5 0 1 0 0 0 0 0 0 0 
P04264;P14136 
Keratin, type II cytoskeletal 1 
OS=Homo sapiens GN=KRT1 
PE=1 SV=6 3176.55 38 25 33 36 27 25 29 35 31 
P22528 
Cornifin-B OS=Homo sapiens 
GN=SPRR1B PE=1 SV=2 27.66 0 1 0 0 0 0 0 1 0 
P31947 
14-3-3 protein sigma 
OS=Homo sapiens GN=SFN 
PE=1 SV=1 256.38 0 3 0 0 0 1 0 0 0 
Q5QNW6;Q96A08 
Histone H2B type 2-F 
OS=Homo sapiens 
GN=HIST2H2BF PE=1 SV=3 226.48 0 0 0 0 1 0 0 0 0 
P61313 
60S ribosomal protein L15 
OS=Homo sapiens GN=RPL15 
PE=1 SV=2 41 1 0 0 0 1 0 1 0 0 
P84098 
60S ribosomal protein L19 
OS=Homo sapiens GN=RPL19 
PE=1 SV=1 103.26 1 1 0 0 2 1 1 2 1 
P05386 
60S acidic ribosomal protein 
P1 OS=Homo sapiens 
GN=RPLP1 PE=1 SV=1 64.79 1 1 0 1 1 0 1 1 0 
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P62269 
40S ribosomal protein S18 
OS=Homo sapiens GN=RPS18 
PE=1 SV=3 115.09 1 1 1 2 1 0 2 0 3 
P61247 
40S ribosomal protein S3a 
OS=Homo sapiens GN=RPS3A 
PE=1 SV=2 47.31 0 1 0 0 0 0 1 1 0 
Q71DI3;Q6NXT2 
Histone H3.2 OS=Homo 
sapiens GN=HIST2H3A PE=1 
SV=3 91.14 0 0 0 0 3 0 0 0 1 
P12273 
Prolactin-inducible protein 
OS=Homo sapiens GN=PIP 
PE=1 SV=1 151.5 0 0 0 0 3 0 0 0 0 
P02647 
Apolipoprotein A-I OS=Homo 
sapiens GN=APOA1 PE=1 
SV=1 47.44 1 0 0 0 1 1 0 0 0 
P00558 
Phosphoglycerate kinase 1 
OS=Homo sapiens GN=PGK1 
PE=1 SV=3 89.01 0 2 0 1 0 0 1 1 0 
Q04695;Q9C075 
Keratin, type I cytoskeletal 17 
OS=Homo sapiens GN=KRT17 
PE=1 SV=2 2147.65 0 23 9 1 14 0 2 13 2 
P0C0S8;P0C0S5;P16104;Q8
IUE6 
Histone H2A type 1 OS=Homo 
sapiens GN=HIST1H2AG PE=1 
SV=2 157.98 0 1 0 0 4 0 0 0 1 
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P08670;P17661 
Vimentin OS=Homo sapiens 
GN=VIM PE=1 SV=4 622.22 0 0 0 0 11 0 0 0 0 
Q86YZ3 
Hornerin OS=Homo sapiens 
GN=HRNR PE=1 SV=2 832.02 3 4 3 16 1 1 2 9 9 
P20930 
Filaggrin OS=Homo sapiens 
GN=FLG PE=1 SV=3 28.91 0 0 0 1 0 1 0 1 1 
P04406 
Glyceraldehyde-3-phosphate 
dehydrogenase OS=Homo 
sapiens GN=GAPDH PE=1 
SV=3 518.16 1 5 1 6 3 0 4 8 1 
P04259 
Keratin, type II cytoskeletal 
6B OS=Homo sapiens 
GN=KRT6B PE=1 SV=5 1965.26 0 2 1 0 0 0 0 2 0 
P32969 
60S ribosomal protein L9 
OS=Homo sapiens GN=RPL9 
PE=1 SV=1 26.05 0 0 0 0 0 0 0 1 0 
P62805 
Histone H4 OS=Homo sapiens 
GN=HIST1H4A PE=1 SV=2 387.46 0 1 0 0 7 0 0 0 3 
P02533 
Keratin, type I cytoskeletal 14 
OS=Homo sapiens GN=KRT14 
PE=1 SV=4 2344.3 5 14 9 4 1 4 1 13 6 
Q01469;A8MUU1 
Fatty acid-binding protein, 
epidermal OS=Homo sapiens 
GN=FABP5 PE=1 SV=3 228.68 1 4 1 0 0 5 0 1 0 
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P62917 
60S ribosomal protein L8 
OS=Homo sapiens GN=RPL8 
PE=1 SV=2 38.43 0 0 0 0 1 0 1 0 0 
P35908;Q7Z794;Q9NY12 
Keratin, type II cytoskeletal 2 
epidermal OS=Homo sapiens 
GN=KRT2 PE=1 SV=2 2525.26 25 14 23 14 9 18 15 19 24 
P68363;P68366 
Tubulin alpha-1B chain 
OS=Homo sapiens 
GN=TUBA1B PE=1 SV=1 780.23 1 1 0 1 1 0 1 1 0 
P62753 
40S ribosomal protein S6 
OS=Homo sapiens GN=RPS6 
PE=1 SV=1 31.64 0 0 0 0 1 0 0 0 0 
P13645;Q2M2I5;Q7Z3Y7;Q
7Z3Y8;Q7Z3Z0 
Keratin, type I cytoskeletal 10 
OS=Homo sapiens GN=KRT10 
PE=1 SV=6 2847.53 31 20 26 25 17 29 25 28 30 
P02768 
Serum albumin OS=Homo 
sapiens GN=ALB PE=1 SV=2 629.14 1 12 0 2 3 1 3 3 0 
P62258 
14-3-3 protein epsilon 
OS=Homo sapiens 
GN=YWHAE PE=1 SV=1 105.7 0 1 0 1 0 0 0 0 0 
P46777 
60S ribosomal protein L5 
OS=Homo sapiens GN=RPL5 
PE=1 SV=3 37.52 0 0 0 0 1 0 0 0 0 
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P35579 
Myosin-9 OS=Homo sapiens 
GN=MYH9 PE=1 SV=4 200.19 1 4 0 0 0 0 0 1 0 
P43243 
Matrin-3 OS=Homo sapiens 
GN=MATR3 PE=1 SV=2 31.45 0 0 0 0 1 0 0 0 0 
P06744 
Glucose-6-phosphate 
isomerase OS=Homo sapiens 
GN=GPI PE=1 SV=4 35.13 0 1 0 0 0 0 0 1 0 
P14923 
Junction plakoglobin 
OS=Homo sapiens GN=JUP 
PE=1 SV=3 71.32 0 1 0 1 0 2 0 1 0 
P22531;P22532;P35326;Q9
6RM1 
Small proline-rich protein 2E 
OS=Homo sapiens 
GN=SPRR2E PE=2 SV=2 97.24 1 2 0 2 0 2 0 2 2 
Q5T749 
Keratinocyte proline-rich 
protein OS=Homo sapiens 
GN=KPRP PE=1 SV=1 93.97 2 0 1 1 0 2 0 0 2 
Q02878 
60S ribosomal protein L6 
OS=Homo sapiens GN=RPL6 
PE=1 SV=3 61.84 1 1 0 0 2 0 2 1 1 
P61626 
Lysozyme C OS=Homo 
sapiens GN=LYZ PE=1 SV=1 80.42 0 0 1 1 0 2 0 1 1 
Q02413 
Desmoglein-1 OS=Homo 
sapiens GN=DSG1 PE=1 SV=2 104.91 1 0 0 1 0 2 0 2 0 
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P07355;A6NMY6 
Annexin A2 OS=Homo 
sapiens GN=ANXA2 PE=1 
SV=2 283.63 0 4 1 1 0 2 0 1 2 
P47929 
Galectin-7 OS=Homo sapiens 
GN=LGALS7 PE=1 SV=2 412.47 0 5 0 0 0 2 0 0 0 
P81605 
Dermcidin OS=Homo sapiens 
GN=DCD PE=1 SV=2 222.59 2 2 4 3 4 2 3 1 4 
P01859 
Ig gamma-2 chain C region 
OS=Homo sapiens GN=IGHG2 
PE=1 SV=2 245.3 0 2 0 0 0 0 0 0 0 
P31949 
Protein S100-A11 OS=Homo 
sapiens GN=S100A11 PE=1 
SV=2 55.84 0 1 0 1 1 1 0 1 1 
P35527 
Keratin, type I cytoskeletal 9 
OS=Homo sapiens GN=KRT9 
PE=1 SV=3 3074.34 37 30 34 41 28 11 20 32 38 
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DNA Analysis: 
 
Stock 5x TBE: 
Tris  54 g 
Orthoboric acid 27.5 g 
0.5M EDTA, pH 8.0 20 mL 
dH2O 800 mL 
pH to 8.3 with orthoboric acid  
Make to 1 litre with dH2O  
 
DNA Glycerol loading buffer 
dH2O 5 mL 
Glycerol 1.5 mL 
Bromophenol blue 0.25% (w/v) 
0.5M EDTA 5 µL 
 
NZY+ Broth (per litre) 
NZ amine (casein hydrolysate) 10 g 
Yeast extract 5 g 
NaCl 5 g 
NaOH pH to 7.5 
Add prior to use: 
1 M MgCl2 12.5 mL 
1 M MgSO4 12.5 mL 
20% (w/v) glucose 20 mL 
 
 
 
 
 
220 
 
Protein Analysis: 
 
Lysis buffer: 
β-mercaptoethanol 0.128 M 
Tris 40 mM 
glycerol 10 % v/v 
SDS 1 % w/v 
bromophenol blue ~0.01 % w/v 
 
Use volume appropriately to sample size or tissue culture vessel area. Approximately 200 to 
500 µL per well of a 6 well plate. 
 
10x Loading buffer (Lemmli buffer)  
β-mercaptoethanol 0.625 M 
Tris pH 6.8 62.5 mM 
glycerol 10 % v/v 
SDS 2 % w/v 
bromophenol blue 0.00125% w/v 
 
Used at 2x concentration; with ¼ volume added to sample before heating to denature 
proteins. 
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Resolving gel buffer: 
Tris 3 M 
HCl pH 8.85 
 
Stacking gel buffer: 
Tris 0.25 M 
HCl pH 6.8 
 
Stock 5x Running Buffer: 
(Use at 1x.) 
Tris 0.125 M 
Glycine 1.25 M 
SDS 0.5 %  w/v 
 
Transfer buffer: 
Produced from 5x Running buffer as follows: 100 mL 5x Running Buffer, 233 mL Ethanol, up 
to 1 L with dH2O. 
Tris 0.0125 M 
Glycine 0.125 M 
SDS 0.05 % w/v 
Ethanol 23.3 % v/v 
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Wash buffer: 
Tris 0.02 M 
NaCl 0.137 M 
Tween-20 0.1 % v/v 
 
Blocking Buffer: 
Tris 0.02 M 
NaCl 0.137 M 
Tween-20 0.1 % v/v 
Milk powder 5 % w/v 
 
Stripping solution: 
Tris 0.0624 M 
SDS 2 % w/v 
HCl pH 6.7 
β-mercaptoethanol 0.7 % v/v 
Add β-mercaptoethanol just prior to usage. 
 
RIPA buffer (pH to 8.0): 
NaCl 150 mM 
Tris 10 mM 
IGEPAL CA630 1 % 
Cholic Acid 0.5 % 
EDTA 5 mM 
Add protease inhibitors just prior to use (Promega Protease Inhibitor Cocktail, G6521). 
 
223 
 
SDS Gel recipes: 
Resolving gel (12%): 
 3.5 mL dH2O 
 2.5 mL resolving gel buffer 
 4 mL acrylamide (30%, ) 
 100 µL 10 % SDS 
 100 µL 10 % APS 
 10 µL TEMED 
 
 
Stacking gel (4%): 
 1.85 mL dH2O 
 2.5 mL stacking gel buffer 
 650 µL acrylamide (30%, ) 
 50 µL 10 % SDS 
 50 µL 10 % APS 
 10 µL TEMED 
